#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Dorsal anterior cingulate glutamate is associated with engagement of the default mode network during exposure to smoking cues
#Text=Background
#Text=When exposed to smoking cues, nicotine dependent individuals activate brain regions overlapping with the default mode network (DMN), a network of regions involved in internally-focused cognition.
1-1	0-6	Dorsal	_
1-2	7-15	anterior	_
1-3	16-25	cingulate	_
1-4	26-35	glutamate	_
1-5	36-38	is	_
1-6	39-49	associated	_
1-7	50-54	with	_
1-8	55-65	engagement	_
1-9	66-68	of	_
1-10	69-72	the	_
1-11	73-80	default	_
1-12	81-85	mode	_
1-13	86-93	network	_
1-14	94-100	during	_
1-15	101-109	exposure	_
1-16	110-112	to	_
1-17	113-120	smoking	_
1-18	121-125	cues	_
1-19	126-136	Background	_
1-20	137-141	When	_
1-21	142-149	exposed	_
1-22	150-152	to	_
1-23	153-160	smoking	_
1-24	161-165	cues	_
1-25	165-166	,	_
1-26	167-175	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[1]
1-27	176-185	dependent	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[1]
1-28	186-197	individuals	_
1-29	198-206	activate	_
1-30	207-212	brain	_
1-31	213-220	regions	_
1-32	221-232	overlapping	_
1-33	233-237	with	_
1-34	238-241	the	_
1-35	242-249	default	_
1-36	250-254	mode	_
1-37	255-262	network	_
1-38	263-264	(	_
1-39	264-267	DMN	_
1-40	267-268	)	_
1-41	268-269	,	_
1-42	270-271	a	_
1-43	272-279	network	_
1-44	280-282	of	_
1-45	283-290	regions	_
1-46	291-299	involved	_
1-47	300-302	in	_
1-48	303-321	internally-focused	_
1-49	322-331	cognition	_
1-50	331-332	.	_

#Text=The salience network (SN), which includes the dorsal anterior cingulate cortex (dACC), is thought to interact with the DMN and aids in directing attention toward salient internal or external stimuli.
2-1	333-336	The	_
2-2	337-345	salience	_
2-3	346-353	network	_
2-4	354-355	(	_
2-5	355-357	SN	_
2-6	357-358	)	_
2-7	358-359	,	_
2-8	360-365	which	_
2-9	366-374	includes	_
2-10	375-378	the	_
2-11	379-385	dorsal	_
2-12	386-394	anterior	_
2-13	395-404	cingulate	_
2-14	405-411	cortex	_
2-15	412-413	(	_
2-16	413-417	dACC	_
2-17	417-418	)	_
2-18	418-419	,	_
2-19	420-422	is	_
2-20	423-430	thought	_
2-21	431-433	to	_
2-22	434-442	interact	_
2-23	443-447	with	_
2-24	448-451	the	_
2-25	452-455	DMN	_
2-26	456-459	and	_
2-27	460-464	aids	_
2-28	465-467	in	_
2-29	468-477	directing	_
2-30	478-487	attention	_
2-31	488-494	toward	_
2-32	495-502	salient	_
2-33	503-511	internal	_
2-34	512-514	or	_
2-35	515-523	external	_
2-36	524-531	stimuli	_
2-37	531-532	.	_

#Text=One possibility is that neurochemical variation in SN regions such as the dACC impact DMN reactivity to personally relevant stimuli such as smoking cues.
3-1	533-536	One	_
3-2	537-548	possibility	_
3-3	549-551	is	_
3-4	552-556	that	_
3-5	557-570	neurochemical	_
3-6	571-580	variation	_
3-7	581-583	in	_
3-8	584-586	SN	_
3-9	587-594	regions	_
3-10	595-599	such	_
3-11	600-602	as	_
3-12	603-606	the	_
3-13	607-611	dACC	_
3-14	612-618	impact	_
3-15	619-622	DMN	_
3-16	623-633	reactivity	_
3-17	634-636	to	_
3-18	637-647	personally	_
3-19	648-656	relevant	_
3-20	657-664	stimuli	_
3-21	665-669	such	_
3-22	670-672	as	_
3-23	673-680	smoking	_
3-24	681-685	cues	_
3-25	685-686	.	_

#Text=This is consistent with emerging evidence suggesting an association between midline cortical glutamate (Glu) and activity in brain regions overlapping with the DMN.
4-1	687-691	This	_
4-2	692-694	is	_
4-3	695-705	consistent	_
4-4	706-710	with	_
4-5	711-719	emerging	_
4-6	720-728	evidence	_
4-7	729-739	suggesting	_
4-8	740-742	an	_
4-9	743-754	association	_
4-10	755-762	between	_
4-11	763-770	midline	_
4-12	771-779	cortical	_
4-13	780-789	glutamate	_
4-14	790-791	(	_
4-15	791-794	Glu	_
4-16	794-795	)	_
4-17	796-799	and	_
4-18	800-808	activity	_
4-19	809-811	in	_
4-20	812-817	brain	_
4-21	818-825	regions	_
4-22	826-837	overlapping	_
4-23	838-842	with	_
4-24	843-846	the	_
4-25	847-850	DMN	_
4-26	850-851	.	_

#Text=Methods
#Text=In 18 nicotine-dependent individuals, we assessed the relationship between DMN activation to smoking relative to neutral cues using functional magnetic resonance imaging and dACC Glu as measured by magnetic resonance spectroscopy.
5-1	852-859	Methods	_
5-2	860-862	In	_
5-3	863-865	18	_
5-4	866-884	nicotine-dependent	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse
5-5	885-896	individuals	_
5-6	896-897	,	_
5-7	898-900	we	_
5-8	901-909	assessed	_
5-9	910-913	the	_
5-10	914-926	relationship	_
5-11	927-934	between	_
5-12	935-938	DMN	_
5-13	939-949	activation	_
5-14	950-952	to	_
5-15	953-960	smoking	_
5-16	961-969	relative	_
5-17	970-972	to	_
5-18	973-980	neutral	_
5-19	981-985	cues	_
5-20	986-991	using	_
5-21	992-1002	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[2]
5-22	1003-1011	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[2]
5-23	1012-1021	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[2]
5-24	1022-1029	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[2]
5-25	1030-1033	and	_
5-26	1034-1038	dACC	_
5-27	1039-1042	Glu	_
5-28	1043-1045	as	_
5-29	1046-1054	measured	_
5-30	1055-1057	by	_
5-31	1058-1066	magnetic	_
5-32	1067-1076	resonance	_
5-33	1077-1089	spectroscopy	http://maven.renci.org/NeuroBridge/neurobridge#Spectroscopy
5-34	1089-1090	.	_

#Text=This association also was tested in a replication sample of 14 nicotine-dependent participants.
6-1	1091-1095	This	_
6-2	1096-1107	association	_
6-3	1108-1112	also	_
6-4	1113-1116	was	_
6-5	1117-1123	tested	_
6-6	1124-1126	in	_
6-7	1127-1128	a	_
6-8	1129-1140	replication	_
6-9	1141-1147	sample	_
6-10	1148-1150	of	_
6-11	1151-1153	14	_
6-12	1154-1172	nicotine-dependent	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse
6-13	1173-1185	participants	_
6-14	1185-1186	.	_

#Text=Results
#Text=Not only was the DMN significantly less suppressed during smoking cue exposure, but also there was a positive association between DMN reactivity to smoking relative to neutral cues and dACC Glu (r = 0.56, p < 0.02).
7-1	1187-1194	Results	_
7-2	1195-1198	Not	_
7-3	1199-1203	only	_
7-4	1204-1207	was	_
7-5	1208-1211	the	_
7-6	1212-1215	DMN	_
7-7	1216-1229	significantly	_
7-8	1230-1234	less	_
7-9	1235-1245	suppressed	_
7-10	1246-1252	during	_
7-11	1253-1260	smoking	_
7-12	1261-1264	cue	_
7-13	1265-1273	exposure	_
7-14	1273-1274	,	_
7-15	1275-1278	but	_
7-16	1279-1283	also	_
7-17	1284-1289	there	_
7-18	1290-1293	was	_
7-19	1294-1295	a	_
7-20	1296-1304	positive	_
7-21	1305-1316	association	_
7-22	1317-1324	between	_
7-23	1325-1328	DMN	_
7-24	1329-1339	reactivity	_
7-25	1340-1342	to	_
7-26	1343-1350	smoking	_
7-27	1351-1359	relative	_
7-28	1360-1362	to	_
7-29	1363-1370	neutral	_
7-30	1371-1375	cues	_
7-31	1376-1379	and	_
7-32	1380-1384	dACC	_
7-33	1385-1388	Glu	_
7-34	1389-1390	(	_
7-35	1390-1391	r	_
7-36	1392-1393	=	_
7-37	1394-1398	0.56	_
7-38	1398-1399	,	_
7-39	1400-1401	p	_
7-40	1402-1403	<	_
7-41	1404-1408	0.02	_
7-42	1408-1409	)	_
7-43	1409-1410	.	_

#Text=This finding was confirmed in the independent replication cohort (r = 0.64, p < 0.02).
8-1	1411-1415	This	_
8-2	1416-1423	finding	_
8-3	1424-1427	was	_
8-4	1428-1437	confirmed	_
8-5	1438-1440	in	_
8-6	1441-1444	the	_
8-7	1445-1456	independent	_
8-8	1457-1468	replication	_
8-9	1469-1475	cohort	_
8-10	1476-1477	(	_
8-11	1477-1478	r	_
8-12	1479-1480	=	_
8-13	1481-1485	0.64	_
8-14	1485-1486	,	_
8-15	1487-1488	p	_
8-16	1489-1490	<	_
8-17	1491-1495	0.02	_
8-18	1495-1496	)	_
8-19	1496-1497	.	_

#Text=Conclusions
#Text=The current findings confirm that the DMN is less suppressed when smokers view smoking relative to neutral cues, suggesting that smoking cues engage self-relevant processing.
9-1	1498-1509	Conclusions	_
9-2	1510-1513	The	_
9-3	1514-1521	current	_
9-4	1522-1530	findings	_
9-5	1531-1538	confirm	_
9-6	1539-1543	that	_
9-7	1544-1547	the	_
9-8	1548-1551	DMN	_
9-9	1552-1554	is	_
9-10	1555-1559	less	_
9-11	1560-1570	suppressed	_
9-12	1571-1575	when	_
9-13	1576-1583	smokers	_
9-14	1584-1588	view	_
9-15	1589-1596	smoking	_
9-16	1597-1605	relative	_
9-17	1606-1608	to	_
9-18	1609-1616	neutral	_
9-19	1617-1621	cues	_
9-20	1621-1622	,	_
9-21	1623-1633	suggesting	_
9-22	1634-1638	that	_
9-23	1639-1646	smoking	_
9-24	1647-1651	cues	_
9-25	1652-1658	engage	_
9-26	1659-1672	self-relevant	_
9-27	1673-1683	processing	_
9-28	1683-1684	.	_

#Text=Furthermore, these results indicate that dACC Glu is associated with enhanced DMN engagement when nicotine-dependent individuals are exposed to self-relevant smoking cues.
#Text=1.
10-1	1685-1696	Furthermore	_
10-2	1696-1697	,	_
10-3	1698-1703	these	_
10-4	1704-1711	results	_
10-5	1712-1720	indicate	_
10-6	1721-1725	that	_
10-7	1726-1730	dACC	_
10-8	1731-1734	Glu	_
10-9	1735-1737	is	_
10-10	1738-1748	associated	_
10-11	1749-1753	with	_
10-12	1754-1762	enhanced	_
10-13	1763-1766	DMN	_
10-14	1767-1777	engagement	_
10-15	1778-1782	when	_
10-16	1783-1801	nicotine-dependent	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse
10-17	1802-1813	individuals	_
10-18	1814-1817	are	_
10-19	1818-1825	exposed	_
10-20	1826-1828	to	_
10-21	1829-1842	self-relevant	_
10-22	1843-1850	smoking	_
10-23	1851-1855	cues	_
10-24	1855-1856	.	_
10-25	1857-1858	1	_
10-26	1858-1859	.	_

#Text=INTRODUCTION
#Text=Smoking cues are highly relevant for nicotine dependent individuals.
11-1	1860-1872	INTRODUCTION	_
11-2	1873-1880	Smoking	_
11-3	1881-1885	cues	_
11-4	1886-1889	are	_
11-5	1890-1896	highly	_
11-6	1897-1905	relevant	_
11-7	1906-1909	for	_
11-8	1910-1918	nicotine	_
11-9	1919-1928	dependent	_
11-10	1929-1940	individuals	_
11-11	1940-1941	.	_

#Text=For tobacco smokers, these cues have been associated with the rewarding effects of nicotine, signal the potential end of withdrawal symptoms, and have the ability to motivate continued drug use.
12-1	1942-1945	For	_
12-2	1946-1953	tobacco	_
12-3	1954-1961	smokers	_
12-4	1961-1962	,	_
12-5	1963-1968	these	_
12-6	1969-1973	cues	_
12-7	1974-1978	have	_
12-8	1979-1983	been	_
12-9	1984-1994	associated	_
12-10	1995-1999	with	_
12-11	2000-2003	the	_
12-12	2004-2013	rewarding	_
12-13	2014-2021	effects	_
12-14	2022-2024	of	_
12-15	2025-2033	nicotine	_
12-16	2033-2034	,	_
12-17	2035-2041	signal	_
12-18	2042-2045	the	_
12-19	2046-2055	potential	_
12-20	2056-2059	end	_
12-21	2060-2062	of	_
12-22	2063-2073	withdrawal	_
12-23	2074-2082	symptoms	_
12-24	2082-2083	,	_
12-25	2084-2087	and	_
12-26	2088-2092	have	_
12-27	2093-2096	the	_
12-28	2097-2104	ability	_
12-29	2105-2107	to	_
12-30	2108-2116	motivate	_
12-31	2117-2126	continued	_
12-32	2127-2131	drug	_
12-33	2132-2135	use	_
12-34	2135-2136	.	_

#Text=Thus, it is unsurprising that cortical brain regions involved in self-relevant processing show enhanced activity when smokers view such cues.
13-1	2137-2141	Thus	_
13-2	2141-2142	,	_
13-3	2143-2145	it	_
13-4	2146-2148	is	_
13-5	2149-2161	unsurprising	_
13-6	2162-2166	that	_
13-7	2167-2175	cortical	_
13-8	2176-2181	brain	_
13-9	2182-2189	regions	_
13-10	2190-2198	involved	_
13-11	2199-2201	in	_
13-12	2202-2215	self-relevant	_
13-13	2216-2226	processing	_
13-14	2227-2231	show	_
13-15	2232-2240	enhanced	_
13-16	2241-2249	activity	_
13-17	2250-2254	when	_
13-18	2255-2262	smokers	_
13-19	2263-2267	view	_
13-20	2268-2272	such	_
13-21	2273-2277	cues	_
13-22	2277-2278	.	_

#Text=A meta-analysis showed that brain regions typically reactive to smoking cues include the medial prefrontal cortex (mPFC) extending into the rostral anterior cingulate cortex (rACC) and the precuneus (PrC) extending into the posterior cingulate cortex (PCC).
14-1	2279-2280	A	_
14-2	2281-2294	meta-analysis	_
14-3	2295-2301	showed	_
14-4	2302-2306	that	_
14-5	2307-2312	brain	_
14-6	2313-2320	regions	_
14-7	2321-2330	typically	_
14-8	2331-2339	reactive	_
14-9	2340-2342	to	_
14-10	2343-2350	smoking	_
14-11	2351-2355	cues	_
14-12	2356-2363	include	_
14-13	2364-2367	the	_
14-14	2368-2374	medial	_
14-15	2375-2385	prefrontal	_
14-16	2386-2392	cortex	_
14-17	2393-2394	(	_
14-18	2394-2398	mPFC	_
14-19	2398-2399	)	_
14-20	2400-2409	extending	_
14-21	2410-2414	into	_
14-22	2415-2418	the	_
14-23	2419-2426	rostral	_
14-24	2427-2435	anterior	_
14-25	2436-2445	cingulate	_
14-26	2446-2452	cortex	_
14-27	2453-2454	(	_
14-28	2454-2458	rACC	_
14-29	2458-2459	)	_
14-30	2460-2463	and	_
14-31	2464-2467	the	_
14-32	2468-2477	precuneus	_
14-33	2478-2479	(	_
14-34	2479-2482	PrC	_
14-35	2482-2483	)	_
14-36	2484-2493	extending	_
14-37	2494-2498	into	_
14-38	2499-2502	the	_
14-39	2503-2512	posterior	_
14-40	2513-2522	cingulate	_
14-41	2523-2529	cortex	_
14-42	2530-2531	(	_
14-43	2531-2534	PCC	_
14-44	2534-2535	)	_
14-45	2535-2536	.	_

#Text=It has been pointed out that this pattern of activation overlaps with the default mode network (DMN), which is a commonly studied network of brain regions involved in self-referential processing.
15-1	2537-2539	It	_
15-2	2540-2543	has	_
15-3	2544-2548	been	_
15-4	2549-2556	pointed	_
15-5	2557-2560	out	_
15-6	2561-2565	that	_
15-7	2566-2570	this	_
15-8	2571-2578	pattern	_
15-9	2579-2581	of	_
15-10	2582-2592	activation	_
15-11	2593-2601	overlaps	_
15-12	2602-2606	with	_
15-13	2607-2610	the	_
15-14	2611-2618	default	_
15-15	2619-2623	mode	_
15-16	2624-2631	network	_
15-17	2632-2633	(	_
15-18	2633-2636	DMN	_
15-19	2636-2637	)	_
15-20	2637-2638	,	_
15-21	2639-2644	which	_
15-22	2645-2647	is	_
15-23	2648-2649	a	_
15-24	2650-2658	commonly	_
15-25	2659-2666	studied	_
15-26	2667-2674	network	_
15-27	2675-2677	of	_
15-28	2678-2683	brain	_
15-29	2684-2691	regions	_
15-30	2692-2700	involved	_
15-31	2701-2703	in	_
15-32	2704-2720	self-referential	_
15-33	2721-2731	processing	_
15-34	2731-2732	.	_

#Text=While DMN activity is associated with cognitive processes involving an internal focus such as self-reference, when recalling one’s past, and planning one’s personal future, the DMN is typically less active during cognitive tasks that require an external focus.
16-1	2733-2738	While	_
16-2	2739-2742	DMN	_
16-3	2743-2751	activity	_
16-4	2752-2754	is	_
16-5	2755-2765	associated	_
16-6	2766-2770	with	_
16-7	2771-2780	cognitive	_
16-8	2781-2790	processes	_
16-9	2791-2800	involving	_
16-10	2801-2803	an	_
16-11	2804-2812	internal	_
16-12	2813-2818	focus	_
16-13	2819-2823	such	_
16-14	2824-2826	as	_
16-15	2827-2841	self-reference	_
16-16	2841-2842	,	_
16-17	2843-2847	when	_
16-18	2848-2857	recalling	_
16-19	2858-2861	one	_
16-20	2861-2862	’	_
16-21	2862-2863	s	_
16-22	2864-2868	past	_
16-23	2868-2869	,	_
16-24	2870-2873	and	_
16-25	2874-2882	planning	_
16-26	2883-2886	one	_
16-27	2886-2887	’	_
16-28	2887-2888	s	_
16-29	2889-2897	personal	_
16-30	2898-2904	future	_
16-31	2904-2905	,	_
16-32	2906-2909	the	_
16-33	2910-2913	DMN	_
16-34	2914-2916	is	_
16-35	2917-2926	typically	_
16-36	2927-2931	less	_
16-37	2932-2938	active	_
16-38	2939-2945	during	_
16-39	2946-2955	cognitive	_
16-40	2956-2961	tasks	_
16-41	2962-2966	that	_
16-42	2967-2974	require	_
16-43	2975-2977	an	_
16-44	2978-2986	external	_
16-45	2987-2992	focus	_
16-46	2992-2993	.	_

#Text=Some evidence suggests that cortical midline glutamate (Glu) may play a role in regulating DMN suppression during externally focused cognition.
17-1	2994-2998	Some	_
17-2	2999-3007	evidence	_
17-3	3008-3016	suggests	_
17-4	3017-3021	that	_
17-5	3022-3030	cortical	_
17-6	3031-3038	midline	_
17-7	3039-3048	glutamate	_
17-8	3049-3050	(	_
17-9	3050-3053	Glu	_
17-10	3053-3054	)	_
17-11	3055-3058	may	_
17-12	3059-3063	play	_
17-13	3064-3065	a	_
17-14	3066-3070	role	_
17-15	3071-3073	in	_
17-16	3074-3084	regulating	_
17-17	3085-3088	DMN	_
17-18	3089-3100	suppression	_
17-19	3101-3107	during	_
17-20	3108-3118	externally	_
17-21	3119-3126	focused	_
17-22	3127-3136	cognition	_
17-23	3136-3137	.	_

#Text=Specifically, a high level of Glu in the PCC/precuneus is associated with reduced task-related DMN suppression.
18-1	3138-3150	Specifically	_
18-2	3150-3151	,	_
18-3	3152-3153	a	_
18-4	3154-3158	high	_
18-5	3159-3164	level	_
18-6	3165-3167	of	_
18-7	3168-3171	Glu	_
18-8	3172-3174	in	_
18-9	3175-3178	the	_
18-10	3179-3182	PCC	_
18-11	3182-3183	/	_
18-12	3183-3192	precuneus	_
18-13	3193-3195	is	_
18-14	3196-3206	associated	_
18-15	3207-3211	with	_
18-16	3212-3219	reduced	_
18-17	3220-3232	task-related	_
18-18	3233-3236	DMN	_
18-19	3237-3248	suppression	_
18-20	3248-3249	.	_

#Text=Further, dorsal anterior cingulate (dACC) Glu may modulate task-related activity in regions of the DMN during cognitive control.
19-1	3250-3257	Further	_
19-2	3257-3258	,	_
19-3	3259-3265	dorsal	_
19-4	3266-3274	anterior	_
19-5	3275-3284	cingulate	_
19-6	3285-3286	(	_
19-7	3286-3290	dACC	_
19-8	3290-3291	)	_
19-9	3292-3295	Glu	_
19-10	3296-3299	may	_
19-11	3300-3308	modulate	_
19-12	3309-3321	task-related	_
19-13	3322-3330	activity	_
19-14	3331-3333	in	_
19-15	3334-3341	regions	_
19-16	3342-3344	of	_
19-17	3345-3348	the	_
19-18	3349-3352	DMN	_
19-19	3353-3359	during	_
19-20	3360-3369	cognitive	_
19-21	3370-3377	control	_
19-22	3377-3378	.	_

#Text=This concept is consistent with nicotine dependence research as the smoking cessation therapy varenicline not only facilitated DMN suppression during externally focused cognition, but also reduced dACC Glu.
20-1	3379-3383	This	_
20-2	3384-3391	concept	_
20-3	3392-3394	is	_
20-4	3395-3405	consistent	_
20-5	3406-3410	with	_
20-6	3411-3419	nicotine	_
20-7	3420-3430	dependence	_
20-8	3431-3439	research	_
20-9	3440-3442	as	_
20-10	3443-3446	the	_
20-11	3447-3454	smoking	_
20-12	3455-3464	cessation	_
20-13	3465-3472	therapy	_
20-14	3473-3484	varenicline	_
20-15	3485-3488	not	_
20-16	3489-3493	only	_
20-17	3494-3505	facilitated	_
20-18	3506-3509	DMN	_
20-19	3510-3521	suppression	_
20-20	3522-3528	during	_
20-21	3529-3539	externally	_
20-22	3540-3547	focused	_
20-23	3548-3557	cognition	_
20-24	3557-3558	,	_
20-25	3559-3562	but	_
20-26	3563-3567	also	_
20-27	3568-3575	reduced	_
20-28	3576-3580	dACC	_
20-29	3581-3584	Glu	_
20-30	3584-3585	.	_

#Text=The relationship between dACC Glu and DMN activity is particularly relevant considering the fact that the dACC is a primary hub of the salience network (SN), which is thought to guide task-specific suppression or engagement of the DMN by identifying the most relevant internal or extrapersonal stimuli.
21-1	3586-3589	The	_
21-2	3590-3602	relationship	_
21-3	3603-3610	between	_
21-4	3611-3615	dACC	_
21-5	3616-3619	Glu	_
21-6	3620-3623	and	_
21-7	3624-3627	DMN	_
21-8	3628-3636	activity	_
21-9	3637-3639	is	_
21-10	3640-3652	particularly	_
21-11	3653-3661	relevant	_
21-12	3662-3673	considering	_
21-13	3674-3677	the	_
21-14	3678-3682	fact	_
21-15	3683-3687	that	_
21-16	3688-3691	the	_
21-17	3692-3696	dACC	_
21-18	3697-3699	is	_
21-19	3700-3701	a	_
21-20	3702-3709	primary	_
21-21	3710-3713	hub	_
21-22	3714-3716	of	_
21-23	3717-3720	the	_
21-24	3721-3729	salience	_
21-25	3730-3737	network	_
21-26	3738-3739	(	_
21-27	3739-3741	SN	_
21-28	3741-3742	)	_
21-29	3742-3743	,	_
21-30	3744-3749	which	_
21-31	3750-3752	is	_
21-32	3753-3760	thought	_
21-33	3761-3763	to	_
21-34	3764-3769	guide	_
21-35	3770-3783	task-specific	_
21-36	3784-3795	suppression	_
21-37	3796-3798	or	_
21-38	3799-3809	engagement	_
21-39	3810-3812	of	_
21-40	3813-3816	the	_
21-41	3817-3820	DMN	_
21-42	3821-3823	by	_
21-43	3824-3835	identifying	_
21-44	3836-3839	the	_
21-45	3840-3844	most	_
21-46	3845-3853	relevant	_
21-47	3854-3862	internal	_
21-48	3863-3865	or	_
21-49	3866-3879	extrapersonal	_
21-50	3880-3887	stimuli	_
21-51	3887-3888	.	_

#Text=For instance, SN brain regions, which include the dACC and insula, co-activate with the DMN during tasks requiring an internal focus such as autobiographical planning, and these regions are strongly implicated in smoking cue-reactivity, craving, and dependence severity.
22-1	3889-3892	For	_
22-2	3893-3901	instance	_
22-3	3901-3902	,	_
22-4	3903-3905	SN	_
22-5	3906-3911	brain	_
22-6	3912-3919	regions	_
22-7	3919-3920	,	_
22-8	3921-3926	which	_
22-9	3927-3934	include	_
22-10	3935-3938	the	_
22-11	3939-3943	dACC	_
22-12	3944-3947	and	_
22-13	3948-3954	insula	_
22-14	3954-3955	,	_
22-15	3956-3967	co-activate	_
22-16	3968-3972	with	_
22-17	3973-3976	the	_
22-18	3977-3980	DMN	_
22-19	3981-3987	during	_
22-20	3988-3993	tasks	_
22-21	3994-4003	requiring	_
22-22	4004-4006	an	_
22-23	4007-4015	internal	_
22-24	4016-4021	focus	_
22-25	4022-4026	such	_
22-26	4027-4029	as	_
22-27	4030-4046	autobiographical	_
22-28	4047-4055	planning	_
22-29	4055-4056	,	_
22-30	4057-4060	and	_
22-31	4061-4066	these	_
22-32	4067-4074	regions	_
22-33	4075-4078	are	_
22-34	4079-4087	strongly	_
22-35	4088-4098	implicated	_
22-36	4099-4101	in	_
22-37	4102-4109	smoking	_
22-38	4110-4124	cue-reactivity	_
22-39	4124-4125	,	_
22-40	4126-4133	craving	_
22-41	4133-4134	,	_
22-42	4135-4138	and	_
22-43	4139-4149	dependence	_
22-44	4150-4158	severity	_
22-45	4158-4159	.	_

#Text=It is still unclear whether DMN reactivity to smoking cues is related to the level of dACC Glu.
23-1	4160-4162	It	_
23-2	4163-4165	is	_
23-3	4166-4171	still	_
23-4	4172-4179	unclear	_
23-5	4180-4187	whether	_
23-6	4188-4191	DMN	_
23-7	4192-4202	reactivity	_
23-8	4203-4205	to	_
23-9	4206-4213	smoking	_
23-10	4214-4218	cues	_
23-11	4219-4221	is	_
23-12	4222-4229	related	_
23-13	4230-4232	to	_
23-14	4233-4236	the	_
23-15	4237-4242	level	_
23-16	4243-4245	of	_
23-17	4246-4250	dACC	_
23-18	4251-4254	Glu	_
23-19	4254-4255	.	_

#Text=Such a finding would support the role of dACC Glu in the self-referential processing of smoking cues, which may influence the impact these cues have on behavior.
24-1	4256-4260	Such	_
24-2	4261-4262	a	_
24-3	4263-4270	finding	_
24-4	4271-4276	would	_
24-5	4277-4284	support	_
24-6	4285-4288	the	_
24-7	4289-4293	role	_
24-8	4294-4296	of	_
24-9	4297-4301	dACC	_
24-10	4302-4305	Glu	_
24-11	4306-4308	in	_
24-12	4309-4312	the	_
24-13	4313-4329	self-referential	_
24-14	4330-4340	processing	_
24-15	4341-4343	of	_
24-16	4344-4351	smoking	_
24-17	4352-4356	cues	_
24-18	4356-4357	,	_
24-19	4358-4363	which	_
24-20	4364-4367	may	_
24-21	4368-4377	influence	_
24-22	4378-4381	the	_
24-23	4382-4388	impact	_
24-24	4389-4394	these	_
24-25	4395-4399	cues	_
24-26	4400-4404	have	_
24-27	4405-4407	on	_
24-28	4408-4416	behavior	_
24-29	4416-4417	.	_

#Text=We hypothesized a positive association between dACC Glu and DMN activity during smoking cue-reactivity due to the self-relevant nature of these stimuli.
25-1	4418-4420	We	_
25-2	4421-4433	hypothesized	_
25-3	4434-4435	a	_
25-4	4436-4444	positive	_
25-5	4445-4456	association	_
25-6	4457-4464	between	_
25-7	4465-4469	dACC	_
25-8	4470-4473	Glu	_
25-9	4474-4477	and	_
25-10	4478-4481	DMN	_
25-11	4482-4490	activity	_
25-12	4491-4497	during	_
25-13	4498-4505	smoking	_
25-14	4506-4520	cue-reactivity	_
25-15	4521-4524	due	_
25-16	4525-4527	to	_
25-17	4528-4531	the	_
25-18	4532-4545	self-relevant	_
25-19	4546-4552	nature	_
25-20	4553-4555	of	_
25-21	4556-4561	these	_
25-22	4562-4569	stimuli	_
25-23	4569-4570	.	_

#Text=This conjecture is supported by the prior work linking heightened cortical midline Glu and disrupted suppression of DMN regions during tasks requiring external focus.
26-1	4571-4575	This	_
26-2	4576-4586	conjecture	_
26-3	4587-4589	is	_
26-4	4590-4599	supported	_
26-5	4600-4602	by	_
26-6	4603-4606	the	_
26-7	4607-4612	prior	_
26-8	4613-4617	work	_
26-9	4618-4625	linking	_
26-10	4626-4636	heightened	_
26-11	4637-4645	cortical	_
26-12	4646-4653	midline	_
26-13	4654-4657	Glu	_
26-14	4658-4661	and	_
26-15	4662-4671	disrupted	_
26-16	4672-4683	suppression	_
26-17	4684-4686	of	_
26-18	4687-4690	DMN	_
26-19	4691-4698	regions	_
26-20	4699-4705	during	_
26-21	4706-4711	tasks	_
26-22	4712-4721	requiring	_
26-23	4722-4730	external	_
26-24	4731-4736	focus	_
26-25	4736-4737	.	_

#Text=Additionally, structural integrity of the salience network impacts DMN function (Bonnelle et al., 2012), which begs the question of whether neurochemical variation in the salience network also impacts DMN function.
27-1	4738-4750	Additionally	_
27-2	4750-4751	,	_
27-3	4752-4762	structural	_
27-4	4763-4772	integrity	_
27-5	4773-4775	of	_
27-6	4776-4779	the	_
27-7	4780-4788	salience	_
27-8	4789-4796	network	_
27-9	4797-4804	impacts	_
27-10	4805-4808	DMN	_
27-11	4809-4817	function	_
27-12	4818-4819	(	_
27-13	4819-4827	Bonnelle	_
27-14	4828-4830	et	_
27-15	4831-4833	al	_
27-16	4833-4834	.	_
27-17	4834-4835	,	_
27-18	4836-4840	2012	_
27-19	4840-4841	)	_
27-20	4841-4842	,	_
27-21	4843-4848	which	_
27-22	4849-4853	begs	_
27-23	4854-4857	the	_
27-24	4858-4866	question	_
27-25	4867-4869	of	_
27-26	4870-4877	whether	_
27-27	4878-4891	neurochemical	_
27-28	4892-4901	variation	_
27-29	4902-4904	in	_
27-30	4905-4908	the	_
27-31	4909-4917	salience	_
27-32	4918-4925	network	_
27-33	4926-4930	also	_
27-34	4931-4938	impacts	_
27-35	4939-4942	DMN	_
27-36	4943-4951	function	_
27-37	4951-4952	.	_

#Text=To address this question we measured dACC Glu using magnetic resonance spectroscopy (MRS) and brain reactivity to smoking cues using functional magnetic resonance imaging (fMRI) in two previously published independent samples of nicotine dependent individuals.
#Text=2.
28-1	4953-4955	To	_
28-2	4956-4963	address	_
28-3	4964-4968	this	_
28-4	4969-4977	question	_
28-5	4978-4980	we	_
28-6	4981-4989	measured	_
28-7	4990-4994	dACC	_
28-8	4995-4998	Glu	_
28-9	4999-5004	using	_
28-10	5005-5013	magnetic	_
28-11	5014-5023	resonance	_
28-12	5024-5036	spectroscopy	_
28-13	5037-5038	(	_
28-14	5038-5041	MRS	_
28-15	5041-5042	)	_
28-16	5043-5046	and	_
28-17	5047-5052	brain	_
28-18	5053-5063	reactivity	_
28-19	5064-5066	to	_
28-20	5067-5074	smoking	_
28-21	5075-5079	cues	_
28-22	5080-5085	using	_
28-23	5086-5096	functional	_
28-24	5097-5105	magnetic	_
28-25	5106-5115	resonance	_
28-26	5116-5123	imaging	_
28-27	5124-5125	(	_
28-28	5125-5129	fMRI	_
28-29	5129-5130	)	_
28-30	5131-5133	in	_
28-31	5134-5137	two	_
28-32	5138-5148	previously	_
28-33	5149-5158	published	_
28-34	5159-5170	independent	_
28-35	5171-5178	samples	_
28-36	5179-5181	of	_
28-37	5182-5190	nicotine	_
28-38	5191-5200	dependent	_
28-39	5201-5212	individuals	_
28-40	5212-5213	.	_
28-41	5214-5215	2	_
28-42	5215-5216	.	_

#Text=MATERIALS AND METHODS
#Text=2.1 Participants
#Text=Data were evaluated in two independent samples of individuals who participated in all study elements at McLean Hospital’s Imaging Center.
29-1	5217-5226	MATERIALS	http://www.case.edu/ProvCaRe/provcare#StudyMethod[3]
29-2	5227-5230	AND	http://www.case.edu/ProvCaRe/provcare#StudyMethod[3]
29-3	5231-5238	METHODS	http://www.case.edu/ProvCaRe/provcare#StudyMethod[3]
29-4	5239-5242	2.1	_
29-5	5243-5255	Participants	_
29-6	5256-5260	Data	_
29-7	5261-5265	were	_
29-8	5266-5275	evaluated	_
29-9	5276-5278	in	_
29-10	5279-5282	two	_
29-11	5283-5294	independent	_
29-12	5295-5302	samples	_
29-13	5303-5305	of	_
29-14	5306-5317	individuals	_
29-15	5318-5321	who	_
29-16	5322-5334	participated	_
29-17	5335-5337	in	_
29-18	5338-5341	all	_
29-19	5342-5347	study	_
29-20	5348-5356	elements	_
29-21	5357-5359	at	_
29-22	5360-5366	McLean	_
29-23	5367-5375	Hospital	_
29-24	5375-5376	’	_
29-25	5376-5377	s	_
29-26	5378-5385	Imaging	_
29-27	5386-5392	Center	_
29-28	5392-5393	.	_

#Text=The primary analysis was conducted using data from our prior work where nicotine dependent individuals were exposed to smoking vs. neutral cues, while our replication cohort was exposed to smoking vs. neutral cues within the context of a working memory task.
30-1	5394-5397	The	_
30-2	5398-5405	primary	_
30-3	5406-5414	analysis	_
30-4	5415-5418	was	_
30-5	5419-5428	conducted	_
30-6	5429-5434	using	_
30-7	5435-5439	data	_
30-8	5440-5444	from	_
30-9	5445-5448	our	_
30-10	5449-5454	prior	_
30-11	5455-5459	work	_
30-12	5460-5465	where	_
30-13	5466-5474	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[4]
30-14	5475-5484	dependent	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[4]
30-15	5485-5496	individuals	_
30-16	5497-5501	were	_
30-17	5502-5509	exposed	_
30-18	5510-5512	to	_
30-19	5513-5520	smoking	_
30-20	5521-5523	vs	_
30-21	5523-5524	.	_
30-22	5525-5532	neutral	_
30-23	5533-5537	cues	_
30-24	5537-5538	,	_
30-25	5539-5544	while	_
30-26	5545-5548	our	_
30-27	5549-5560	replication	_
30-28	5561-5567	cohort	_
30-29	5568-5571	was	_
30-30	5572-5579	exposed	_
30-31	5580-5582	to	_
30-32	5583-5590	smoking	_
30-33	5591-5593	vs	_
30-34	5593-5594	.	_
30-35	5595-5602	neutral	_
30-36	5603-5607	cues	_
30-37	5608-5614	within	_
30-38	5615-5618	the	_
30-39	5619-5626	context	_
30-40	5627-5629	of	_
30-41	5630-5631	a	_
30-42	5632-5639	working	http://maven.renci.org/NeuroBridge/neurobridge#WorkingMemoryTask[5]
30-43	5640-5646	memory	http://maven.renci.org/NeuroBridge/neurobridge#WorkingMemoryTask[5]
30-44	5647-5651	task	http://maven.renci.org/NeuroBridge/neurobridge#WorkingMemoryTask[5]
30-45	5651-5652	.	_

#Text=Our primary cohort was comprised of 18 nicotine-dependent individuals aged 31.4 ± 1.4 years (10 women / 8 men), while our replication cohort was comprised of 14 nicotine-dependent individuals aged 26 ± 1.22 years (8 women / 6 men).
31-1	5653-5656	Our	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-2	5657-5664	primary	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-3	5665-5671	cohort	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-4	5672-5675	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-5	5676-5685	comprised	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-6	5686-5688	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-7	5689-5691	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-8	5692-5710	nicotine-dependent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[7]
31-9	5711-5722	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-10	5723-5727	aged	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-11	5728-5732	31.4	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-12	5733-5734	±	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-13	5735-5738	1.4	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-14	5739-5744	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-15	5745-5746	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-16	5746-5748	10	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-17	5749-5754	women	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-18	5755-5756	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-19	5757-5758	8	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-20	5759-5762	men	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-21	5762-5763	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-22	5763-5764	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-23	5765-5770	while	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-24	5771-5774	our	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-25	5775-5786	replication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-26	5787-5793	cohort	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-27	5794-5797	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-28	5798-5807	comprised	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-29	5808-5810	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-30	5811-5813	14	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-31	5814-5832	nicotine-dependent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[8]
31-32	5833-5844	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-33	5845-5849	aged	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-34	5850-5852	26	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-35	5853-5854	±	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-36	5855-5859	1.22	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-37	5860-5865	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-38	5866-5867	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-39	5867-5868	8	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-40	5869-5874	women	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-41	5875-5876	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-42	5877-5878	6	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-43	5879-5882	men	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-44	5882-5883	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
31-45	5883-5884	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]

#Text=Both cohorts were moderately nicotine dependent as indicated by the Fagerstrom test of nicotine dependence and reported smoking ≥10 cig/day over the last 6 months.
32-1	5885-5889	Both	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
32-2	5890-5897	cohorts	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
32-3	5898-5902	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
32-4	5903-5913	moderately	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
32-5	5914-5922	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[9]
32-6	5923-5932	dependent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[9]
32-7	5933-5935	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
32-8	5936-5945	indicated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
32-9	5946-5948	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
32-10	5949-5952	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
32-11	5953-5963	Fagerstrom	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[10]
32-12	5964-5968	test	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[10]
32-13	5969-5971	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[10]
32-14	5972-5980	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[10]
32-15	5981-5991	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[10]
32-16	5992-5995	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
32-17	5996-6004	reported	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
32-18	6005-6012	smoking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
32-19	6013-6014	≥	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
32-20	6014-6016	10	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
32-21	6017-6020	cig	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
32-22	6020-6021	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
32-23	6021-6024	day	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
32-24	6025-6029	over	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
32-25	6030-6033	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
32-26	6034-6038	last	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
32-27	6039-6040	6	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
32-28	6041-6047	months	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
32-29	6047-6048	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]

#Text=Smoking status was confirmed by expired carbon monoxide immediately upon entering the study (CO: Micro Smokerlyzer II, Bedfont Scientific Instruments, Kent UK).
33-1	6049-6056	Smoking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
33-2	6057-6063	status	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
33-3	6064-6067	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
33-4	6068-6077	confirmed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
33-5	6078-6080	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
33-6	6081-6088	expired	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
33-7	6089-6095	carbon	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
33-8	6096-6104	monoxide	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
33-9	6105-6116	immediately	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
33-10	6117-6121	upon	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
33-11	6122-6130	entering	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
33-12	6131-6134	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
33-13	6135-6140	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
33-14	6141-6142	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
33-15	6142-6144	CO	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
33-16	6144-6145	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
33-17	6146-6151	Micro	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
33-18	6152-6163	Smokerlyzer	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
33-19	6164-6166	II	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
33-20	6166-6167	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
33-21	6168-6175	Bedfont	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
33-22	6176-6186	Scientific	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
33-23	6187-6198	Instruments	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
33-24	6198-6199	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
33-25	6200-6204	Kent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
33-26	6205-6207	UK	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
33-27	6207-6208	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
33-28	6208-6209	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]

#Text=For full demographics see table 1.
34-1	6210-6213	For	_
34-2	6214-6218	full	_
34-3	6219-6231	demographics	_
34-4	6232-6235	see	_
34-5	6236-6241	table	_
34-6	6242-6243	1	_
34-7	6243-6244	.	_

#Text=The structured clinical interview for DSM IV-TR was used to exclude participants with the following conditions: organic mental disorder, bipolar disorder, and schizophrenia spectrum disorder.
35-1	6245-6248	The	_
35-2	6249-6259	structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[11]
35-3	6260-6268	clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[11]
35-4	6269-6278	interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[11]
35-5	6279-6282	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[11]
35-6	6283-6286	DSM	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[11]
35-7	6287-6292	IV-TR	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[11]
35-8	6293-6296	was	_
35-9	6297-6301	used	_
35-10	6302-6304	to	_
35-11	6305-6312	exclude	_
35-12	6313-6325	participants	_
35-13	6326-6330	with	_
35-14	6331-6334	the	_
35-15	6335-6344	following	_
35-16	6345-6355	conditions	_
35-17	6355-6356	:	_
35-18	6357-6364	organic	_
35-19	6365-6371	mental	_
35-20	6372-6380	disorder	_
35-21	6380-6381	,	_
35-22	6382-6389	bipolar	_
35-23	6390-6398	disorder	_
35-24	6398-6399	,	_
35-25	6400-6403	and	_
35-26	6404-6417	schizophrenia	_
35-27	6418-6426	spectrum	_
35-28	6427-6435	disorder	_
35-29	6435-6436	.	_

#Text=Participants also were excluded for a substance use disorder other than nicotine dependence, current depressive episode, psychotropic drug use, pregnancy, and were required to have a zero blood alcohol level as measured by a breath sample (Alco-Sensor IV, Intoximeters, St Louis, MO).
36-1	6437-6449	Participants	_
36-2	6450-6454	also	_
36-3	6455-6459	were	_
36-4	6460-6468	excluded	_
36-5	6469-6472	for	_
36-6	6473-6474	a	_
36-7	6475-6484	substance	_
36-8	6485-6488	use	_
36-9	6489-6497	disorder	_
36-10	6498-6503	other	_
36-11	6504-6508	than	_
36-12	6509-6517	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[12]
36-13	6518-6528	dependence	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[12]
36-14	6528-6529	,	_
36-15	6530-6537	current	_
36-16	6538-6548	depressive	_
36-17	6549-6556	episode	_
36-18	6556-6557	,	_
36-19	6558-6570	psychotropic	_
36-20	6571-6575	drug	_
36-21	6576-6579	use	_
36-22	6579-6580	,	_
36-23	6581-6590	pregnancy	_
36-24	6590-6591	,	_
36-25	6592-6595	and	_
36-26	6596-6600	were	_
36-27	6601-6609	required	_
36-28	6610-6612	to	_
36-29	6613-6617	have	_
36-30	6618-6619	a	_
36-31	6620-6624	zero	_
36-32	6625-6630	blood	_
36-33	6631-6638	alcohol	_
36-34	6639-6644	level	_
36-35	6645-6647	as	_
36-36	6648-6656	measured	_
36-37	6657-6659	by	_
36-38	6660-6661	a	_
36-39	6662-6668	breath	_
36-40	6669-6675	sample	_
36-41	6676-6677	(	_
36-42	6677-6688	Alco-Sensor	_
36-43	6689-6691	IV	_
36-44	6691-6692	,	_
36-45	6693-6705	Intoximeters	_
36-46	6705-6706	,	_
36-47	6707-6709	St	_
36-48	6710-6715	Louis	_
36-49	6715-6716	,	_
36-50	6717-6719	MO	_
36-51	6719-6720	)	_
36-52	6720-6721	.	_

#Text=All participants gave verbal and written consent prior to participating in any study procedures and this research was approved by the Partners Human Research Committee, which is the institutional review board of Partners Healthcare hospitals.
#Text=2.2 Functional Neuroimaging
#Text=To standardize the time since a cigarette was last smoked relative to all study procedures, all participants in both cohorts smoked one of their own cigarettes after signing the informed consent approximately 1.5 hours prior to MR scanning.
37-1	6722-6725	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
37-2	6726-6738	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
37-3	6739-6743	gave	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
37-4	6744-6750	verbal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
37-5	6751-6754	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
37-6	6755-6762	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
37-7	6763-6770	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
37-8	6771-6776	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
37-9	6777-6779	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
37-10	6780-6793	participating	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
37-11	6794-6796	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
37-12	6797-6800	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
37-13	6801-6806	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
37-14	6807-6817	procedures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
37-15	6818-6821	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
37-16	6822-6826	this	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
37-17	6827-6835	research	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
37-18	6836-6839	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
37-19	6840-6848	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
37-20	6849-6851	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
37-21	6852-6855	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
37-22	6856-6864	Partners	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
37-23	6865-6870	Human	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
37-24	6871-6879	Research	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
37-25	6880-6889	Committee	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
37-26	6889-6890	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
37-27	6891-6896	which	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
37-28	6897-6899	is	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
37-29	6900-6903	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
37-30	6904-6917	institutional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
37-31	6918-6924	review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
37-32	6925-6930	board	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
37-33	6931-6933	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
37-34	6934-6942	Partners	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
37-35	6943-6953	Healthcare	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
37-36	6954-6963	hospitals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
37-37	6963-6964	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
37-38	6965-6968	2.2	_
37-39	6969-6979	Functional	_
37-40	6980-6992	Neuroimaging	_
37-41	6993-6995	To	_
37-42	6996-7007	standardize	_
37-43	7008-7011	the	_
37-44	7012-7016	time	_
37-45	7017-7022	since	_
37-46	7023-7024	a	_
37-47	7025-7034	cigarette	_
37-48	7035-7038	was	_
37-49	7039-7043	last	_
37-50	7044-7050	smoked	_
37-51	7051-7059	relative	_
37-52	7060-7062	to	_
37-53	7063-7066	all	_
37-54	7067-7072	study	_
37-55	7073-7083	procedures	_
37-56	7083-7084	,	_
37-57	7085-7088	all	_
37-58	7089-7101	participants	_
37-59	7102-7104	in	_
37-60	7105-7109	both	_
37-61	7110-7117	cohorts	_
37-62	7118-7124	smoked	_
37-63	7125-7128	one	_
37-64	7129-7131	of	_
37-65	7132-7137	their	_
37-66	7138-7141	own	_
37-67	7142-7152	cigarettes	_
37-68	7153-7158	after	_
37-69	7159-7166	signing	_
37-70	7167-7170	the	_
37-71	7171-7179	informed	_
37-72	7180-7187	consent	_
37-73	7188-7201	approximately	_
37-74	7202-7205	1.5	_
37-75	7206-7211	hours	_
37-76	7212-7217	prior	_
37-77	7218-7220	to	_
37-78	7221-7223	MR	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
37-79	7224-7232	scanning	_
37-80	7232-7233	.	_

#Text=Expired carbon monoxide was measured immediately before and after scanning.
38-1	7234-7241	Expired	_
38-2	7242-7248	carbon	_
38-3	7249-7257	monoxide	_
38-4	7258-7261	was	_
38-5	7262-7270	measured	_
38-6	7271-7282	immediately	_
38-7	7283-7289	before	_
38-8	7290-7293	and	_
38-9	7294-7299	after	_
38-10	7300-7308	scanning	_
38-11	7308-7309	.	_

#Text=Subjective craving to smoking and neutral images also was assessed after scanning by asking participants to rate how much craving they experienced when viewing each image on a five-point scale.
39-1	7310-7320	Subjective	_
39-2	7321-7328	craving	_
39-3	7329-7331	to	_
39-4	7332-7339	smoking	_
39-5	7340-7343	and	_
39-6	7344-7351	neutral	_
39-7	7352-7358	images	_
39-8	7359-7363	also	_
39-9	7364-7367	was	_
39-10	7368-7376	assessed	_
39-11	7377-7382	after	_
39-12	7383-7391	scanning	_
39-13	7392-7394	by	_
39-14	7395-7401	asking	_
39-15	7402-7414	participants	_
39-16	7415-7417	to	_
39-17	7418-7422	rate	_
39-18	7423-7426	how	_
39-19	7427-7431	much	_
39-20	7432-7439	craving	_
39-21	7440-7444	they	_
39-22	7445-7456	experienced	_
39-23	7457-7461	when	_
39-24	7462-7469	viewing	_
39-25	7470-7474	each	_
39-26	7475-7480	image	_
39-27	7481-7483	on	_
39-28	7484-7485	a	_
39-29	7486-7496	five-point	_
39-30	7497-7502	scale	_
39-31	7502-7503	.	_

#Text=Acquisition parameters were identical between cohorts.
40-1	7504-7515	Acquisition	_
40-2	7516-7526	parameters	_
40-3	7527-7531	were	_
40-4	7532-7541	identical	_
40-5	7542-7549	between	_
40-6	7550-7557	cohorts	_
40-7	7557-7558	.	_

#Text=Imaging was completed on a Siemens Trio 3T (2.89T) scanner (Erlangen, Germany) using a 32-channel head coil.
41-1	7559-7566	Imaging	_
41-2	7567-7570	was	_
41-3	7571-7580	completed	_
41-4	7581-7583	on	_
41-5	7584-7585	a	_
41-6	7586-7593	Siemens	_
41-7	7594-7598	Trio	_
41-8	7599-7601	3T	_
41-9	7602-7603	(	_
41-10	7603-7608	2.89T	_
41-11	7608-7609	)	_
41-12	7610-7617	scanner	_
41-13	7618-7619	(	_
41-14	7619-7627	Erlangen	_
41-15	7627-7628	,	_
41-16	7629-7636	Germany	_
41-17	7636-7637	)	_
41-18	7638-7643	using	_
41-19	7644-7645	a	_
41-20	7646-7648	32	_
41-21	7648-7649	-	_
41-22	7649-7656	channel	_
41-23	7657-7661	head	_
41-24	7662-7666	coil	_
41-25	7666-7667	.	_

#Text=Multiecho multi-planar rapidly acquired gradient echostructural images were acquired with the following parameters (TR = 2.1 s, TE = 3.3 ms, slices = 128, matrix = 256 × 256, flip angle 7 degrees, resolution = 1.0 × 1.0 × 1.33 mm).
42-1	7668-7677	Multiecho	_
42-2	7678-7690	multi-planar	_
42-3	7691-7698	rapidly	_
42-4	7699-7707	acquired	_
42-5	7708-7716	gradient	_
42-6	7717-7731	echostructural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[14]
42-7	7732-7738	images	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[14]
42-8	7739-7743	were	_
42-9	7744-7752	acquired	_
42-10	7753-7757	with	_
42-11	7758-7761	the	_
42-12	7762-7771	following	_
42-13	7772-7782	parameters	_
42-14	7783-7784	(	_
42-15	7784-7786	TR	_
42-16	7787-7788	=	_
42-17	7789-7792	2.1	_
42-18	7793-7794	s	_
42-19	7794-7795	,	_
42-20	7796-7798	TE	_
42-21	7799-7800	=	_
42-22	7801-7804	3.3	_
42-23	7805-7807	ms	_
42-24	7807-7808	,	_
42-25	7809-7815	slices	_
42-26	7816-7817	=	_
42-27	7818-7821	128	_
42-28	7821-7822	,	_
42-29	7823-7829	matrix	_
42-30	7830-7831	=	_
42-31	7832-7835	256	_
42-32	7836-7837	×	_
42-33	7838-7841	256	_
42-34	7841-7842	,	_
42-35	7843-7847	flip	_
42-36	7848-7853	angle	_
42-37	7854-7855	7	_
42-38	7856-7863	degrees	_
42-39	7863-7864	,	_
42-40	7865-7875	resolution	_
42-41	7876-7877	=	_
42-42	7878-7881	1.0	_
42-43	7882-7883	×	_
42-44	7884-7887	1.0	_
42-45	7888-7889	×	_
42-46	7890-7894	1.33	_
42-47	7895-7897	mm	_
42-48	7897-7898	)	_
42-49	7898-7899	.	_

#Text=Task-related fMRI was collected using a gradient echo echoplanar sequence with the following parameters (TR = 2 s, TE = 30 ms, flip angle = 75 degrees, slices = 37, distance factor 10%, voxel size = 3.5 mm isotropic and a GRAPPA acceleration factor of 2).
#Text=2.3 Magnetic Resonance Spectroscopy
#Text=Magnetic Resonance Spectroscopy also was identical between cohorts and was collected following procedures outlined in our prior work.
43-1	7900-7912	Task-related	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[15]
43-2	7913-7917	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[15]
43-3	7918-7921	was	_
43-4	7922-7931	collected	_
43-5	7932-7937	using	_
43-6	7938-7939	a	_
43-7	7940-7948	gradient	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[16]
43-8	7949-7953	echo	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[16]
43-9	7954-7964	echoplanar	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[16]
43-10	7965-7973	sequence	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[16]
43-11	7974-7978	with	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[16]
43-12	7979-7982	the	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[16]
43-13	7983-7992	following	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[16]
43-14	7993-8003	parameters	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[16]
43-15	8004-8005	(	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[16]
43-16	8005-8007	TR	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[16]
43-17	8008-8009	=	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[16]
43-18	8010-8011	2	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[16]
43-19	8012-8013	s	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[16]
43-20	8013-8014	,	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[16]
43-21	8015-8017	TE	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[16]
43-22	8018-8019	=	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[16]
43-23	8020-8022	30	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[16]
43-24	8023-8025	ms	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[16]
43-25	8025-8026	,	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[16]
43-26	8027-8031	flip	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[16]
43-27	8032-8037	angle	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[16]
43-28	8038-8039	=	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[16]
43-29	8040-8042	75	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[16]
43-30	8043-8050	degrees	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[16]
43-31	8050-8051	,	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[16]
43-32	8052-8058	slices	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[16]
43-33	8059-8060	=	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[16]
43-34	8061-8063	37	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[16]
43-35	8063-8064	,	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[16]
43-36	8065-8073	distance	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[16]
43-37	8074-8080	factor	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[16]
43-38	8081-8084	10%	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[16]
43-39	8084-8085	,	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[16]
43-40	8086-8091	voxel	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[16]
43-41	8092-8096	size	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[16]
43-42	8097-8098	=	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[16]
43-43	8099-8102	3.5	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[16]
43-44	8103-8105	mm	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[16]
43-45	8106-8115	isotropic	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[16]
43-46	8116-8119	and	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[16]
43-47	8120-8121	a	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[16]
43-48	8122-8128	GRAPPA	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[16]
43-49	8129-8141	acceleration	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[16]
43-50	8142-8148	factor	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[16]
43-51	8149-8151	of	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[16]
43-52	8152-8153	2	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[16]
43-53	8153-8154	)	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[16]
43-54	8154-8155	.	_
43-55	8156-8159	2.3	_
43-56	8160-8168	Magnetic	_
43-57	8169-8178	Resonance	_
43-58	8179-8191	Spectroscopy	_
43-59	8192-8200	Magnetic	http://maven.renci.org/NeuroBridge/neurobridge#Spectroscopy[17]
43-60	8201-8210	Resonance	http://maven.renci.org/NeuroBridge/neurobridge#Spectroscopy[17]
43-61	8211-8223	Spectroscopy	http://maven.renci.org/NeuroBridge/neurobridge#Spectroscopy[17]
43-62	8224-8228	also	_
43-63	8229-8232	was	_
43-64	8233-8242	identical	_
43-65	8243-8250	between	_
43-66	8251-8258	cohorts	_
43-67	8259-8262	and	_
43-68	8263-8266	was	_
43-69	8267-8276	collected	_
43-70	8277-8286	following	_
43-71	8287-8297	procedures	_
43-72	8298-8306	outlined	_
43-73	8307-8309	in	_
43-74	8310-8313	our	_
43-75	8314-8319	prior	_
43-76	8320-8324	work	_
43-77	8324-8325	.	_

#Text=Proton spectra were acquired using a modified J-resolved PRESS protocol (two-dimensional (2D)-JPRESS).
44-1	8326-8332	Proton	_
44-2	8333-8340	spectra	_
44-3	8341-8345	were	_
44-4	8346-8354	acquired	_
44-5	8355-8360	using	_
44-6	8361-8362	a	_
44-7	8363-8371	modified	_
44-8	8372-8382	J-resolved	_
44-9	8383-8388	PRESS	_
44-10	8389-8397	protocol	_
44-11	8398-8399	(	_
44-12	8399-8414	two-dimensional	_
44-13	8415-8416	(	_
44-14	8416-8418	2D	_
44-15	8418-8419	)	_
44-16	8419-8420	-	_
44-17	8420-8426	JPRESS	_
44-18	8426-8427	)	_
44-19	8427-8428	.	_

#Text=A single 2 × 2 × 3 cm voxel was placed in the dACC using the high-resolution T1-weighted anatomical images.
45-1	8429-8430	A	_
45-2	8431-8437	single	_
45-3	8438-8439	2	_
45-4	8440-8441	×	_
45-5	8442-8443	2	_
45-6	8444-8445	×	_
45-7	8446-8447	3	_
45-8	8448-8450	cm	_
45-9	8451-8456	voxel	_
45-10	8457-8460	was	_
45-11	8461-8467	placed	_
45-12	8468-8470	in	_
45-13	8471-8474	the	_
45-14	8475-8479	dACC	_
45-15	8480-8485	using	_
45-16	8486-8489	the	_
45-17	8490-8505	high-resolution	_
45-18	8506-8508	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[18]
45-19	8508-8509	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[18]
45-20	8509-8517	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[18]
45-21	8518-8528	anatomical	_
45-22	8529-8535	images	_
45-23	8535-8536	.	_

#Text=Shimming of the magnetic field within the prescribed voxel was done automatically using an automated shimming routine.
46-1	8537-8545	Shimming	_
46-2	8546-8548	of	_
46-3	8549-8552	the	_
46-4	8553-8561	magnetic	_
46-5	8562-8567	field	_
46-6	8568-8574	within	_
46-7	8575-8578	the	_
46-8	8579-8589	prescribed	_
46-9	8590-8595	voxel	_
46-10	8596-8599	was	_
46-11	8600-8604	done	_
46-12	8605-8618	automatically	_
46-13	8619-8624	using	_
46-14	8625-8627	an	_
46-15	8628-8637	automated	_
46-16	8638-8646	shimming	_
46-17	8647-8654	routine	_
46-18	8654-8655	.	_

#Text=Automated optimization also included water suppression power, carrier frequency, tip angles, and coil tuning.
47-1	8656-8665	Automated	_
47-2	8666-8678	optimization	_
47-3	8679-8683	also	_
47-4	8684-8692	included	_
47-5	8693-8698	water	_
47-6	8699-8710	suppression	_
47-7	8711-8716	power	_
47-8	8716-8717	,	_
47-9	8718-8725	carrier	_
47-10	8726-8735	frequency	_
47-11	8735-8736	,	_
47-12	8737-8740	tip	_
47-13	8741-8747	angles	_
47-14	8747-8748	,	_
47-15	8749-8752	and	_
47-16	8753-8757	coil	_
47-17	8758-8764	tuning	_
47-18	8764-8765	.	_

#Text=The 2D-JPRESS sequence collected 22 echo time (TE)-stepped spectra with the TE ranging from 30 to 350 ms in 15 ms increments.
48-1	8766-8769	The	_
48-2	8770-8779	2D-JPRESS	_
48-3	8780-8788	sequence	_
48-4	8789-8798	collected	_
48-5	8799-8801	22	_
48-6	8802-8806	echo	_
48-7	8807-8811	time	_
48-8	8812-8813	(	_
48-9	8813-8815	TE	_
48-10	8815-8816	)	_
48-11	8816-8817	-	_
48-12	8817-8824	stepped	_
48-13	8825-8832	spectra	_
48-14	8833-8837	with	_
48-15	8838-8841	the	_
48-16	8842-8844	TE	_
48-17	8845-8852	ranging	_
48-18	8853-8857	from	_
48-19	8858-8860	30	_
48-20	8861-8863	to	_
48-21	8864-8867	350	_
48-22	8868-8870	ms	_
48-23	8871-8873	in	_
48-24	8874-8876	15	_
48-25	8877-8879	ms	_
48-26	8880-8890	increments	_
48-27	8890-8891	.	_

#Text=Acquisition parameters were: TR: 2 s, acquisition bandwidth = 67 Hz, spectral bandwith = 2 kHz, readout duration = 512 ms, NEX = 16/TE-step.
#Text=2.4 MRS Processing and Analysis
#Text=To quantify Glu with the JPRESS data, the 22 TE-stepped free-induction decay was zero-filled out to 64 points, Gaussian-filtered and Fourier transformed.
49-1	8892-8903	Acquisition	_
49-2	8904-8914	parameters	_
49-3	8915-8919	were	_
49-4	8919-8920	:	_
49-5	8921-8923	TR	_
49-6	8923-8924	:	_
49-7	8925-8926	2	_
49-8	8927-8928	s	_
49-9	8928-8929	,	_
49-10	8930-8941	acquisition	_
49-11	8942-8951	bandwidth	_
49-12	8952-8953	=	_
49-13	8954-8956	67	_
49-14	8957-8959	Hz	_
49-15	8959-8960	,	_
49-16	8961-8969	spectral	_
49-17	8970-8978	bandwith	_
49-18	8979-8980	=	_
49-19	8981-8982	2	_
49-20	8983-8986	kHz	_
49-21	8986-8987	,	_
49-22	8988-8995	readout	_
49-23	8996-9004	duration	_
49-24	9005-9006	=	_
49-25	9007-9010	512	_
49-26	9011-9013	ms	_
49-27	9013-9014	,	_
49-28	9015-9018	NEX	_
49-29	9019-9020	=	_
49-30	9021-9023	16	_
49-31	9023-9024	/	_
49-32	9024-9031	TE-step	_
49-33	9031-9032	.	_
49-34	9033-9036	2.4	_
49-35	9037-9040	MRS	_
49-36	9041-9051	Processing	_
49-37	9052-9055	and	_
49-38	9056-9064	Analysis	_
49-39	9065-9067	To	_
49-40	9068-9076	quantify	_
49-41	9077-9080	Glu	_
49-42	9081-9085	with	_
49-43	9086-9089	the	_
49-44	9090-9096	JPRESS	_
49-45	9097-9101	data	_
49-46	9101-9102	,	_
49-47	9103-9106	the	_
49-48	9107-9109	22	_
49-49	9110-9120	TE-stepped	_
49-50	9121-9135	free-induction	_
49-51	9136-9141	decay	_
49-52	9142-9145	was	_
49-53	9146-9157	zero-filled	_
49-54	9158-9161	out	_
49-55	9162-9164	to	_
49-56	9165-9167	64	_
49-57	9168-9174	points	_
49-58	9174-9175	,	_
49-59	9176-9193	Gaussian-filtered	_
49-60	9194-9197	and	_
49-61	9198-9205	Fourier	_
49-62	9206-9217	transformed	_
49-63	9217-9218	.	_

#Text=Using our previously published methods, every J-resolved spectral extraction (64 in total) within the 67 Hz bandwith was fitted with LCModel and its theoretically-correct template, which is optimized GAMMA-simulated J-resolved basis sets modeled for 2.89 T.
50-1	9219-9224	Using	_
50-2	9225-9228	our	_
50-3	9229-9239	previously	_
50-4	9240-9249	published	_
50-5	9250-9257	methods	_
50-6	9257-9258	,	_
50-7	9259-9264	every	_
50-8	9265-9275	J-resolved	_
50-9	9276-9284	spectral	_
50-10	9285-9295	extraction	_
50-11	9296-9297	(	_
50-12	9297-9299	64	_
50-13	9300-9302	in	_
50-14	9303-9308	total	_
50-15	9308-9309	)	_
50-16	9310-9316	within	_
50-17	9317-9320	the	_
50-18	9321-9323	67	_
50-19	9324-9326	Hz	_
50-20	9327-9335	bandwith	_
50-21	9336-9339	was	_
50-22	9340-9346	fitted	_
50-23	9347-9351	with	_
50-24	9352-9359	LCModel	_
50-25	9360-9363	and	_
50-26	9364-9367	its	_
50-27	9368-9389	theoretically-correct	_
50-28	9390-9398	template	_
50-29	9398-9399	,	_
50-30	9400-9405	which	_
50-31	9406-9408	is	_
50-32	9409-9418	optimized	_
50-33	9419-9434	GAMMA-simulated	_
50-34	9435-9445	J-resolved	_
50-35	9446-9451	basis	_
50-36	9452-9456	sets	_
50-37	9457-9464	modeled	_
50-38	9465-9468	for	_
50-39	9469-9473	2.89	_
50-40	9474-9475	T	_
50-41	9475-9476	.	_

#Text=All spectral data were modeled for 2.89 T field strength (123.05 MHz) to match that of our TRIO scanner.
51-1	9477-9480	All	_
51-2	9481-9489	spectral	_
51-3	9490-9494	data	_
51-4	9495-9499	were	_
51-5	9500-9507	modeled	_
51-6	9508-9511	for	_
51-7	9512-9516	2.89	_
51-8	9517-9518	T	_
51-9	9519-9524	field	_
51-10	9525-9533	strength	_
51-11	9534-9535	(	_
51-12	9535-9541	123.05	_
51-13	9542-9545	MHz	_
51-14	9545-9546	)	_
51-15	9547-9549	to	_
51-16	9550-9555	match	_
51-17	9556-9560	that	_
51-18	9561-9563	of	_
51-19	9564-9567	our	_
51-20	9568-9572	TRIO	_
51-21	9573-9580	scanner	_
51-22	9580-9581	.	_

#Text=The integrated area under the 2D surface for each metabolite was calculated by summing the raw peak areas across all 64 J-resolved extractions.
52-1	9582-9585	The	_
52-2	9586-9596	integrated	_
52-3	9597-9601	area	_
52-4	9602-9607	under	_
52-5	9608-9611	the	_
52-6	9612-9614	2D	_
52-7	9615-9622	surface	_
52-8	9623-9626	for	_
52-9	9627-9631	each	_
52-10	9632-9642	metabolite	_
52-11	9643-9646	was	_
52-12	9647-9657	calculated	_
52-13	9658-9660	by	_
52-14	9661-9668	summing	_
52-15	9669-9672	the	_
52-16	9673-9676	raw	_
52-17	9677-9681	peak	_
52-18	9682-9687	areas	_
52-19	9688-9694	across	_
52-20	9695-9698	all	_
52-21	9699-9701	64	_
52-22	9702-9712	J-resolved	_
52-23	9713-9724	extractions	_
52-24	9724-9725	.	_

#Text=Glutamate metabolites were expressed as ratios of total creatine (Cr).
#Text=2.5 Image Segmentation/voxel Tissue Analysis
#Text=As in our prior work, all image segmentation was performed using FSL.
53-1	9726-9735	Glutamate	_
53-2	9736-9747	metabolites	_
53-3	9748-9752	were	_
53-4	9753-9762	expressed	_
53-5	9763-9765	as	_
53-6	9766-9772	ratios	_
53-7	9773-9775	of	_
53-8	9776-9781	total	_
53-9	9782-9790	creatine	_
53-10	9791-9792	(	_
53-11	9792-9794	Cr	_
53-12	9794-9795	)	_
53-13	9795-9796	.	_
53-14	9797-9800	2.5	_
53-15	9801-9806	Image	_
53-16	9807-9819	Segmentation	_
53-17	9819-9820	/	_
53-18	9820-9825	voxel	_
53-19	9826-9832	Tissue	_
53-20	9833-9841	Analysis	_
53-21	9842-9844	As	_
53-22	9845-9847	in	_
53-23	9848-9851	our	_
53-24	9852-9857	prior	_
53-25	9858-9862	work	_
53-26	9862-9863	,	_
53-27	9864-9867	all	_
53-28	9868-9873	image	_
53-29	9874-9886	segmentation	_
53-30	9887-9890	was	_
53-31	9891-9900	performed	_
53-32	9901-9906	using	_
53-33	9907-9910	FSL	_
53-34	9910-9911	.	_

#Text=The FSL segmentation tool was used to automatically segment cortical gray matter (GM), white matter (WM), and cerebral spinal fluid (CSF).
54-1	9912-9915	The	_
54-2	9916-9919	FSL	_
54-3	9920-9932	segmentation	_
54-4	9933-9937	tool	_
54-5	9938-9941	was	_
54-6	9942-9946	used	_
54-7	9947-9949	to	_
54-8	9950-9963	automatically	_
54-9	9964-9971	segment	_
54-10	9972-9980	cortical	_
54-11	9981-9985	gray	_
54-12	9986-9992	matter	_
54-13	9993-9994	(	_
54-14	9994-9996	GM	_
54-15	9996-9997	)	_
54-16	9997-9998	,	_
54-17	9999-10004	white	_
54-18	10005-10011	matter	_
54-19	10012-10013	(	_
54-20	10013-10015	WM	_
54-21	10015-10016	)	_
54-22	10016-10017	,	_
54-23	10018-10021	and	_
54-24	10022-10030	cerebral	_
54-25	10031-10037	spinal	_
54-26	10038-10043	fluid	_
54-27	10044-10045	(	_
54-28	10045-10048	CSF	_
54-29	10048-10049	)	_
54-30	10049-10050	.	_

#Text=These segmented images were evaluated using an automated voxel coregistration and partial-volume analysis in-house program written in C-code.
55-1	10051-10056	These	_
55-2	10057-10066	segmented	_
55-3	10067-10073	images	_
55-4	10074-10078	were	_
55-5	10079-10088	evaluated	_
55-6	10089-10094	using	_
55-7	10095-10097	an	_
55-8	10098-10107	automated	_
55-9	10108-10113	voxel	_
55-10	10114-10128	coregistration	_
55-11	10129-10132	and	_
55-12	10133-10147	partial-volume	_
55-13	10148-10156	analysis	_
55-14	10157-10165	in-house	_
55-15	10166-10173	program	_
55-16	10174-10181	written	_
55-17	10182-10184	in	_
55-18	10185-10191	C-code	_
55-19	10191-10192	.	_

#Text=Subsequently, the volumetric tissue contribution for each oblique dACC voxel was determined and volumetric contributions of total GM, WM, and CSF calculated.
#Text=2.6 fMRI and Smoking Cues
#Text=Evaluating brain reactivity to smoking > neutral cues was done in the context of one of two studies involving either the traditional cue reactivity task or working memory for smoking cues.
56-1	10193-10205	Subsequently	_
56-2	10205-10206	,	_
56-3	10207-10210	the	_
56-4	10211-10221	volumetric	_
56-5	10222-10228	tissue	_
56-6	10229-10241	contribution	_
56-7	10242-10245	for	_
56-8	10246-10250	each	_
56-9	10251-10258	oblique	_
56-10	10259-10263	dACC	_
56-11	10264-10269	voxel	_
56-12	10270-10273	was	_
56-13	10274-10284	determined	_
56-14	10285-10288	and	_
56-15	10289-10299	volumetric	_
56-16	10300-10313	contributions	_
56-17	10314-10316	of	_
56-18	10317-10322	total	_
56-19	10323-10325	GM	_
56-20	10325-10326	,	_
56-21	10327-10329	WM	_
56-22	10329-10330	,	_
56-23	10331-10334	and	_
56-24	10335-10338	CSF	_
56-25	10339-10349	calculated	_
56-26	10349-10350	.	_
56-27	10351-10354	2.6	_
56-28	10355-10359	fMRI	_
56-29	10360-10363	and	_
56-30	10364-10371	Smoking	_
56-31	10372-10376	Cues	_
56-32	10377-10387	Evaluating	_
56-33	10388-10393	brain	_
56-34	10394-10404	reactivity	_
56-35	10405-10407	to	_
56-36	10408-10415	smoking	_
56-37	10416-10417	>	_
56-38	10418-10425	neutral	_
56-39	10426-10430	cues	_
56-40	10431-10434	was	_
56-41	10435-10439	done	_
56-42	10440-10442	in	_
56-43	10443-10446	the	_
56-44	10447-10454	context	_
56-45	10455-10457	of	_
56-46	10458-10461	one	_
56-47	10462-10464	of	_
56-48	10465-10468	two	_
56-49	10469-10476	studies	_
56-50	10477-10486	involving	_
56-51	10487-10493	either	_
56-52	10494-10497	the	_
56-53	10498-10509	traditional	_
56-54	10510-10513	cue	_
56-55	10514-10524	reactivity	_
56-56	10525-10529	task	_
56-57	10530-10532	or	_
56-58	10533-10540	working	_
56-59	10541-10547	memory	_
56-60	10548-10551	for	_
56-61	10552-10559	smoking	_
56-62	10560-10564	cues	_
56-63	10564-10565	.	_

#Text=These tasks are explained in detail in our prior work.
57-1	10566-10571	These	_
57-2	10572-10577	tasks	_
57-3	10578-10581	are	_
57-4	10582-10591	explained	_
57-5	10592-10594	in	_
57-6	10595-10601	detail	_
57-7	10602-10604	in	_
57-8	10605-10608	our	_
57-9	10609-10614	prior	_
57-10	10615-10619	work	_
57-11	10619-10620	.	_

#Text=In both tasks, the same smoking and neutral cues were used.
58-1	10621-10623	In	_
58-2	10624-10628	both	_
58-3	10629-10634	tasks	_
58-4	10634-10635	,	_
58-5	10636-10639	the	_
58-6	10640-10644	same	_
58-7	10645-10652	smoking	_
58-8	10653-10656	and	_
58-9	10657-10664	neutral	_
58-10	10665-10669	cues	_
58-11	10670-10674	were	_
58-12	10675-10679	used	_
58-13	10679-10680	.	_

#Text=Smoking images included smoking-related content such as people smoking, people holding cigarettes, or cigarettes alone.
59-1	10681-10688	Smoking	_
59-2	10689-10695	images	_
59-3	10696-10704	included	_
59-4	10705-10720	smoking-related	_
59-5	10721-10728	content	_
59-6	10729-10733	such	_
59-7	10734-10736	as	_
59-8	10737-10743	people	_
59-9	10744-10751	smoking	_
59-10	10751-10752	,	_
59-11	10753-10759	people	_
59-12	10760-10767	holding	_
59-13	10768-10778	cigarettes	_
59-14	10778-10779	,	_
59-15	10780-10782	or	_
59-16	10783-10793	cigarettes	_
59-17	10794-10799	alone	_
59-18	10799-10800	.	_

#Text=Neutral images were matched for content in that they involved people, hands, or objects such as pens or paintbrushes.
60-1	10801-10808	Neutral	_
60-2	10809-10815	images	_
60-3	10816-10820	were	_
60-4	10821-10828	matched	_
60-5	10829-10832	for	_
60-6	10833-10840	content	_
60-7	10841-10843	in	_
60-8	10844-10848	that	_
60-9	10849-10853	they	_
60-10	10854-10862	involved	_
60-11	10863-10869	people	_
60-12	10869-10870	,	_
60-13	10871-10876	hands	_
60-14	10876-10877	,	_
60-15	10878-10880	or	_
60-16	10881-10888	objects	_
60-17	10889-10893	such	_
60-18	10894-10896	as	_
60-19	10897-10901	pens	_
60-20	10902-10904	or	_
60-21	10905-10917	paintbrushes	_
60-22	10917-10918	.	_

#Text=In the traditional cue-reactivity task, presented to our primary cohort, target images were also presented to ensure participants were awake and attending to the task.
61-1	10919-10921	In	_
61-2	10922-10925	the	_
61-3	10926-10937	traditional	_
61-4	10938-10952	cue-reactivity	_
61-5	10953-10957	task	_
61-6	10957-10958	,	_
61-7	10959-10968	presented	_
61-8	10969-10971	to	_
61-9	10972-10975	our	_
61-10	10976-10983	primary	_
61-11	10984-10990	cohort	_
61-12	10990-10991	,	_
61-13	10992-10998	target	_
61-14	10999-11005	images	_
61-15	11006-11010	were	_
61-16	11011-11015	also	_
61-17	11016-11025	presented	_
61-18	11026-11028	to	_
61-19	11029-11035	ensure	_
61-20	11036-11048	participants	_
61-21	11049-11053	were	_
61-22	11054-11059	awake	_
61-23	11060-11063	and	_
61-24	11064-11073	attending	_
61-25	11074-11076	to	_
61-26	11077-11080	the	_
61-27	11081-11085	task	_
61-28	11085-11086	.	_

#Text=Targets were pictures of animals and participants were asked to press a button when a target appeared.
62-1	11087-11094	Targets	_
62-2	11095-11099	were	_
62-3	11100-11108	pictures	_
62-4	11109-11111	of	_
62-5	11112-11119	animals	_
62-6	11120-11123	and	_
62-7	11124-11136	participants	_
62-8	11137-11141	were	_
62-9	11142-11147	asked	_
62-10	11148-11150	to	_
62-11	11151-11156	press	_
62-12	11157-11158	a	_
62-13	11159-11165	button	_
62-14	11166-11170	when	_
62-15	11171-11172	a	_
62-16	11173-11179	target	_
62-17	11180-11188	appeared	_
62-18	11188-11189	.	_

#Text=This data only was used to ensure participants were attending to the task.
63-1	11190-11194	This	_
63-2	11195-11199	data	_
63-3	11200-11204	only	_
63-4	11205-11208	was	_
63-5	11209-11213	used	_
63-6	11214-11216	to	_
63-7	11217-11223	ensure	_
63-8	11224-11236	participants	_
63-9	11237-11241	were	_
63-10	11242-11251	attending	_
63-11	11252-11254	to	_
63-12	11255-11258	the	_
63-13	11259-11263	task	_
63-14	11263-11264	.	_

#Text=Our primary cohort was shown 60 smoking, 60 neutral and 12 target images divided evenly across 5 blocks lasting 5 m and 18 s each.
64-1	11265-11268	Our	_
64-2	11269-11276	primary	_
64-3	11277-11283	cohort	_
64-4	11284-11287	was	_
64-5	11288-11293	shown	_
64-6	11294-11296	60	_
64-7	11297-11304	smoking	_
64-8	11304-11305	,	_
64-9	11306-11308	60	_
64-10	11309-11316	neutral	_
64-11	11317-11320	and	_
64-12	11321-11323	12	_
64-13	11324-11330	target	_
64-14	11331-11337	images	_
64-15	11338-11345	divided	_
64-16	11346-11352	evenly	_
64-17	11353-11359	across	_
64-18	11360-11361	5	_
64-19	11362-11368	blocks	_
64-20	11369-11376	lasting	_
64-21	11377-11378	5	_
64-22	11379-11380	m	_
64-23	11381-11384	and	_
64-24	11385-11387	18	_
64-25	11388-11389	s	_
64-26	11390-11394	each	_
64-27	11394-11395	.	_

#Text=Images were presented for 4 s in a pseudorandom order with no more than 2 of the same picture type occurring in a row as performed in our prior work.
65-1	11396-11402	Images	_
65-2	11403-11407	were	_
65-3	11408-11417	presented	_
65-4	11418-11421	for	_
65-5	11422-11423	4	_
65-6	11424-11425	s	_
65-7	11426-11428	in	_
65-8	11429-11430	a	_
65-9	11431-11443	pseudorandom	_
65-10	11444-11449	order	_
65-11	11450-11454	with	_
65-12	11455-11457	no	_
65-13	11458-11462	more	_
65-14	11463-11467	than	_
65-15	11468-11469	2	_
65-16	11470-11472	of	_
65-17	11473-11476	the	_
65-18	11477-11481	same	_
65-19	11482-11489	picture	_
65-20	11490-11494	type	_
65-21	11495-11504	occurring	_
65-22	11505-11507	in	_
65-23	11508-11509	a	_
65-24	11510-11513	row	_
65-25	11514-11516	as	_
65-26	11517-11526	performed	_
65-27	11527-11529	in	_
65-28	11530-11533	our	_
65-29	11534-11539	prior	_
65-30	11540-11544	work	_
65-31	11544-11545	.	_

#Text=Images were divided by a jittered inter-trial-interval ranging from 6 – 14s in intervals of 2 s with a 10 s average across block.
66-1	11546-11552	Images	_
66-2	11553-11557	were	_
66-3	11558-11565	divided	_
66-4	11566-11568	by	_
66-5	11569-11570	a	_
66-6	11571-11579	jittered	_
66-7	11580-11600	inter-trial-interval	_
66-8	11601-11608	ranging	_
66-9	11609-11613	from	_
66-10	11614-11615	6	_
66-11	11616-11617	–	_
66-12	11618-11621	14s	_
66-13	11622-11624	in	_
66-14	11625-11634	intervals	_
66-15	11635-11637	of	_
66-16	11638-11639	2	_
66-17	11640-11641	s	_
66-18	11642-11646	with	_
66-19	11647-11648	a	_
66-20	11649-11651	10	_
66-21	11652-11653	s	_
66-22	11654-11661	average	_
66-23	11662-11668	across	_
66-24	11669-11674	block	_
66-25	11674-11675	.	_

#Text=During this inter-trial interval, participants in the primary cohort were shown a white fixation cross on a black screen.
67-1	11676-11682	During	_
67-2	11683-11687	this	_
67-3	11688-11699	inter-trial	_
67-4	11700-11708	interval	_
67-5	11708-11709	,	_
67-6	11710-11722	participants	_
67-7	11723-11725	in	_
67-8	11726-11729	the	_
67-9	11730-11737	primary	_
67-10	11738-11744	cohort	_
67-11	11745-11749	were	_
67-12	11750-11755	shown	_
67-13	11756-11757	a	_
67-14	11758-11763	white	_
67-15	11764-11772	fixation	_
67-16	11773-11778	cross	_
67-17	11779-11781	on	_
67-18	11782-11783	a	_
67-19	11784-11789	black	_
67-20	11790-11796	screen	_
67-21	11796-11797	.	_

#Text=The replication cohort was exposed to smoking cues in the context of the delay-match-to-sample working memory task.
68-1	11798-11801	The	_
68-2	11802-11813	replication	_
68-3	11814-11820	cohort	_
68-4	11821-11824	was	_
68-5	11825-11832	exposed	_
68-6	11833-11835	to	_
68-7	11836-11843	smoking	_
68-8	11844-11848	cues	_
68-9	11849-11851	in	_
68-10	11852-11855	the	_
68-11	11856-11863	context	_
68-12	11864-11866	of	_
68-13	11867-11870	the	_
68-14	11871-11892	delay-match-to-sample	_
68-15	11893-11900	working	_
68-16	11901-11907	memory	_
68-17	11908-11912	task	_
68-18	11912-11913	.	_

#Text=For the purposes of the present study only the “sample” portion of this task was analyzed, as this corresponds most closely to the traditional cue-reactivity task.
69-1	11914-11917	For	_
69-2	11918-11921	the	_
69-3	11922-11930	purposes	_
69-4	11931-11933	of	_
69-5	11934-11937	the	_
69-6	11938-11945	present	_
69-7	11946-11951	study	_
69-8	11952-11956	only	_
69-9	11957-11960	the	_
69-10	11961-11962	“	_
69-11	11962-11968	sample	_
69-12	11968-11969	”	_
69-13	11970-11977	portion	_
69-14	11978-11980	of	_
69-15	11981-11985	this	_
69-16	11986-11990	task	_
69-17	11991-11994	was	_
69-18	11995-12003	analyzed	_
69-19	12003-12004	,	_
69-20	12005-12007	as	_
69-21	12008-12012	this	_
69-22	12013-12024	corresponds	_
69-23	12025-12029	most	_
69-24	12030-12037	closely	_
69-25	12038-12040	to	_
69-26	12041-12044	the	_
69-27	12045-12056	traditional	_
69-28	12057-12071	cue-reactivity	_
69-29	12072-12076	task	_
69-30	12076-12077	.	_

#Text=During the sample period, participants were shown either a smoking or neutral image for 2 s that they would have to match to a subsequent image following a 10 s delay.
70-1	12078-12084	During	_
70-2	12085-12088	the	_
70-3	12089-12095	sample	_
70-4	12096-12102	period	_
70-5	12102-12103	,	_
70-6	12104-12116	participants	_
70-7	12117-12121	were	_
70-8	12122-12127	shown	_
70-9	12128-12134	either	_
70-10	12135-12136	a	_
70-11	12137-12144	smoking	_
70-12	12145-12147	or	_
70-13	12148-12155	neutral	_
70-14	12156-12161	image	_
70-15	12162-12165	for	_
70-16	12166-12167	2	_
70-17	12168-12169	s	_
70-18	12170-12174	that	_
70-19	12175-12179	they	_
70-20	12180-12185	would	_
70-21	12186-12190	have	_
70-22	12191-12193	to	_
70-23	12194-12199	match	_
70-24	12200-12202	to	_
70-25	12203-12204	a	_
70-26	12205-12215	subsequent	_
70-27	12216-12221	image	_
70-28	12222-12231	following	_
70-29	12232-12233	a	_
70-30	12234-12236	10	_
70-31	12237-12238	s	_
70-32	12239-12244	delay	_
70-33	12244-12245	.	_

#Text=Thus, the sample period allows for the smoking > neutral contrast to be conducted without involving the working memory component involved in the other task elements and closely resembles the traditional cue reactivity task.
71-1	12246-12250	Thus	_
71-2	12250-12251	,	_
71-3	12252-12255	the	_
71-4	12256-12262	sample	_
71-5	12263-12269	period	_
71-6	12270-12276	allows	_
71-7	12277-12280	for	_
71-8	12281-12284	the	_
71-9	12285-12292	smoking	_
71-10	12293-12294	>	_
71-11	12295-12302	neutral	_
71-12	12303-12311	contrast	_
71-13	12312-12314	to	_
71-14	12315-12317	be	_
71-15	12318-12327	conducted	_
71-16	12328-12335	without	_
71-17	12336-12345	involving	_
71-18	12346-12349	the	_
71-19	12350-12357	working	_
71-20	12358-12364	memory	_
71-21	12365-12374	component	_
71-22	12375-12383	involved	_
71-23	12384-12386	in	_
71-24	12387-12390	the	_
71-25	12391-12396	other	_
71-26	12397-12401	task	_
71-27	12402-12410	elements	_
71-28	12411-12414	and	_
71-29	12415-12422	closely	_
71-30	12423-12432	resembles	_
71-31	12433-12436	the	_
71-32	12437-12448	traditional	_
71-33	12449-12452	cue	_
71-34	12453-12463	reactivity	_
71-35	12464-12468	task	_
71-36	12468-12469	.	_

#Text=To insure participants were attending, only trials where participants performed accurately were included in the analysis.
72-1	12470-12472	To	_
72-2	12473-12479	insure	_
72-3	12480-12492	participants	_
72-4	12493-12497	were	_
72-5	12498-12507	attending	_
72-6	12507-12508	,	_
72-7	12509-12513	only	_
72-8	12514-12520	trials	_
72-9	12521-12526	where	_
72-10	12527-12539	participants	_
72-11	12540-12549	performed	_
72-12	12550-12560	accurately	_
72-13	12561-12565	were	_
72-14	12566-12574	included	_
72-15	12575-12577	in	_
72-16	12578-12581	the	_
72-17	12582-12590	analysis	_
72-18	12590-12591	.	_

#Text=The majority of trials were included, as accuracy ranged from 0.92 ± 0.01 – 0.97 ± 0.07 depending on trial type.
#Text=2.7 fMRI Pre-Processing
#Text=Tools from the fMRI of the brain (FMRIB) software Library (FSL; http://www.fmrib.ox.ac.uk/fsl) were used to process all fMRI data.
73-1	12592-12595	The	_
73-2	12596-12604	majority	_
73-3	12605-12607	of	_
73-4	12608-12614	trials	_
73-5	12615-12619	were	_
73-6	12620-12628	included	_
73-7	12628-12629	,	_
73-8	12630-12632	as	_
73-9	12633-12641	accuracy	_
73-10	12642-12648	ranged	_
73-11	12649-12653	from	_
73-12	12654-12658	0.92	_
73-13	12659-12660	±	_
73-14	12661-12665	0.01	_
73-15	12666-12667	–	_
73-16	12668-12672	0.97	_
73-17	12673-12674	±	_
73-18	12675-12679	0.07	_
73-19	12680-12689	depending	_
73-20	12690-12692	on	_
73-21	12693-12698	trial	_
73-22	12699-12703	type	_
73-23	12703-12704	.	_
73-24	12705-12708	2.7	_
73-25	12709-12713	fMRI	_
73-26	12714-12728	Pre-Processing	_
73-27	12729-12734	Tools	_
73-28	12735-12739	from	_
73-29	12740-12743	the	_
73-30	12744-12748	fMRI	_
73-31	12749-12751	of	_
73-32	12752-12755	the	_
73-33	12756-12761	brain	_
73-34	12762-12763	(	_
73-35	12763-12768	FMRIB	_
73-36	12768-12769	)	_
73-37	12770-12778	software	_
73-38	12779-12786	Library	_
73-39	12787-12788	(	_
73-40	12788-12791	FSL	_
73-41	12791-12792	;	_
73-42	12793-12797	http	_
73-43	12797-12798	:	_
73-44	12798-12799	/	_
73-45	12799-12800	/	_
73-46	12800-12818	www.fmrib.ox.ac.uk	_
73-47	12818-12819	/	_
73-48	12819-12822	fsl	_
73-49	12822-12823	)	_
73-50	12824-12828	were	_
73-51	12829-12833	used	_
73-52	12834-12836	to	_
73-53	12837-12844	process	_
73-54	12845-12848	all	_
73-55	12849-12853	fMRI	_
73-56	12854-12858	data	_
73-57	12858-12859	.	_

#Text=For all analyses, the first 5 volumes were removed to allow for signal stabilization.
74-1	12860-12863	For	_
74-2	12864-12867	all	_
74-3	12868-12876	analyses	_
74-4	12876-12877	,	_
74-5	12878-12881	the	_
74-6	12882-12887	first	_
74-7	12888-12889	5	_
74-8	12890-12897	volumes	_
74-9	12898-12902	were	_
74-10	12903-12910	removed	_
74-11	12911-12913	to	_
74-12	12914-12919	allow	_
74-13	12920-12923	for	_
74-14	12924-12930	signal	_
74-15	12931-12944	stabilization	_
74-16	12944-12945	.	_

#Text=Functional data were then pre-processed including motion correction, brain extraction, slice timing correction, spatial smoothing with a Gaussian kernel for a full-width half-maximum 6 mm, and a high-pass temporal filter with Gaussian-weighted least-squares straight-line fitting with 100 s.
75-1	12946-12956	Functional	_
75-2	12957-12961	data	_
75-3	12962-12966	were	_
75-4	12967-12971	then	_
75-5	12972-12985	pre-processed	_
75-6	12986-12995	including	_
75-7	12996-13002	motion	_
75-8	13003-13013	correction	_
75-9	13013-13014	,	_
75-10	13015-13020	brain	_
75-11	13021-13031	extraction	_
75-12	13031-13032	,	_
75-13	13033-13038	slice	_
75-14	13039-13045	timing	_
75-15	13046-13056	correction	_
75-16	13056-13057	,	_
75-17	13058-13065	spatial	_
75-18	13066-13075	smoothing	_
75-19	13076-13080	with	_
75-20	13081-13082	a	_
75-21	13083-13091	Gaussian	_
75-22	13092-13098	kernel	_
75-23	13099-13102	for	_
75-24	13103-13104	a	_
75-25	13105-13115	full-width	_
75-26	13116-13128	half-maximum	_
75-27	13129-13130	6	_
75-28	13131-13133	mm	_
75-29	13133-13134	,	_
75-30	13135-13138	and	_
75-31	13139-13140	a	_
75-32	13141-13150	high-pass	_
75-33	13151-13159	temporal	_
75-34	13160-13166	filter	_
75-35	13167-13171	with	_
75-36	13172-13189	Gaussian-weighted	_
75-37	13190-13203	least-squares	_
75-38	13204-13217	straight-line	_
75-39	13218-13225	fitting	_
75-40	13226-13230	with	_
75-41	13231-13234	100	_
75-42	13235-13236	s	_
75-43	13236-13237	.	_

#Text=Each individual participant’s data was registered to the MNI152 2 mm3 standard space template (Montreal Neurological Institute, Montreal, QC, Canada).
76-1	13238-13242	Each	_
76-2	13243-13253	individual	_
76-3	13254-13265	participant	_
76-4	13265-13266	’	_
76-5	13266-13267	s	_
76-6	13268-13272	data	_
76-7	13273-13276	was	_
76-8	13277-13287	registered	_
76-9	13288-13290	to	_
76-10	13291-13294	the	_
76-11	13295-13301	MNI152	_
76-12	13302-13303	2	_
76-13	13304-13307	mm3	_
76-14	13308-13316	standard	_
76-15	13317-13322	space	_
76-16	13323-13331	template	_
76-17	13332-13333	(	_
76-18	13333-13341	Montreal	_
76-19	13342-13354	Neurological	_
76-20	13355-13364	Institute	_
76-21	13364-13365	,	_
76-22	13366-13374	Montreal	_
76-23	13374-13375	,	_
76-24	13376-13378	QC	_
76-25	13378-13379	,	_
76-26	13380-13386	Canada	_
76-27	13386-13387	)	_
76-28	13387-13388	.	_

#Text=For task-related data, an in-house program used in our prior work was used to detect and adjust for artifacts generated by intensity spiking.
#Text=2.8 Cue-Reactivity
#Text=For both the traditional cue-reactivity and working memory tasks, the first-level analysis was conducted on each of the participant’s individual task runs separately and all task-related regressors were convolved with the gamma hemodynamic response function.
77-1	13389-13392	For	_
77-2	13393-13405	task-related	_
77-3	13406-13410	data	_
77-4	13410-13411	,	_
77-5	13412-13414	an	_
77-6	13415-13423	in-house	_
77-7	13424-13431	program	_
77-8	13432-13436	used	_
77-9	13437-13439	in	_
77-10	13440-13443	our	_
77-11	13444-13449	prior	_
77-12	13450-13454	work	_
77-13	13455-13458	was	_
77-14	13459-13463	used	_
77-15	13464-13466	to	_
77-16	13467-13473	detect	_
77-17	13474-13477	and	_
77-18	13478-13484	adjust	_
77-19	13485-13488	for	_
77-20	13489-13498	artifacts	_
77-21	13499-13508	generated	_
77-22	13509-13511	by	_
77-23	13512-13521	intensity	_
77-24	13522-13529	spiking	_
77-25	13529-13530	.	_
77-26	13531-13534	2.8	_
77-27	13535-13549	Cue-Reactivity	_
77-28	13550-13553	For	_
77-29	13554-13558	both	_
77-30	13559-13562	the	_
77-31	13563-13574	traditional	_
77-32	13575-13589	cue-reactivity	_
77-33	13590-13593	and	_
77-34	13594-13601	working	_
77-35	13602-13608	memory	_
77-36	13609-13614	tasks	_
77-37	13614-13615	,	_
77-38	13616-13619	the	_
77-39	13620-13631	first-level	_
77-40	13632-13640	analysis	_
77-41	13641-13644	was	_
77-42	13645-13654	conducted	_
77-43	13655-13657	on	_
77-44	13658-13662	each	_
77-45	13663-13665	of	_
77-46	13666-13669	the	_
77-47	13670-13681	participant	_
77-48	13681-13682	’	_
77-49	13682-13683	s	_
77-50	13684-13694	individual	_
77-51	13695-13699	task	_
77-52	13700-13704	runs	_
77-53	13705-13715	separately	_
77-54	13716-13719	and	_
77-55	13720-13723	all	_
77-56	13724-13736	task-related	_
77-57	13737-13747	regressors	_
77-58	13748-13752	were	_
77-59	13753-13762	convolved	_
77-60	13763-13767	with	_
77-61	13768-13771	the	_
77-62	13772-13777	gamma	_
77-63	13778-13789	hemodynamic	_
77-64	13790-13798	response	_
77-65	13799-13807	function	_
77-66	13807-13808	.	_

#Text=Confound regressors representing motion were also included in the model.
78-1	13809-13817	Confound	_
78-2	13818-13828	regressors	_
78-3	13829-13841	representing	_
78-4	13842-13848	motion	_
78-5	13849-13853	were	_
78-6	13854-13858	also	_
78-7	13859-13867	included	_
78-8	13868-13870	in	_
78-9	13871-13874	the	_
78-10	13875-13880	model	_
78-11	13880-13881	.	_

#Text=Contrasts were conducted between the smoking and neutral image conditions.
79-1	13882-13891	Contrasts	_
79-2	13892-13896	were	_
79-3	13897-13906	conducted	_
79-4	13907-13914	between	_
79-5	13915-13918	the	_
79-6	13919-13926	smoking	_
79-7	13927-13930	and	_
79-8	13931-13938	neutral	_
79-9	13939-13944	image	_
79-10	13945-13955	conditions	_
79-11	13955-13956	.	_

#Text=For the working memory task these contrasts were conducted during the sample period of the delay-match-to-sample task.
80-1	13957-13960	For	_
80-2	13961-13964	the	_
80-3	13965-13972	working	_
80-4	13973-13979	memory	_
80-5	13980-13984	task	_
80-6	13985-13990	these	_
80-7	13991-14000	contrasts	_
80-8	14001-14005	were	_
80-9	14006-14015	conducted	_
80-10	14016-14022	during	_
80-11	14023-14026	the	_
80-12	14027-14033	sample	_
80-13	14034-14040	period	_
80-14	14041-14043	of	_
80-15	14044-14047	the	_
80-16	14048-14069	delay-match-to-sample	_
80-17	14070-14074	task	_
80-18	14074-14075	.	_

#Text=In both instances, these lower level individual runs were combined in the second level to generate the average brain reactivity for each individual participant.
81-1	14076-14078	In	_
81-2	14079-14083	both	_
81-3	14084-14093	instances	_
81-4	14093-14094	,	_
81-5	14095-14100	these	_
81-6	14101-14106	lower	_
81-7	14107-14112	level	_
81-8	14113-14123	individual	_
81-9	14124-14128	runs	_
81-10	14129-14133	were	_
81-11	14134-14142	combined	_
81-12	14143-14145	in	_
81-13	14146-14149	the	_
81-14	14150-14156	second	_
81-15	14157-14162	level	_
81-16	14163-14165	to	_
81-17	14166-14174	generate	_
81-18	14175-14178	the	_
81-19	14179-14186	average	_
81-20	14187-14192	brain	_
81-21	14193-14203	reactivity	_
81-22	14204-14207	for	_
81-23	14208-14212	each	_
81-24	14213-14223	individual	_
81-25	14224-14235	participant	_
81-26	14235-14236	.	_

#Text=For the primary cohort we conducted a group level mixed effects (FLAME) whole brain analysis for the smoking vs. neutral contrast.
82-1	14237-14240	For	_
82-2	14241-14244	the	_
82-3	14245-14252	primary	_
82-4	14253-14259	cohort	_
82-5	14260-14262	we	_
82-6	14263-14272	conducted	_
82-7	14273-14274	a	_
82-8	14275-14280	group	_
82-9	14281-14286	level	_
82-10	14287-14292	mixed	_
82-11	14293-14300	effects	_
82-12	14301-14302	(	_
82-13	14302-14307	FLAME	_
82-14	14307-14308	)	_
82-15	14309-14314	whole	_
82-16	14315-14320	brain	_
82-17	14321-14329	analysis	_
82-18	14330-14333	for	_
82-19	14334-14337	the	_
82-20	14338-14345	smoking	_
82-21	14346-14348	vs	_
82-22	14348-14349	.	_
82-23	14350-14357	neutral	_
82-24	14358-14366	contrast	_
82-25	14366-14367	.	_

#Text=Multiple comparisons were corrected to p < 0.05 using a cluster-based threshold across the entire brain Z – 2.3.
83-1	14368-14376	Multiple	_
83-2	14377-14388	comparisons	_
83-3	14389-14393	were	_
83-4	14394-14403	corrected	_
83-5	14404-14406	to	_
83-6	14407-14408	p	_
83-7	14409-14410	<	_
83-8	14411-14415	0.05	_
83-9	14416-14421	using	_
83-10	14422-14423	a	_
83-11	14424-14437	cluster-based	_
83-12	14438-14447	threshold	_
83-13	14448-14454	across	_
83-14	14455-14458	the	_
83-15	14459-14465	entire	_
83-16	14466-14471	brain	_
83-17	14472-14473	Z	_
83-18	14474-14475	–	_
83-19	14476-14479	2.3	_
83-20	14479-14480	.	_

#Text=This whole brain activation to the smoking vs. neutral contrast was compared to the DMN region of interest (ROI) defined by, Fig.1) by calculating the cross correlation between these maps using the FSL command fslcc.
84-1	14481-14485	This	_
84-2	14486-14491	whole	_
84-3	14492-14497	brain	_
84-4	14498-14508	activation	_
84-5	14509-14511	to	_
84-6	14512-14515	the	_
84-7	14516-14523	smoking	_
84-8	14524-14526	vs	_
84-9	14526-14527	.	_
84-10	14528-14535	neutral	_
84-11	14536-14544	contrast	_
84-12	14545-14548	was	_
84-13	14549-14557	compared	_
84-14	14558-14560	to	_
84-15	14561-14564	the	_
84-16	14565-14568	DMN	_
84-17	14569-14575	region	_
84-18	14576-14578	of	_
84-19	14579-14587	interest	_
84-20	14588-14589	(	_
84-21	14589-14592	ROI	_
84-22	14592-14593	)	_
84-23	14594-14601	defined	_
84-24	14602-14604	by	_
84-25	14604-14605	,	_
84-26	14606-14609	Fig	_
84-27	14609-14611	.1	_
84-28	14611-14612	)	_
84-29	14613-14615	by	_
84-30	14616-14627	calculating	_
84-31	14628-14631	the	_
84-32	14632-14637	cross	_
84-33	14638-14649	correlation	_
84-34	14650-14657	between	_
84-35	14658-14663	these	_
84-36	14664-14668	maps	_
84-37	14669-14674	using	_
84-38	14675-14678	the	_
84-39	14679-14682	FSL	_
84-40	14683-14690	command	_
84-41	14691-14696	fslcc	_
84-42	14696-14697	.	_

#Text=To more directly evaluate how the DMN responds to smoking > neutral cues, beta-weights from the DMN ROI were extracted using FSL’s featquery from each individual.
85-1	14698-14700	To	_
85-2	14701-14705	more	_
85-3	14706-14714	directly	_
85-4	14715-14723	evaluate	_
85-5	14724-14727	how	_
85-6	14728-14731	the	_
85-7	14732-14735	DMN	_
85-8	14736-14744	responds	_
85-9	14745-14747	to	_
85-10	14748-14755	smoking	_
85-11	14756-14757	>	_
85-12	14758-14765	neutral	_
85-13	14766-14770	cues	_
85-14	14770-14771	,	_
85-15	14772-14784	beta-weights	_
85-16	14785-14789	from	_
85-17	14790-14793	the	_
85-18	14794-14797	DMN	_
85-19	14798-14801	ROI	_
85-20	14802-14806	were	_
85-21	14807-14816	extracted	_
85-22	14817-14822	using	_
85-23	14823-14826	FSL	_
85-24	14826-14827	’	_
85-25	14827-14828	s	_
85-26	14829-14838	featquery	_
85-27	14839-14843	from	_
85-28	14844-14848	each	_
85-29	14849-14859	individual	_
85-30	14859-14860	.	_

#Text=The Pearson’s correlation coefficient was then calculated between DMN beta-weights and dACC Glu/Cr for each cohort to assess the association between these measures.
#Text=3.
86-1	14861-14864	The	_
86-2	14865-14872	Pearson	_
86-3	14872-14873	’	_
86-4	14873-14874	s	_
86-5	14875-14886	correlation	_
86-6	14887-14898	coefficient	_
86-7	14899-14902	was	_
86-8	14903-14907	then	_
86-9	14908-14918	calculated	_
86-10	14919-14926	between	_
86-11	14927-14930	DMN	_
86-12	14931-14943	beta-weights	_
86-13	14944-14947	and	_
86-14	14948-14952	dACC	_
86-15	14953-14956	Glu	_
86-16	14956-14957	/	_
86-17	14957-14959	Cr	_
86-18	14960-14963	for	_
86-19	14964-14968	each	_
86-20	14969-14975	cohort	_
86-21	14976-14978	to	_
86-22	14979-14985	assess	_
86-23	14986-14989	the	_
86-24	14990-15001	association	_
86-25	15002-15009	between	_
86-26	15010-15015	these	_
86-27	15016-15024	measures	_
86-28	15024-15025	.	_
86-29	15026-15027	3	_
86-30	15027-15028	.	_

#Text=RESULTS
#Text=3.1 Demographics
#Text=All demographics are presented in table 1.
87-1	15029-15036	RESULTS	_
87-2	15037-15040	3.1	_
87-3	15041-15053	Demographics	_
87-4	15054-15057	All	_
87-5	15058-15070	demographics	_
87-6	15071-15074	are	_
87-7	15075-15084	presented	_
87-8	15085-15087	in	_
87-9	15088-15093	table	_
87-10	15094-15095	1	_
87-11	15095-15096	.	_

#Text=The primary and replication cohorts differed in age (t = 2.3, p < 0.04), expired CO at intake (t = 2.2, p < 0.04), and nicotine dependence level as measured by the FTND (t = 2.3 p < 0.02), where the primary cohort was older, had lower expired CO, and was less nicotine dependent.
88-1	15097-15100	The	_
88-2	15101-15108	primary	_
88-3	15109-15112	and	_
88-4	15113-15124	replication	_
88-5	15125-15132	cohorts	_
88-6	15133-15141	differed	_
88-7	15142-15144	in	_
88-8	15145-15148	age	_
88-9	15149-15150	(	_
88-10	15150-15151	t	_
88-11	15152-15153	=	_
88-12	15154-15157	2.3	_
88-13	15157-15158	,	_
88-14	15159-15160	p	_
88-15	15161-15162	<	_
88-16	15163-15167	0.04	_
88-17	15167-15168	)	_
88-18	15168-15169	,	_
88-19	15170-15177	expired	_
88-20	15178-15180	CO	_
88-21	15181-15183	at	_
88-22	15184-15190	intake	_
88-23	15191-15192	(	_
88-24	15192-15193	t	_
88-25	15194-15195	=	_
88-26	15196-15199	2.2	_
88-27	15199-15200	,	_
88-28	15201-15202	p	_
88-29	15203-15204	<	_
88-30	15205-15209	0.04	_
88-31	15209-15210	)	_
88-32	15210-15211	,	_
88-33	15212-15215	and	_
88-34	15216-15224	nicotine	_
88-35	15225-15235	dependence	_
88-36	15236-15241	level	_
88-37	15242-15244	as	_
88-38	15245-15253	measured	_
88-39	15254-15256	by	_
88-40	15257-15260	the	_
88-41	15261-15265	FTND	_
88-42	15266-15267	(	_
88-43	15267-15268	t	_
88-44	15269-15270	=	_
88-45	15271-15274	2.3	_
88-46	15275-15276	p	_
88-47	15277-15278	<	_
88-48	15279-15283	0.02	_
88-49	15283-15284	)	_
88-50	15284-15285	,	_
88-51	15286-15291	where	_
88-52	15292-15295	the	_
88-53	15296-15303	primary	_
88-54	15304-15310	cohort	_
88-55	15311-15314	was	_
88-56	15315-15320	older	_
88-57	15320-15321	,	_
88-58	15322-15325	had	_
88-59	15326-15331	lower	_
88-60	15332-15339	expired	_
88-61	15340-15342	CO	_
88-62	15342-15343	,	_
88-63	15344-15347	and	_
88-64	15348-15351	was	_
88-65	15352-15356	less	_
88-66	15357-15365	nicotine	_
88-67	15366-15375	dependent	_
88-68	15375-15376	.	_

#Text=However, the FTND scores indicate that both cohorts are moderately nicotine dependent.
89-1	15377-15384	However	_
89-2	15384-15385	,	_
89-3	15386-15389	the	_
89-4	15390-15394	FTND	_
89-5	15395-15401	scores	_
89-6	15402-15410	indicate	_
89-7	15411-15415	that	_
89-8	15416-15420	both	_
89-9	15421-15428	cohorts	_
89-10	15429-15432	are	_
89-11	15433-15443	moderately	_
89-12	15444-15452	nicotine	_
89-13	15453-15462	dependent	_
89-14	15462-15463	.	_

#Text=Subjective evaluation of all images shown during the in-scanner tasks indicated that participants reported higher craving to smoking than neutral cues in the primary (t = 4.2, p < 0.001) and replication cohorts (t = 5.6, p< 0.001).
90-1	15464-15474	Subjective	_
90-2	15475-15485	evaluation	_
90-3	15486-15488	of	_
90-4	15489-15492	all	_
90-5	15493-15499	images	_
90-6	15500-15505	shown	_
90-7	15506-15512	during	_
90-8	15513-15516	the	_
90-9	15517-15527	in-scanner	_
90-10	15528-15533	tasks	_
90-11	15534-15543	indicated	_
90-12	15544-15548	that	_
90-13	15549-15561	participants	_
90-14	15562-15570	reported	_
90-15	15571-15577	higher	_
90-16	15578-15585	craving	_
90-17	15586-15588	to	_
90-18	15589-15596	smoking	_
90-19	15597-15601	than	_
90-20	15602-15609	neutral	_
90-21	15610-15614	cues	_
90-22	15615-15617	in	_
90-23	15618-15621	the	_
90-24	15622-15629	primary	_
90-25	15630-15631	(	_
90-26	15631-15632	t	_
90-27	15633-15634	=	_
90-28	15635-15638	4.2	_
90-29	15638-15639	,	_
90-30	15640-15641	p	_
90-31	15642-15643	<	_
90-32	15644-15649	0.001	_
90-33	15649-15650	)	_
90-34	15651-15654	and	_
90-35	15655-15666	replication	_
90-36	15667-15674	cohorts	_
90-37	15675-15676	(	_
90-38	15676-15677	t	_
90-39	15678-15679	=	_
90-40	15680-15683	5.6	_
90-41	15683-15684	,	_
90-42	15685-15686	p	_
90-43	15686-15687	<	_
90-44	15688-15693	0.001	_
90-45	15693-15694	)	_
90-46	15694-15695	.	_

#Text=Following scanning, there was a significant decrease in expired carbon monoxide within the primary (t = 5.2, p < 0.01) and replication cohorts (t = 5.9, p < 0.001).
#Text=3.2 Functional magnetic resonance imaging
#Text=Within the primary cohort, the smoking vs. neutral contrast has been presented in our prior work.
91-1	15696-15705	Following	_
91-2	15706-15714	scanning	_
91-3	15714-15715	,	_
91-4	15716-15721	there	_
91-5	15722-15725	was	_
91-6	15726-15727	a	_
91-7	15728-15739	significant	_
91-8	15740-15748	decrease	_
91-9	15749-15751	in	_
91-10	15752-15759	expired	_
91-11	15760-15766	carbon	_
91-12	15767-15775	monoxide	_
91-13	15776-15782	within	_
91-14	15783-15786	the	_
91-15	15787-15794	primary	_
91-16	15795-15796	(	_
91-17	15796-15797	t	_
91-18	15798-15799	=	_
91-19	15800-15803	5.2	_
91-20	15803-15804	,	_
91-21	15805-15806	p	_
91-22	15807-15808	<	_
91-23	15809-15813	0.01	_
91-24	15813-15814	)	_
91-25	15815-15818	and	_
91-26	15819-15830	replication	_
91-27	15831-15838	cohorts	_
91-28	15839-15840	(	_
91-29	15840-15841	t	_
91-30	15842-15843	=	_
91-31	15844-15847	5.9	_
91-32	15847-15848	,	_
91-33	15849-15850	p	_
91-34	15851-15852	<	_
91-35	15853-15858	0.001	_
91-36	15858-15859	)	_
91-37	15859-15860	.	_
91-38	15861-15864	3.2	_
91-39	15865-15875	Functional	_
91-40	15876-15884	magnetic	_
91-41	15885-15894	resonance	_
91-42	15895-15902	imaging	_
91-43	15903-15909	Within	_
91-44	15910-15913	the	_
91-45	15914-15921	primary	_
91-46	15922-15928	cohort	_
91-47	15928-15929	,	_
91-48	15930-15933	the	_
91-49	15934-15941	smoking	_
91-50	15942-15944	vs	_
91-51	15944-15945	.	_
91-52	15946-15953	neutral	_
91-53	15954-15962	contrast	_
91-54	15963-15966	has	_
91-55	15967-15971	been	_
91-56	15972-15981	presented	_
91-57	15982-15984	in	_
91-58	15985-15988	our	_
91-59	15989-15994	prior	_
91-60	15995-15999	work	_
91-61	15999-16000	.	_

#Text=There was substantial overlap between this map generated by the whole brain smoking vs. neutral contrast and the DMN ROI (r = 0.46, Fig. 1).
92-1	16001-16006	There	_
92-2	16007-16010	was	_
92-3	16011-16022	substantial	_
92-4	16023-16030	overlap	_
92-5	16031-16038	between	_
92-6	16039-16043	this	_
92-7	16044-16047	map	_
92-8	16048-16057	generated	_
92-9	16058-16060	by	_
92-10	16061-16064	the	_
92-11	16065-16070	whole	_
92-12	16071-16076	brain	_
92-13	16077-16084	smoking	_
92-14	16085-16087	vs	_
92-15	16087-16088	.	_
92-16	16089-16096	neutral	_
92-17	16097-16105	contrast	_
92-18	16106-16109	and	_
92-19	16110-16113	the	_
92-20	16114-16117	DMN	_
92-21	16118-16121	ROI	_
92-22	16122-16123	(	_
92-23	16123-16124	r	_
92-24	16125-16126	=	_
92-25	16127-16131	0.46	_
92-26	16131-16132	,	_
92-27	16133-16136	Fig	_
92-28	16136-16137	.	_
92-29	16138-16139	1	_
92-30	16139-16140	)	_
92-31	16140-16141	.	_

#Text=When evaluating brain reactivity to smoking cues using an ROI approach, the DMN was significantly less suppressed when individuals were exposed to smoking cues in comparison to neutral cues (t = 5.2 p < 0.001; Fig. 1).
93-1	16142-16146	When	_
93-2	16147-16157	evaluating	_
93-3	16158-16163	brain	_
93-4	16164-16174	reactivity	_
93-5	16175-16177	to	_
93-6	16178-16185	smoking	_
93-7	16186-16190	cues	_
93-8	16191-16196	using	_
93-9	16197-16199	an	_
93-10	16200-16203	ROI	_
93-11	16204-16212	approach	_
93-12	16212-16213	,	_
93-13	16214-16217	the	_
93-14	16218-16221	DMN	_
93-15	16222-16225	was	_
93-16	16226-16239	significantly	_
93-17	16240-16244	less	_
93-18	16245-16255	suppressed	_
93-19	16256-16260	when	_
93-20	16261-16272	individuals	_
93-21	16273-16277	were	_
93-22	16278-16285	exposed	_
93-23	16286-16288	to	_
93-24	16289-16296	smoking	_
93-25	16297-16301	cues	_
93-26	16302-16304	in	_
93-27	16305-16315	comparison	_
93-28	16316-16318	to	_
93-29	16319-16326	neutral	_
93-30	16327-16331	cues	_
93-31	16332-16333	(	_
93-32	16333-16334	t	_
93-33	16335-16336	=	_
93-34	16337-16340	5.2	_
93-35	16341-16342	p	_
93-36	16343-16344	<	_
93-37	16345-16350	0.001	_
93-38	16350-16351	;	_
93-39	16352-16355	Fig	_
93-40	16355-16356	.	_
93-41	16357-16358	1	_
93-42	16358-16359	)	_
93-43	16359-16360	.	_

#Text=This finding was confirmed in our replication cohort (t = 3.9 p < 0.002)
#Text=3.3 Magnetic resonance spectroscopy
#Text=Participants in the primary cohort had an average Cramer Rao lower bound of 5.4% ± 0.3 for Glu and 1.8% ± 0.12 for Cr (representative spectra shown in Fig. 2).
94-1	16361-16365	This	_
94-2	16366-16373	finding	_
94-3	16374-16377	was	_
94-4	16378-16387	confirmed	_
94-5	16388-16390	in	_
94-6	16391-16394	our	_
94-7	16395-16406	replication	_
94-8	16407-16413	cohort	_
94-9	16414-16415	(	_
94-10	16415-16416	t	_
94-11	16417-16418	=	_
94-12	16419-16422	3.9	_
94-13	16423-16424	p	_
94-14	16425-16426	<	_
94-15	16427-16432	0.002	_
94-16	16432-16433	)	_
94-17	16434-16437	3.3	_
94-18	16438-16446	Magnetic	_
94-19	16447-16456	resonance	_
94-20	16457-16469	spectroscopy	_
94-21	16470-16482	Participants	_
94-22	16483-16485	in	_
94-23	16486-16489	the	_
94-24	16490-16497	primary	_
94-25	16498-16504	cohort	_
94-26	16505-16508	had	_
94-27	16509-16511	an	_
94-28	16512-16519	average	_
94-29	16520-16526	Cramer	_
94-30	16527-16530	Rao	_
94-31	16531-16536	lower	_
94-32	16537-16542	bound	_
94-33	16543-16545	of	_
94-34	16546-16550	5.4%	_
94-35	16551-16552	±	_
94-36	16553-16556	0.3	_
94-37	16557-16560	for	_
94-38	16561-16564	Glu	_
94-39	16565-16568	and	_
94-40	16569-16573	1.8%	_
94-41	16574-16575	±	_
94-42	16576-16580	0.12	_
94-43	16581-16584	for	_
94-44	16585-16587	Cr	_
94-45	16588-16589	(	_
94-46	16589-16603	representative	_
94-47	16604-16611	spectra	_
94-48	16612-16617	shown	_
94-49	16618-16620	in	_
94-50	16621-16624	Fig	_
94-51	16624-16625	.	_
94-52	16626-16627	2	_
94-53	16627-16628	)	_
94-54	16628-16629	.	_

#Text=The values for the replication cohort were comparable with 5.2% ± 0.16 for Glu and 1.7% ± 0.16 for Cr.
95-1	16630-16633	The	_
95-2	16634-16640	values	_
95-3	16641-16644	for	_
95-4	16645-16648	the	_
95-5	16649-16660	replication	_
95-6	16661-16667	cohort	_
95-7	16668-16672	were	_
95-8	16673-16683	comparable	_
95-9	16684-16688	with	_
95-10	16689-16693	5.2%	_
95-11	16694-16695	±	_
95-12	16696-16700	0.16	_
95-13	16701-16704	for	_
95-14	16705-16708	Glu	_
95-15	16709-16712	and	_
95-16	16713-16717	1.7%	_
95-17	16718-16719	±	_
95-18	16720-16724	0.16	_
95-19	16725-16728	for	_
95-20	16729-16731	Cr	_
95-21	16731-16732	.	_

#Text=Dorsal ACC Glu/Cr was positively correlated with DMN reactivity for the smoking > neutral contrast within the primary cohort (r = 0.56, p < 0.02, Fig. 3).
96-1	16733-16739	Dorsal	_
96-2	16740-16743	ACC	_
96-3	16744-16747	Glu	_
96-4	16747-16748	/	_
96-5	16748-16750	Cr	_
96-6	16751-16754	was	_
96-7	16755-16765	positively	_
96-8	16766-16776	correlated	_
96-9	16777-16781	with	_
96-10	16782-16785	DMN	_
96-11	16786-16796	reactivity	_
96-12	16797-16800	for	_
96-13	16801-16804	the	_
96-14	16805-16812	smoking	_
96-15	16813-16814	>	_
96-16	16815-16822	neutral	_
96-17	16823-16831	contrast	_
96-18	16832-16838	within	_
96-19	16839-16842	the	_
96-20	16843-16850	primary	_
96-21	16851-16857	cohort	_
96-22	16858-16859	(	_
96-23	16859-16860	r	_
96-24	16861-16862	=	_
96-25	16863-16867	0.56	_
96-26	16867-16868	,	_
96-27	16869-16870	p	_
96-28	16871-16872	<	_
96-29	16873-16877	0.02	_
96-30	16877-16878	,	_
96-31	16879-16882	Fig	_
96-32	16882-16883	.	_
96-33	16884-16885	3	_
96-34	16885-16886	)	_
96-35	16886-16887	.	_

#Text=This finding was confirmed in the replication cohort (r = 0.64, p < 0.02).
97-1	16888-16892	This	_
97-2	16893-16900	finding	_
97-3	16901-16904	was	_
97-4	16905-16914	confirmed	_
97-5	16915-16917	in	_
97-6	16918-16921	the	_
97-7	16922-16933	replication	_
97-8	16934-16940	cohort	_
97-9	16941-16942	(	_
97-10	16942-16943	r	_
97-11	16944-16945	=	_
97-12	16946-16950	0.64	_
97-13	16950-16951	,	_
97-14	16952-16953	p	_
97-15	16954-16955	<	_
97-16	16956-16960	0.02	_
97-17	16960-16961	)	_
97-18	16961-16962	.	_

#Text=A correlation between the smoking > neutral contrast and Cr was conducted and showed that the association between Glu/Cr and cue reactivity was not driven by Cr in either the primary (r = 0.04, p = 0.87) or replication cohort (r = −2.7, p = 0.53).
98-1	16963-16964	A	_
98-2	16965-16976	correlation	_
98-3	16977-16984	between	_
98-4	16985-16988	the	_
98-5	16989-16996	smoking	_
98-6	16997-16998	>	_
98-7	16999-17006	neutral	_
98-8	17007-17015	contrast	_
98-9	17016-17019	and	_
98-10	17020-17022	Cr	_
98-11	17023-17026	was	_
98-12	17027-17036	conducted	_
98-13	17037-17040	and	_
98-14	17041-17047	showed	_
98-15	17048-17052	that	_
98-16	17053-17056	the	_
98-17	17057-17068	association	_
98-18	17069-17076	between	_
98-19	17077-17080	Glu	_
98-20	17080-17081	/	_
98-21	17081-17083	Cr	_
98-22	17084-17087	and	_
98-23	17088-17091	cue	_
98-24	17092-17102	reactivity	_
98-25	17103-17106	was	_
98-26	17107-17110	not	_
98-27	17111-17117	driven	_
98-28	17118-17120	by	_
98-29	17121-17123	Cr	_
98-30	17124-17126	in	_
98-31	17127-17133	either	_
98-32	17134-17137	the	_
98-33	17138-17145	primary	_
98-34	17146-17147	(	_
98-35	17147-17148	r	_
98-36	17149-17150	=	_
98-37	17151-17155	0.04	_
98-38	17155-17156	,	_
98-39	17157-17158	p	_
98-40	17159-17160	=	_
98-41	17161-17165	0.87	_
98-42	17165-17166	)	_
98-43	17167-17169	or	_
98-44	17170-17181	replication	_
98-45	17182-17188	cohort	_
98-46	17189-17190	(	_
98-47	17190-17191	r	_
98-48	17192-17193	=	_
98-49	17194-17195	−	_
98-50	17195-17198	2.7	_
98-51	17198-17199	,	_
98-52	17200-17201	p	_
98-53	17202-17203	=	_
98-54	17204-17208	0.53	_
98-55	17208-17209	)	_
98-56	17209-17210	.	_

#Text=Follow-up analyses suggest that this relationship between DMN smoking > neutral cue-reactivity and dACC Glu/Cr is driven by reactivity to smoking images.
99-1	17211-17220	Follow-up	_
99-2	17221-17229	analyses	_
99-3	17230-17237	suggest	_
99-4	17238-17242	that	_
99-5	17243-17247	this	_
99-6	17248-17260	relationship	_
99-7	17261-17268	between	_
99-8	17269-17272	DMN	_
99-9	17273-17280	smoking	_
99-10	17281-17282	>	_
99-11	17283-17290	neutral	_
99-12	17291-17305	cue-reactivity	_
99-13	17306-17309	and	_
99-14	17310-17314	dACC	_
99-15	17315-17318	Glu	_
99-16	17318-17319	/	_
99-17	17319-17321	Cr	_
99-18	17322-17324	is	_
99-19	17325-17331	driven	_
99-20	17332-17334	by	_
99-21	17335-17345	reactivity	_
99-22	17346-17348	to	_
99-23	17349-17356	smoking	_
99-24	17357-17363	images	_
99-25	17363-17364	.	_

#Text=Specifically, there was a trend association between DMN reactivity to smoking cues (relative to baseline when a fixation is presented) and dACC Glu/Cr in our primary (r = 0.41, p < 0.09) and replication cohorts (r = 0.46, p < 0.09).
100-1	17365-17377	Specifically	_
100-2	17377-17378	,	_
100-3	17379-17384	there	_
100-4	17385-17388	was	_
100-5	17389-17390	a	_
100-6	17391-17396	trend	_
100-7	17397-17408	association	_
100-8	17409-17416	between	_
100-9	17417-17420	DMN	_
100-10	17421-17431	reactivity	_
100-11	17432-17434	to	_
100-12	17435-17442	smoking	_
100-13	17443-17447	cues	_
100-14	17448-17449	(	_
100-15	17449-17457	relative	_
100-16	17458-17460	to	_
100-17	17461-17469	baseline	_
100-18	17470-17474	when	_
100-19	17475-17476	a	_
100-20	17477-17485	fixation	_
100-21	17486-17488	is	_
100-22	17489-17498	presented	_
100-23	17498-17499	)	_
100-24	17500-17503	and	_
100-25	17504-17508	dACC	_
100-26	17509-17512	Glu	_
100-27	17512-17513	/	_
100-28	17513-17515	Cr	_
100-29	17516-17518	in	_
100-30	17519-17522	our	_
100-31	17523-17530	primary	_
100-32	17531-17532	(	_
100-33	17532-17533	r	_
100-34	17534-17535	=	_
100-35	17536-17540	0.41	_
100-36	17540-17541	,	_
100-37	17542-17543	p	_
100-38	17544-17545	<	_
100-39	17546-17550	0.09	_
100-40	17550-17551	)	_
100-41	17552-17555	and	_
100-42	17556-17567	replication	_
100-43	17568-17575	cohorts	_
100-44	17576-17577	(	_
100-45	17577-17578	r	_
100-46	17579-17580	=	_
100-47	17581-17585	0.46	_
100-48	17585-17586	,	_
100-49	17587-17588	p	_
100-50	17589-17590	<	_
100-51	17591-17595	0.09	_
100-52	17595-17596	)	_
100-53	17596-17597	.	_

#Text=The relationship between dACC Glu/Cr and DMN reactivity to smoking cues becomes significant when both cohorts are combined into a single group (r = 0.39, p < 0.03).
101-1	17598-17601	The	_
101-2	17602-17614	relationship	_
101-3	17615-17622	between	_
101-4	17623-17627	dACC	_
101-5	17628-17631	Glu	_
101-6	17631-17632	/	_
101-7	17632-17634	Cr	_
101-8	17635-17638	and	_
101-9	17639-17642	DMN	_
101-10	17643-17653	reactivity	_
101-11	17654-17656	to	_
101-12	17657-17664	smoking	_
101-13	17665-17669	cues	_
101-14	17670-17677	becomes	_
101-15	17678-17689	significant	_
101-16	17690-17694	when	_
101-17	17695-17699	both	_
101-18	17700-17707	cohorts	_
101-19	17708-17711	are	_
101-20	17712-17720	combined	_
101-21	17721-17725	into	_
101-22	17726-17727	a	_
101-23	17728-17734	single	_
101-24	17735-17740	group	_
101-25	17741-17742	(	_
101-26	17742-17743	r	_
101-27	17744-17745	=	_
101-28	17746-17750	0.39	_
101-29	17750-17751	,	_
101-30	17752-17753	p	_
101-31	17754-17755	<	_
101-32	17756-17760	0.03	_
101-33	17760-17761	)	_
101-34	17761-17762	.	_

#Text=Such an association was not found between dACC Glu/Cr and DMN reactivity to neutral cues (relative to baseline) in either the primary (r = 0.1, p = 0.75) or replication cohort (r = 0.1, p = 0.70).
#Text=3.4 Voxel Tissue
#Text=On average, for both groups, the dACC voxel was comprised of 56.86 ± 0.91 percent gray matter, 27.6 ± 1.1 percent white matter, and 15.9 ± 1.2 percent CSF.
102-1	17763-17767	Such	_
102-2	17768-17770	an	_
102-3	17771-17782	association	_
102-4	17783-17786	was	_
102-5	17787-17790	not	_
102-6	17791-17796	found	_
102-7	17797-17804	between	_
102-8	17805-17809	dACC	_
102-9	17810-17813	Glu	_
102-10	17813-17814	/	_
102-11	17814-17816	Cr	_
102-12	17817-17820	and	_
102-13	17821-17824	DMN	_
102-14	17825-17835	reactivity	_
102-15	17836-17838	to	_
102-16	17839-17846	neutral	_
102-17	17847-17851	cues	_
102-18	17852-17853	(	_
102-19	17853-17861	relative	_
102-20	17862-17864	to	_
102-21	17865-17873	baseline	_
102-22	17873-17874	)	_
102-23	17875-17877	in	_
102-24	17878-17884	either	_
102-25	17885-17888	the	_
102-26	17889-17896	primary	_
102-27	17897-17898	(	_
102-28	17898-17899	r	_
102-29	17900-17901	=	_
102-30	17902-17905	0.1	_
102-31	17905-17906	,	_
102-32	17907-17908	p	_
102-33	17909-17910	=	_
102-34	17911-17915	0.75	_
102-35	17915-17916	)	_
102-36	17917-17919	or	_
102-37	17920-17931	replication	_
102-38	17932-17938	cohort	_
102-39	17939-17940	(	_
102-40	17940-17941	r	_
102-41	17942-17943	=	_
102-42	17944-17947	0.1	_
102-43	17947-17948	,	_
102-44	17949-17950	p	_
102-45	17951-17952	=	_
102-46	17953-17957	0.70	_
102-47	17957-17958	)	_
102-48	17958-17959	.	_
102-49	17960-17963	3.4	_
102-50	17964-17969	Voxel	_
102-51	17970-17976	Tissue	_
102-52	17977-17979	On	_
102-53	17980-17987	average	_
102-54	17987-17988	,	_
102-55	17989-17992	for	_
102-56	17993-17997	both	_
102-57	17998-18004	groups	_
102-58	18004-18005	,	_
102-59	18006-18009	the	_
102-60	18010-18014	dACC	_
102-61	18015-18020	voxel	_
102-62	18021-18024	was	_
102-63	18025-18034	comprised	_
102-64	18035-18037	of	_
102-65	18038-18043	56.86	_
102-66	18044-18045	±	_
102-67	18046-18050	0.91	_
102-68	18051-18058	percent	_
102-69	18059-18063	gray	_
102-70	18064-18070	matter	_
102-71	18070-18071	,	_
102-72	18072-18076	27.6	_
102-73	18077-18078	±	_
102-74	18079-18082	1.1	_
102-75	18083-18090	percent	_
102-76	18091-18096	white	_
102-77	18097-18103	matter	_
102-78	18103-18104	,	_
102-79	18105-18108	and	_
102-80	18109-18113	15.9	_
102-81	18114-18115	±	_
102-82	18116-18119	1.2	_
102-83	18120-18127	percent	_
102-84	18128-18131	CSF	_
102-85	18131-18132	.	_

#Text=No correlation was found between dACC Glu/Cr and the volume of grey matter (primary cohort: r = −0.18, replication cohort: r = 0.09), white matter (primary cohort: r = − 0.03, replication cohort, r = − 0.25), or CSF (primary cohort: r = 0.19, replication cohort r = 0.15) within the dACC voxel used for all MRS measurements.
#Text=4.
103-1	18133-18135	No	_
103-2	18136-18147	correlation	_
103-3	18148-18151	was	_
103-4	18152-18157	found	_
103-5	18158-18165	between	_
103-6	18166-18170	dACC	_
103-7	18171-18174	Glu	_
103-8	18174-18175	/	_
103-9	18175-18177	Cr	_
103-10	18178-18181	and	_
103-11	18182-18185	the	_
103-12	18186-18192	volume	_
103-13	18193-18195	of	_
103-14	18196-18200	grey	_
103-15	18201-18207	matter	_
103-16	18208-18209	(	_
103-17	18209-18216	primary	_
103-18	18217-18223	cohort	_
103-19	18223-18224	:	_
103-20	18225-18226	r	_
103-21	18227-18228	=	_
103-22	18229-18230	−	_
103-23	18230-18234	0.18	_
103-24	18234-18235	,	_
103-25	18236-18247	replication	_
103-26	18248-18254	cohort	_
103-27	18254-18255	:	_
103-28	18256-18257	r	_
103-29	18258-18259	=	_
103-30	18260-18264	0.09	_
103-31	18264-18265	)	_
103-32	18265-18266	,	_
103-33	18267-18272	white	_
103-34	18273-18279	matter	_
103-35	18280-18281	(	_
103-36	18281-18288	primary	_
103-37	18289-18295	cohort	_
103-38	18295-18296	:	_
103-39	18297-18298	r	_
103-40	18299-18300	=	_
103-41	18301-18302	−	_
103-42	18303-18307	0.03	_
103-43	18307-18308	,	_
103-44	18309-18320	replication	_
103-45	18321-18327	cohort	_
103-46	18327-18328	,	_
103-47	18329-18330	r	_
103-48	18331-18332	=	_
103-49	18333-18334	−	_
103-50	18335-18339	0.25	_
103-51	18339-18340	)	_
103-52	18340-18341	,	_
103-53	18342-18344	or	_
103-54	18345-18348	CSF	_
103-55	18349-18350	(	_
103-56	18350-18357	primary	_
103-57	18358-18364	cohort	_
103-58	18364-18365	:	_
103-59	18366-18367	r	_
103-60	18368-18369	=	_
103-61	18370-18374	0.19	_
103-62	18374-18375	,	_
103-63	18376-18387	replication	_
103-64	18388-18394	cohort	_
103-65	18395-18396	r	_
103-66	18397-18398	=	_
103-67	18399-18403	0.15	_
103-68	18403-18404	)	_
103-69	18405-18411	within	_
103-70	18412-18415	the	_
103-71	18416-18420	dACC	_
103-72	18421-18426	voxel	_
103-73	18427-18431	used	_
103-74	18432-18435	for	_
103-75	18436-18439	all	_
103-76	18440-18443	MRS	_
103-77	18444-18456	measurements	_
103-78	18456-18457	.	_
103-79	18458-18459	4	_
103-80	18459-18460	.	_

#Text=DISCUSSION
#Text=Numerous studies indicate that smokers have significant reactivity to smoking cues in brain regions overlapping with the DMN.
104-1	18461-18471	DISCUSSION	_
104-2	18472-18480	Numerous	_
104-3	18481-18488	studies	_
104-4	18489-18497	indicate	_
104-5	18498-18502	that	_
104-6	18503-18510	smokers	_
104-7	18511-18515	have	_
104-8	18516-18527	significant	_
104-9	18528-18538	reactivity	_
104-10	18539-18541	to	_
104-11	18542-18549	smoking	_
104-12	18550-18554	cues	_
104-13	18555-18557	in	_
104-14	18558-18563	brain	_
104-15	18564-18571	regions	_
104-16	18572-18583	overlapping	_
104-17	18584-18588	with	_
104-18	18589-18592	the	_
104-19	18593-18596	DMN	_
104-20	18596-18597	.	_

#Text=Further, DMN regions such as the precuneus and posterior cingulate cortex (PCC) are linked with craving and nicotine dependence (; Courtney et al. 2013).
105-1	18598-18605	Further	_
105-2	18605-18606	,	_
105-3	18607-18610	DMN	_
105-4	18611-18618	regions	_
105-5	18619-18623	such	_
105-6	18624-18626	as	_
105-7	18627-18630	the	_
105-8	18631-18640	precuneus	_
105-9	18641-18644	and	_
105-10	18645-18654	posterior	_
105-11	18655-18664	cingulate	_
105-12	18665-18671	cortex	_
105-13	18672-18673	(	_
105-14	18673-18676	PCC	_
105-15	18676-18677	)	_
105-16	18678-18681	are	_
105-17	18682-18688	linked	_
105-18	18689-18693	with	_
105-19	18694-18701	craving	_
105-20	18702-18705	and	_
105-21	18706-18714	nicotine	_
105-22	18715-18725	dependence	_
105-23	18726-18727	(	_
105-24	18727-18728	;	_
105-25	18729-18737	Courtney	_
105-26	18738-18740	et	_
105-27	18741-18743	al	_
105-28	18743-18744	.	_
105-29	18745-18749	2013	_
105-30	18749-18750	)	_
105-31	18750-18751	.	_

#Text=By studying the DMN directly, the results of the present study confirm that the DMN is less suppressed when smokers view smoking cues relative to neutral cues.
106-1	18752-18754	By	_
106-2	18755-18763	studying	_
106-3	18764-18767	the	_
106-4	18768-18771	DMN	_
106-5	18772-18780	directly	_
106-6	18780-18781	,	_
106-7	18782-18785	the	_
106-8	18786-18793	results	_
106-9	18794-18796	of	_
106-10	18797-18800	the	_
106-11	18801-18808	present	_
106-12	18809-18814	study	_
106-13	18815-18822	confirm	_
106-14	18823-18827	that	_
106-15	18828-18831	the	_
106-16	18832-18835	DMN	_
106-17	18836-18838	is	_
106-18	18839-18843	less	_
106-19	18844-18854	suppressed	_
106-20	18855-18859	when	_
106-21	18860-18867	smokers	_
106-22	18868-18872	view	_
106-23	18873-18880	smoking	_
106-24	18881-18885	cues	_
106-25	18886-18894	relative	_
106-26	18895-18897	to	_
106-27	18898-18905	neutral	_
106-28	18906-18910	cues	_
106-29	18910-18911	.	_

#Text=This point was further validated by showing a strong overlap between the DMN ROI as defined by and the whole brain reactivity to smoking cues presented in the current work.
107-1	18912-18916	This	_
107-2	18917-18922	point	_
107-3	18923-18926	was	_
107-4	18927-18934	further	_
107-5	18935-18944	validated	_
107-6	18945-18947	by	_
107-7	18948-18955	showing	_
107-8	18956-18957	a	_
107-9	18958-18964	strong	_
107-10	18965-18972	overlap	_
107-11	18973-18980	between	_
107-12	18981-18984	the	_
107-13	18985-18988	DMN	_
107-14	18989-18992	ROI	_
107-15	18993-18995	as	_
107-16	18996-19003	defined	_
107-17	19004-19006	by	_
107-18	19007-19010	and	_
107-19	19011-19014	the	_
107-20	19015-19020	whole	_
107-21	19021-19026	brain	_
107-22	19027-19037	reactivity	_
107-23	19038-19040	to	_
107-24	19041-19048	smoking	_
107-25	19049-19053	cues	_
107-26	19054-19063	presented	_
107-27	19064-19066	in	_
107-28	19067-19070	the	_
107-29	19071-19078	current	_
107-30	19079-19083	work	_
107-31	19083-19084	.	_

#Text=Further, the strength of DMN reactivity to smoking > neutral cues is positively associated with dACC Glu/Cr, a finding that was confirmed in an independent sample.
108-1	19085-19092	Further	_
108-2	19092-19093	,	_
108-3	19094-19097	the	_
108-4	19098-19106	strength	_
108-5	19107-19109	of	_
108-6	19110-19113	DMN	_
108-7	19114-19124	reactivity	_
108-8	19125-19127	to	_
108-9	19128-19135	smoking	_
108-10	19136-19137	>	_
108-11	19138-19145	neutral	_
108-12	19146-19150	cues	_
108-13	19151-19153	is	_
108-14	19154-19164	positively	_
108-15	19165-19175	associated	_
108-16	19176-19180	with	_
108-17	19181-19185	dACC	_
108-18	19186-19189	Glu	_
108-19	19189-19190	/	_
108-20	19190-19192	Cr	_
108-21	19192-19193	,	_
108-22	19194-19195	a	_
108-23	19196-19203	finding	_
108-24	19204-19208	that	_
108-25	19209-19212	was	_
108-26	19213-19222	confirmed	_
108-27	19223-19225	in	_
108-28	19226-19228	an	_
108-29	19229-19240	independent	_
108-30	19241-19247	sample	_
108-31	19247-19248	.	_

#Text=Follow-up analyses suggest that this relationship between DMN smoking > neutral cue-reactivity and dACC Glu/Cr is driven by reactivity to smoking images.
109-1	19249-19258	Follow-up	_
109-2	19259-19267	analyses	_
109-3	19268-19275	suggest	_
109-4	19276-19280	that	_
109-5	19281-19285	this	_
109-6	19286-19298	relationship	_
109-7	19299-19306	between	_
109-8	19307-19310	DMN	_
109-9	19311-19318	smoking	_
109-10	19319-19320	>	_
109-11	19321-19328	neutral	_
109-12	19329-19343	cue-reactivity	_
109-13	19344-19347	and	_
109-14	19348-19352	dACC	_
109-15	19353-19356	Glu	_
109-16	19356-19357	/	_
109-17	19357-19359	Cr	_
109-18	19360-19362	is	_
109-19	19363-19369	driven	_
109-20	19370-19372	by	_
109-21	19373-19383	reactivity	_
109-22	19384-19386	to	_
109-23	19387-19394	smoking	_
109-24	19395-19401	images	_
109-25	19401-19402	.	_

#Text=Prior work has shown that individuals with greater dACC Glu had enhanced activity in regions of the DMN during a low cognitive demand task.
110-1	19403-19408	Prior	_
110-2	19409-19413	work	_
110-3	19414-19417	has	_
110-4	19418-19423	shown	_
110-5	19424-19428	that	_
110-6	19429-19440	individuals	_
110-7	19441-19445	with	_
110-8	19446-19453	greater	_
110-9	19454-19458	dACC	_
110-10	19459-19462	Glu	_
110-11	19463-19466	had	_
110-12	19467-19475	enhanced	_
110-13	19476-19484	activity	_
110-14	19485-19487	in	_
110-15	19488-19495	regions	_
110-16	19496-19498	of	_
110-17	19499-19502	the	_
110-18	19503-19506	DMN	_
110-19	19507-19513	during	_
110-20	19514-19515	a	_
110-21	19516-19519	low	_
110-22	19520-19529	cognitive	_
110-23	19530-19536	demand	_
110-24	19537-19541	task	_
110-25	19541-19542	.	_

#Text=Together with the present findings, these data indicate a relationship exists between of higher dACC Glu and DMN engagement when this network is typically active, namely during periods of low cognitive demand and during exposure to personally relevant stimuli.
111-1	19543-19551	Together	_
111-2	19552-19556	with	_
111-3	19557-19560	the	_
111-4	19561-19568	present	_
111-5	19569-19577	findings	_
111-6	19577-19578	,	_
111-7	19579-19584	these	_
111-8	19585-19589	data	_
111-9	19590-19598	indicate	_
111-10	19599-19600	a	_
111-11	19601-19613	relationship	_
111-12	19614-19620	exists	_
111-13	19621-19628	between	_
111-14	19629-19631	of	_
111-15	19632-19638	higher	_
111-16	19639-19643	dACC	_
111-17	19644-19647	Glu	_
111-18	19648-19651	and	_
111-19	19652-19655	DMN	_
111-20	19656-19666	engagement	_
111-21	19667-19671	when	_
111-22	19672-19676	this	_
111-23	19677-19684	network	_
111-24	19685-19687	is	_
111-25	19688-19697	typically	_
111-26	19698-19704	active	_
111-27	19704-19705	,	_
111-28	19706-19712	namely	_
111-29	19713-19719	during	_
111-30	19720-19727	periods	_
111-31	19728-19730	of	_
111-32	19731-19734	low	_
111-33	19735-19744	cognitive	_
111-34	19745-19751	demand	_
111-35	19752-19755	and	_
111-36	19756-19762	during	_
111-37	19763-19771	exposure	_
111-38	19772-19774	to	_
111-39	19775-19785	personally	_
111-40	19786-19794	relevant	_
111-41	19795-19802	stimuli	_
111-42	19802-19803	.	_

#Text=The link between dACC Glu and DMN reactivity to smoking cues also is supported by the finding that varenicline induced the suppression of both dACC Glu and DMN activity during a cognitive task in participants suggesting a relationship between these neurobiological factors.
112-1	19804-19807	The	_
112-2	19808-19812	link	_
112-3	19813-19820	between	_
112-4	19821-19825	dACC	_
112-5	19826-19829	Glu	_
112-6	19830-19833	and	_
112-7	19834-19837	DMN	_
112-8	19838-19848	reactivity	_
112-9	19849-19851	to	_
112-10	19852-19859	smoking	_
112-11	19860-19864	cues	_
112-12	19865-19869	also	_
112-13	19870-19872	is	_
112-14	19873-19882	supported	_
112-15	19883-19885	by	_
112-16	19886-19889	the	_
112-17	19890-19897	finding	_
112-18	19898-19902	that	_
112-19	19903-19914	varenicline	_
112-20	19915-19922	induced	_
112-21	19923-19926	the	_
112-22	19927-19938	suppression	_
112-23	19939-19941	of	_
112-24	19942-19946	both	_
112-25	19947-19951	dACC	_
112-26	19952-19955	Glu	_
112-27	19956-19959	and	_
112-28	19960-19963	DMN	_
112-29	19964-19972	activity	_
112-30	19973-19979	during	_
112-31	19980-19981	a	_
112-32	19982-19991	cognitive	_
112-33	19992-19996	task	_
112-34	19997-19999	in	_
112-35	20000-20012	participants	_
112-36	20013-20023	suggesting	_
112-37	20024-20025	a	_
112-38	20026-20038	relationship	_
112-39	20039-20046	between	_
112-40	20047-20052	these	_
112-41	20053-20068	neurobiological	_
112-42	20069-20076	factors	_
112-43	20076-20077	.	_

#Text=Further, linking the interaction between these regions is that others have shown that the structural integrity of the SN, which is comprised of the dACC and insula, influences DMN activity (Bonnelle et al 2012), making it tempting to speculate that neurochemical variations within nodes of the SN, such as the dACC, may also impact DMN activity.
113-1	20078-20085	Further	_
113-2	20085-20086	,	_
113-3	20087-20094	linking	_
113-4	20095-20098	the	_
113-5	20099-20110	interaction	_
113-6	20111-20118	between	_
113-7	20119-20124	these	_
113-8	20125-20132	regions	_
113-9	20133-20135	is	_
113-10	20136-20140	that	_
113-11	20141-20147	others	_
113-12	20148-20152	have	_
113-13	20153-20158	shown	_
113-14	20159-20163	that	_
113-15	20164-20167	the	_
113-16	20168-20178	structural	_
113-17	20179-20188	integrity	_
113-18	20189-20191	of	_
113-19	20192-20195	the	_
113-20	20196-20198	SN	_
113-21	20198-20199	,	_
113-22	20200-20205	which	_
113-23	20206-20208	is	_
113-24	20209-20218	comprised	_
113-25	20219-20221	of	_
113-26	20222-20225	the	_
113-27	20226-20230	dACC	_
113-28	20231-20234	and	_
113-29	20235-20241	insula	_
113-30	20241-20242	,	_
113-31	20243-20253	influences	_
113-32	20254-20257	DMN	_
113-33	20258-20266	activity	_
113-34	20267-20268	(	_
113-35	20268-20276	Bonnelle	_
113-36	20277-20279	et	_
113-37	20280-20282	al	_
113-38	20283-20287	2012	_
113-39	20287-20288	)	_
113-40	20288-20289	,	_
113-41	20290-20296	making	_
113-42	20297-20299	it	_
113-43	20300-20308	tempting	_
113-44	20309-20311	to	_
113-45	20312-20321	speculate	_
113-46	20322-20326	that	_
113-47	20327-20340	neurochemical	_
113-48	20341-20351	variations	_
113-49	20352-20358	within	_
113-50	20359-20364	nodes	_
113-51	20365-20367	of	_
113-52	20368-20371	the	_
113-53	20372-20374	SN	_
113-54	20374-20375	,	_
113-55	20376-20380	such	_
113-56	20381-20383	as	_
113-57	20384-20387	the	_
113-58	20388-20392	dACC	_
113-59	20392-20393	,	_
113-60	20394-20397	may	_
113-61	20398-20402	also	_
113-62	20403-20409	impact	_
113-63	20410-20413	DMN	_
113-64	20414-20422	activity	_
113-65	20422-20423	.	_

#Text=While evidence suggests that the SN modulates DMN activity, we are unable to confirm that it is variation in dACC Glu that is driving the association with DMN activity to smoking vs. neutral cues.
114-1	20424-20429	While	_
114-2	20430-20438	evidence	_
114-3	20439-20447	suggests	_
114-4	20448-20452	that	_
114-5	20453-20456	the	_
114-6	20457-20459	SN	_
114-7	20460-20469	modulates	_
114-8	20470-20473	DMN	_
114-9	20474-20482	activity	_
114-10	20482-20483	,	_
114-11	20484-20486	we	_
114-12	20487-20490	are	_
114-13	20491-20497	unable	_
114-14	20498-20500	to	_
114-15	20501-20508	confirm	_
114-16	20509-20513	that	_
114-17	20514-20516	it	_
114-18	20517-20519	is	_
114-19	20520-20529	variation	_
114-20	20530-20532	in	_
114-21	20533-20537	dACC	_
114-22	20538-20541	Glu	_
114-23	20542-20546	that	_
114-24	20547-20549	is	_
114-25	20550-20557	driving	_
114-26	20558-20561	the	_
114-27	20562-20573	association	_
114-28	20574-20578	with	_
114-29	20579-20582	DMN	_
114-30	20583-20591	activity	_
114-31	20592-20594	to	_
114-32	20595-20602	smoking	_
114-33	20603-20605	vs	_
114-34	20605-20606	.	_
114-35	20607-20614	neutral	_
114-36	20615-20619	cues	_
114-37	20619-20620	.	_

#Text=Despite this limitation, there is a growing body of literature implicating the importance of interactions between the SN and DMN (or nodes of these networks) in nicotine dependence.
115-1	20621-20628	Despite	_
115-2	20629-20633	this	_
115-3	20634-20644	limitation	_
115-4	20644-20645	,	_
115-5	20646-20651	there	_
115-6	20652-20654	is	_
115-7	20655-20656	a	_
115-8	20657-20664	growing	_
115-9	20665-20669	body	_
115-10	20670-20672	of	_
115-11	20673-20683	literature	_
115-12	20684-20695	implicating	_
115-13	20696-20699	the	_
115-14	20700-20710	importance	_
115-15	20711-20713	of	_
115-16	20714-20726	interactions	_
115-17	20727-20734	between	_
115-18	20735-20738	the	_
115-19	20739-20741	SN	_
115-20	20742-20745	and	_
115-21	20746-20749	DMN	_
115-22	20750-20751	(	_
115-23	20751-20753	or	_
115-24	20754-20759	nodes	_
115-25	20760-20762	of	_
115-26	20763-20768	these	_
115-27	20769-20777	networks	_
115-28	20777-20778	)	_
115-29	20779-20781	in	_
115-30	20782-20790	nicotine	_
115-31	20791-20801	dependence	_
115-32	20801-20802	.	_

#Text=For instance, stronger dACC-precuneus structural and functional interactions are associated with greater nicotine physical dependence and such functional dACC-precuneus interactions increase during withdrawal.
116-1	20803-20806	For	_
116-2	20807-20815	instance	_
116-3	20815-20816	,	_
116-4	20817-20825	stronger	_
116-5	20826-20840	dACC-precuneus	_
116-6	20841-20851	structural	_
116-7	20852-20855	and	_
116-8	20856-20866	functional	_
116-9	20867-20879	interactions	_
116-10	20880-20883	are	_
116-11	20884-20894	associated	_
116-12	20895-20899	with	_
116-13	20900-20907	greater	_
116-14	20908-20916	nicotine	_
116-15	20917-20925	physical	_
116-16	20926-20936	dependence	_
116-17	20937-20940	and	_
116-18	20941-20945	such	_
116-19	20946-20956	functional	_
116-20	20957-20971	dACC-precuneus	_
116-21	20972-20984	interactions	_
116-22	20985-20993	increase	_
116-23	20994-21000	during	_
116-24	21001-21011	withdrawal	_
116-25	21011-21012	.	_

#Text=As the dACC and precuneus are primary nodes of the SN and DMN respectively, the work of Haung et al is consistent with the finding that SN-DMN interactions also increase during withdrawal.
117-1	21013-21015	As	_
117-2	21016-21019	the	_
117-3	21020-21024	dACC	_
117-4	21025-21028	and	_
117-5	21029-21038	precuneus	_
117-6	21039-21042	are	_
117-7	21043-21050	primary	_
117-8	21051-21056	nodes	_
117-9	21057-21059	of	_
117-10	21060-21063	the	_
117-11	21064-21066	SN	_
117-12	21067-21070	and	_
117-13	21071-21074	DMN	_
117-14	21075-21087	respectively	_
117-15	21087-21088	,	_
117-16	21089-21092	the	_
117-17	21093-21097	work	_
117-18	21098-21100	of	_
117-19	21101-21106	Haung	_
117-20	21107-21109	et	_
117-21	21110-21112	al	_
117-22	21113-21115	is	_
117-23	21116-21126	consistent	_
117-24	21127-21131	with	_
117-25	21132-21135	the	_
117-26	21136-21143	finding	_
117-27	21144-21148	that	_
117-28	21149-21155	SN-DMN	_
117-29	21156-21168	interactions	_
117-30	21169-21173	also	_
117-31	21174-21182	increase	_
117-32	21183-21189	during	_
117-33	21190-21200	withdrawal	_
117-34	21200-21201	.	_

#Text=It has been suggested that these enhanced interactions may bias individuals to engage the DMN and attend to internal states contributing to craving.
118-1	21202-21204	It	_
118-2	21205-21208	has	_
118-3	21209-21213	been	_
118-4	21214-21223	suggested	_
118-5	21224-21228	that	_
118-6	21229-21234	these	_
118-7	21235-21243	enhanced	_
118-8	21244-21256	interactions	_
118-9	21257-21260	may	_
118-10	21261-21265	bias	_
118-11	21266-21277	individuals	_
118-12	21278-21280	to	_
118-13	21281-21287	engage	_
118-14	21288-21291	the	_
118-15	21292-21295	DMN	_
118-16	21296-21299	and	_
118-17	21300-21306	attend	_
118-18	21307-21309	to	_
118-19	21310-21318	internal	_
118-20	21319-21325	states	_
118-21	21326-21338	contributing	_
118-22	21339-21341	to	_
118-23	21342-21349	craving	_
118-24	21349-21350	.	_

#Text=Our work extends these findings by showing that even during satiety, individuals with higher dACC Glu are more prone to engage the DMN when exposed to self-relevant smoking cues.
119-1	21351-21354	Our	_
119-2	21355-21359	work	_
119-3	21360-21367	extends	_
119-4	21368-21373	these	_
119-5	21374-21382	findings	_
119-6	21383-21385	by	_
119-7	21386-21393	showing	_
119-8	21394-21398	that	_
119-9	21399-21403	even	_
119-10	21404-21410	during	_
119-11	21411-21418	satiety	_
119-12	21418-21419	,	_
119-13	21420-21431	individuals	_
119-14	21432-21436	with	_
119-15	21437-21443	higher	_
119-16	21444-21448	dACC	_
119-17	21449-21452	Glu	_
119-18	21453-21456	are	_
119-19	21457-21461	more	_
119-20	21462-21467	prone	_
119-21	21468-21470	to	_
119-22	21471-21477	engage	_
119-23	21478-21481	the	_
119-24	21482-21485	DMN	_
119-25	21486-21490	when	_
119-26	21491-21498	exposed	_
119-27	21499-21501	to	_
119-28	21502-21515	self-relevant	_
119-29	21516-21523	smoking	_
119-30	21524-21528	cues	_
119-31	21528-21529	.	_

#Text=The possibility that dACC Glu may modulate such aspects of brain function is consistent with prior work.
120-1	21530-21533	The	_
120-2	21534-21545	possibility	_
120-3	21546-21550	that	_
120-4	21551-21555	dACC	_
120-5	21556-21559	Glu	_
120-6	21560-21563	may	_
120-7	21564-21572	modulate	_
120-8	21573-21577	such	_
120-9	21578-21585	aspects	_
120-10	21586-21588	of	_
120-11	21589-21594	brain	_
120-12	21595-21603	function	_
120-13	21604-21606	is	_
120-14	21607-21617	consistent	_
120-15	21618-21622	with	_
120-16	21623-21628	prior	_
120-17	21629-21633	work	_
120-18	21633-21634	.	_

#Text=Specifically, heightened Glu in more rostral regions of the ACC, influenced an electroencephalogram (EEG) measure of resting brain function, as well as the perceived self-relatedness of stimuli.
121-1	21635-21647	Specifically	_
121-2	21647-21648	,	_
121-3	21649-21659	heightened	_
121-4	21660-21663	Glu	_
121-5	21664-21666	in	_
121-6	21667-21671	more	_
121-7	21672-21679	rostral	_
121-8	21680-21687	regions	_
121-9	21688-21690	of	_
121-10	21691-21694	the	_
121-11	21695-21698	ACC	_
121-12	21698-21699	,	_
121-13	21700-21710	influenced	_
121-14	21711-21713	an	_
121-15	21714-21734	electroencephalogram	_
121-16	21735-21736	(	_
121-17	21736-21739	EEG	_
121-18	21739-21740	)	_
121-19	21741-21748	measure	_
121-20	21749-21751	of	_
121-21	21752-21759	resting	_
121-22	21760-21765	brain	_
121-23	21766-21774	function	_
121-24	21774-21775	,	_
121-25	21776-21778	as	_
121-26	21779-21783	well	_
121-27	21784-21786	as	_
121-28	21787-21790	the	_
121-29	21791-21800	perceived	_
121-30	21801-21817	self-relatedness	_
121-31	21818-21820	of	_
121-32	21821-21828	stimuli	_
121-33	21828-21829	.	_

#Text=Our prior work suggests that a relationship exists between dACC Glu and treatment outcome as individuals who are more likely to relapse have reduced dACC Glu.
122-1	21830-21833	Our	_
122-2	21834-21839	prior	_
122-3	21840-21844	work	_
122-4	21845-21853	suggests	_
122-5	21854-21858	that	_
122-6	21859-21860	a	_
122-7	21861-21873	relationship	_
122-8	21874-21880	exists	_
122-9	21881-21888	between	_
122-10	21889-21893	dACC	_
122-11	21894-21897	Glu	_
122-12	21898-21901	and	_
122-13	21902-21911	treatment	_
122-14	21912-21919	outcome	_
122-15	21920-21922	as	_
122-16	21923-21934	individuals	_
122-17	21935-21938	who	_
122-18	21939-21942	are	_
122-19	21943-21947	more	_
122-20	21948-21954	likely	_
122-21	21955-21957	to	_
122-22	21958-21965	relapse	_
122-23	21966-21970	have	_
122-24	21971-21978	reduced	_
122-25	21979-21983	dACC	_
122-26	21984-21987	Glu	_
122-27	21987-21988	.	_

#Text=These findings are somewhat in contrast to our current work, which suggests higher dACC Glu enhances self-relevant processing of smoking cues, which could be considered a risk factor for relapse.
123-1	21989-21994	These	_
123-2	21995-22003	findings	_
123-3	22004-22007	are	_
123-4	22008-22016	somewhat	_
123-5	22017-22019	in	_
123-6	22020-22028	contrast	_
123-7	22029-22031	to	_
123-8	22032-22035	our	_
123-9	22036-22043	current	_
123-10	22044-22048	work	_
123-11	22048-22049	,	_
123-12	22050-22055	which	_
123-13	22056-22064	suggests	_
123-14	22065-22071	higher	_
123-15	22072-22076	dACC	_
123-16	22077-22080	Glu	_
123-17	22081-22089	enhances	_
123-18	22090-22103	self-relevant	_
123-19	22104-22114	processing	_
123-20	22115-22117	of	_
123-21	22118-22125	smoking	_
123-22	22126-22130	cues	_
123-23	22130-22131	,	_
123-24	22132-22137	which	_
123-25	22138-22143	could	_
123-26	22144-22146	be	_
123-27	22147-22157	considered	_
123-28	22158-22159	a	_
123-29	22160-22164	risk	_
123-30	22165-22171	factor	_
123-31	22172-22175	for	_
123-32	22176-22183	relapse	_
123-33	22183-22184	.	_

#Text=However, there are several key differences between these two studies.
124-1	22185-22192	However	_
124-2	22192-22193	,	_
124-3	22194-22199	there	_
124-4	22200-22203	are	_
124-5	22204-22211	several	_
124-6	22212-22215	key	_
124-7	22216-22227	differences	_
124-8	22228-22235	between	_
124-9	22236-22241	these	_
124-10	22242-22245	two	_
124-11	22246-22253	studies	_
124-12	22253-22254	.	_

#Text=For instance, there is a significant age difference between the population of smokers in each study where the prior work focused on individuals in their mid to late 40s, suggesting that age-related interactions between dACC Glu and smoking should be considered.
125-1	22255-22258	For	_
125-2	22259-22267	instance	_
125-3	22267-22268	,	_
125-4	22269-22274	there	_
125-5	22275-22277	is	_
125-6	22278-22279	a	_
125-7	22280-22291	significant	_
125-8	22292-22295	age	_
125-9	22296-22306	difference	_
125-10	22307-22314	between	_
125-11	22315-22318	the	_
125-12	22319-22329	population	_
125-13	22330-22332	of	_
125-14	22333-22340	smokers	_
125-15	22341-22343	in	_
125-16	22344-22348	each	_
125-17	22349-22354	study	_
125-18	22355-22360	where	_
125-19	22361-22364	the	_
125-20	22365-22370	prior	_
125-21	22371-22375	work	_
125-22	22376-22383	focused	_
125-23	22384-22386	on	_
125-24	22387-22398	individuals	_
125-25	22399-22401	in	_
125-26	22402-22407	their	_
125-27	22408-22411	mid	_
125-28	22412-22414	to	_
125-29	22415-22419	late	_
125-30	22420-22423	40s	_
125-31	22423-22424	,	_
125-32	22425-22435	suggesting	_
125-33	22436-22440	that	_
125-34	22441-22452	age-related	_
125-35	22453-22465	interactions	_
125-36	22466-22473	between	_
125-37	22474-22478	dACC	_
125-38	22479-22482	Glu	_
125-39	22483-22486	and	_
125-40	22487-22494	smoking	_
125-41	22495-22501	should	_
125-42	22502-22504	be	_
125-43	22505-22515	considered	_
125-44	22515-22516	.	_

#Text=Further, while both studies focused on the dACC, voxel placement was slightly more rostral in the prior work.
126-1	22517-22524	Further	_
126-2	22524-22525	,	_
126-3	22526-22531	while	_
126-4	22532-22536	both	_
126-5	22537-22544	studies	_
126-6	22545-22552	focused	_
126-7	22553-22555	on	_
126-8	22556-22559	the	_
126-9	22560-22564	dACC	_
126-10	22564-22565	,	_
126-11	22566-22571	voxel	_
126-12	22572-22581	placement	_
126-13	22582-22585	was	_
126-14	22586-22594	slightly	_
126-15	22595-22599	more	_
126-16	22600-22607	rostral	_
126-17	22608-22610	in	_
126-18	22611-22614	the	_
126-19	22615-22620	prior	_
126-20	22621-22625	work	_
126-21	22625-22626	.	_

#Text=Finally, the work of Mashhoon et al was highly preliminary and involved an extremely small sample size that only included women.
127-1	22627-22634	Finally	_
127-2	22634-22635	,	_
127-3	22636-22639	the	_
127-4	22640-22644	work	_
127-5	22645-22647	of	_
127-6	22648-22656	Mashhoon	_
127-7	22657-22659	et	_
127-8	22660-22662	al	_
127-9	22663-22666	was	_
127-10	22667-22673	highly	_
127-11	22674-22685	preliminary	_
127-12	22686-22689	and	_
127-13	22690-22698	involved	_
127-14	22699-22701	an	_
127-15	22702-22711	extremely	_
127-16	22712-22717	small	_
127-17	22718-22724	sample	_
127-18	22725-22729	size	_
127-19	22730-22734	that	_
127-20	22735-22739	only	_
127-21	22740-22748	included	_
127-22	22749-22754	women	_
127-23	22754-22755	.	_

#Text=While these methodological differences may account for the apparent incongruity, it is also possible that heightened dACC Glu does not directly contribute to relapse vulnerability.
128-1	22756-22761	While	_
128-2	22762-22767	these	_
128-3	22768-22782	methodological	_
128-4	22783-22794	differences	_
128-5	22795-22798	may	_
128-6	22799-22806	account	_
128-7	22807-22810	for	_
128-8	22811-22814	the	_
128-9	22815-22823	apparent	_
128-10	22824-22835	incongruity	_
128-11	22835-22836	,	_
128-12	22837-22839	it	_
128-13	22840-22842	is	_
128-14	22843-22847	also	_
128-15	22848-22856	possible	_
128-16	22857-22861	that	_
128-17	22862-22872	heightened	_
128-18	22873-22877	dACC	_
128-19	22878-22881	Glu	_
128-20	22882-22886	does	_
128-21	22887-22890	not	_
128-22	22891-22899	directly	_
128-23	22900-22910	contribute	_
128-24	22911-22913	to	_
128-25	22914-22921	relapse	_
128-26	22922-22935	vulnerability	_
128-27	22935-22936	.	_

#Text=Instead, dACC Glu may contribute to one of a constellation of risk factors contributing to relapse, specifically being more prone to self-referential processing during conditions such as exposure to smoking cues.
129-1	22937-22944	Instead	_
129-2	22944-22945	,	_
129-3	22946-22950	dACC	_
129-4	22951-22954	Glu	_
129-5	22955-22958	may	_
129-6	22959-22969	contribute	_
129-7	22970-22972	to	_
129-8	22973-22976	one	_
129-9	22977-22979	of	_
129-10	22980-22981	a	_
129-11	22982-22995	constellation	_
129-12	22996-22998	of	_
129-13	22999-23003	risk	_
129-14	23004-23011	factors	_
129-15	23012-23024	contributing	_
129-16	23025-23027	to	_
129-17	23028-23035	relapse	_
129-18	23035-23036	,	_
129-19	23037-23049	specifically	_
129-20	23050-23055	being	_
129-21	23056-23060	more	_
129-22	23061-23066	prone	_
129-23	23067-23069	to	_
129-24	23070-23086	self-referential	_
129-25	23087-23097	processing	_
129-26	23098-23104	during	_
129-27	23105-23115	conditions	_
129-28	23116-23120	such	_
129-29	23121-23123	as	_
129-30	23124-23132	exposure	_
129-31	23133-23135	to	_
129-32	23136-23143	smoking	_
129-33	23144-23148	cues	_
129-34	23148-23149	.	_

#Text=Additionally, it is possible that existing treatments may aid cessation by targeting these neurobiological systems.
130-1	23150-23162	Additionally	_
130-2	23162-23163	,	_
130-3	23164-23166	it	_
130-4	23167-23169	is	_
130-5	23170-23178	possible	_
130-6	23179-23183	that	_
130-7	23184-23192	existing	_
130-8	23193-23203	treatments	_
130-9	23204-23207	may	_
130-10	23208-23211	aid	_
130-11	23212-23221	cessation	_
130-12	23222-23224	by	_
130-13	23225-23234	targeting	_
130-14	23235-23240	these	_
130-15	23241-23256	neurobiological	_
130-16	23257-23264	systems	_
130-17	23264-23265	.	_

#Text=For example, a 12-week course of varenicline reduced dACC Glu as well as DMN activation during the Stroop color-naming task, which requires external focus.
131-1	23266-23269	For	_
131-2	23270-23277	example	_
131-3	23277-23278	,	_
131-4	23279-23280	a	_
131-5	23281-23283	12	_
131-6	23283-23284	-	_
131-7	23284-23288	week	_
131-8	23289-23295	course	_
131-9	23296-23298	of	_
131-10	23299-23310	varenicline	_
131-11	23311-23318	reduced	_
131-12	23319-23323	dACC	_
131-13	23324-23327	Glu	_
131-14	23328-23330	as	_
131-15	23331-23335	well	_
131-16	23336-23338	as	_
131-17	23339-23342	DMN	_
131-18	23343-23353	activation	_
131-19	23354-23360	during	_
131-20	23361-23364	the	_
131-21	23365-23371	Stroop	_
131-22	23372-23384	color-naming	_
131-23	23385-23389	task	_
131-24	23389-23390	,	_
131-25	23391-23396	which	_
131-26	23397-23405	requires	_
131-27	23406-23414	external	_
131-28	23415-23420	focus	_
131-29	23420-23421	.	_

#Text=It is unclear whether varenicline disrupts the association between dACC Glu and DMN reactivity to smoking relative to neutral cues.
132-1	23422-23424	It	_
132-2	23425-23427	is	_
132-3	23428-23435	unclear	_
132-4	23436-23443	whether	_
132-5	23444-23455	varenicline	_
132-6	23456-23464	disrupts	_
132-7	23465-23468	the	_
132-8	23469-23480	association	_
132-9	23481-23488	between	_
132-10	23489-23493	dACC	_
132-11	23494-23497	Glu	_
132-12	23498-23501	and	_
132-13	23502-23505	DMN	_
132-14	23506-23516	reactivity	_
132-15	23517-23519	to	_
132-16	23520-23527	smoking	_
132-17	23528-23536	relative	_
132-18	23537-23539	to	_
132-19	23540-23547	neutral	_
132-20	23548-23552	cues	_
132-21	23552-23553	.	_

#Text=The relationship between dACC Glu/Cr and DMN reactivity to smoking cues was confirmed in a smaller replication sample where participants were shown cues in the context of a working memory task.
133-1	23554-23557	The	_
133-2	23558-23570	relationship	_
133-3	23571-23578	between	_
133-4	23579-23583	dACC	_
133-5	23584-23587	Glu	_
133-6	23587-23588	/	_
133-7	23588-23590	Cr	_
133-8	23591-23594	and	_
133-9	23595-23598	DMN	_
133-10	23599-23609	reactivity	_
133-11	23610-23612	to	_
133-12	23613-23620	smoking	_
133-13	23621-23625	cues	_
133-14	23626-23629	was	_
133-15	23630-23639	confirmed	_
133-16	23640-23642	in	_
133-17	23643-23644	a	_
133-18	23645-23652	smaller	_
133-19	23653-23664	replication	_
133-20	23665-23671	sample	_
133-21	23672-23677	where	_
133-22	23678-23690	participants	_
133-23	23691-23695	were	_
133-24	23696-23701	shown	_
133-25	23702-23706	cues	_
133-26	23707-23709	in	_
133-27	23710-23713	the	_
133-28	23714-23721	context	_
133-29	23722-23724	of	_
133-30	23725-23726	a	_
133-31	23727-23734	working	_
133-32	23735-23741	memory	_
133-33	23742-23746	task	_
133-34	23746-23747	.	_

#Text=Given the difference in task (cue reactivity vs. memory task) it is plausible that individuals were responding to smoking cues differently.
134-1	23748-23753	Given	_
134-2	23754-23757	the	_
134-3	23758-23768	difference	_
134-4	23769-23771	in	_
134-5	23772-23776	task	_
134-6	23777-23778	(	_
134-7	23778-23781	cue	_
134-8	23782-23792	reactivity	_
134-9	23793-23795	vs	_
134-10	23795-23796	.	_
134-11	23797-23803	memory	_
134-12	23804-23808	task	_
134-13	23808-23809	)	_
134-14	23810-23812	it	_
134-15	23813-23815	is	_
134-16	23816-23825	plausible	_
134-17	23826-23830	that	_
134-18	23831-23842	individuals	_
134-19	23843-23847	were	_
134-20	23848-23858	responding	_
134-21	23859-23861	to	_
134-22	23862-23869	smoking	_
134-23	23870-23874	cues	_
134-24	23875-23886	differently	_
134-25	23886-23887	.	_

#Text=However, the fact that there was still a strong association between dACC Glu/Cr and DMN activity to smoking cues in both samples supports the robustness of these findings.
135-1	23888-23895	However	_
135-2	23895-23896	,	_
135-3	23897-23900	the	_
135-4	23901-23905	fact	_
135-5	23906-23910	that	_
135-6	23911-23916	there	_
135-7	23917-23920	was	_
135-8	23921-23926	still	_
135-9	23927-23928	a	_
135-10	23929-23935	strong	_
135-11	23936-23947	association	_
135-12	23948-23955	between	_
135-13	23956-23960	dACC	_
135-14	23961-23964	Glu	_
135-15	23964-23965	/	_
135-16	23965-23967	Cr	_
135-17	23968-23971	and	_
135-18	23972-23975	DMN	_
135-19	23976-23984	activity	_
135-20	23985-23987	to	_
135-21	23988-23995	smoking	_
135-22	23996-24000	cues	_
135-23	24001-24003	in	_
135-24	24004-24008	both	_
135-25	24009-24016	samples	_
135-26	24017-24025	supports	_
135-27	24026-24029	the	_
135-28	24030-24040	robustness	_
135-29	24041-24043	of	_
135-30	24044-24049	these	_
135-31	24050-24058	findings	_
135-32	24058-24059	.	_

#Text=There also were significant differences between the groups in age, expired CO on entry into the study, and FTND score.
136-1	24060-24065	There	_
136-2	24066-24070	also	_
136-3	24071-24075	were	_
136-4	24076-24087	significant	_
136-5	24088-24099	differences	_
136-6	24100-24107	between	_
136-7	24108-24111	the	_
136-8	24112-24118	groups	_
136-9	24119-24121	in	_
136-10	24122-24125	age	_
136-11	24125-24126	,	_
136-12	24127-24134	expired	_
136-13	24135-24137	CO	_
136-14	24138-24140	on	_
136-15	24141-24146	entry	_
136-16	24147-24151	into	_
136-17	24152-24155	the	_
136-18	24156-24161	study	_
136-19	24161-24162	,	_
136-20	24163-24166	and	_
136-21	24167-24171	FTND	_
136-22	24172-24177	score	_
136-23	24177-24178	.	_

#Text=These group differences further suggest the robustness of the primary findings, as variation in these domains did not diminish the association between dACC Glu and DMN activity.
137-1	24179-24184	These	_
137-2	24185-24190	group	_
137-3	24191-24202	differences	_
137-4	24203-24210	further	_
137-5	24211-24218	suggest	_
137-6	24219-24222	the	_
137-7	24223-24233	robustness	_
137-8	24234-24236	of	_
137-9	24237-24240	the	_
137-10	24241-24248	primary	_
137-11	24249-24257	findings	_
137-12	24257-24258	,	_
137-13	24259-24261	as	_
137-14	24262-24271	variation	_
137-15	24272-24274	in	_
137-16	24275-24280	these	_
137-17	24281-24288	domains	_
137-18	24289-24292	did	_
137-19	24293-24296	not	_
137-20	24297-24305	diminish	_
137-21	24306-24309	the	_
137-22	24310-24321	association	_
137-23	24322-24329	between	_
137-24	24330-24334	dACC	_
137-25	24335-24338	Glu	_
137-26	24339-24342	and	_
137-27	24343-24346	DMN	_
137-28	24347-24355	activity	_
137-29	24355-24356	.	_

#Text=It should be noted that while the groups did differ in age, both groups were comprised of relatively young adults (primary cohort range: 22–41 years, replication cohort: 18–33 years).
138-1	24357-24359	It	_
138-2	24360-24366	should	_
138-3	24367-24369	be	_
138-4	24370-24375	noted	_
138-5	24376-24380	that	_
138-6	24381-24386	while	_
138-7	24387-24390	the	_
138-8	24391-24397	groups	_
138-9	24398-24401	did	_
138-10	24402-24408	differ	_
138-11	24409-24411	in	_
138-12	24412-24415	age	_
138-13	24415-24416	,	_
138-14	24417-24421	both	_
138-15	24422-24428	groups	_
138-16	24429-24433	were	_
138-17	24434-24443	comprised	_
138-18	24444-24446	of	_
138-19	24447-24457	relatively	_
138-20	24458-24463	young	_
138-21	24464-24470	adults	_
138-22	24471-24472	(	_
138-23	24472-24479	primary	_
138-24	24480-24486	cohort	_
138-25	24487-24492	range	_
138-26	24492-24493	:	_
138-27	24494-24496	22	_
138-28	24496-24497	–	_
138-29	24497-24499	41	_
138-30	24500-24505	years	_
138-31	24505-24506	,	_
138-32	24507-24518	replication	_
138-33	24519-24525	cohort	_
138-34	24525-24526	:	_
138-35	24527-24529	18	_
138-36	24529-24530	–	_
138-37	24530-24532	33	_
138-38	24533-24538	years	_
138-39	24538-24539	)	_
138-40	24539-24540	.	_

#Text=Thus, we are unable to determine whether the reported association will be found other age groups such as adolescents or older adults.
139-1	24541-24545	Thus	_
139-2	24545-24546	,	_
139-3	24547-24549	we	_
139-4	24550-24553	are	_
139-5	24554-24560	unable	_
139-6	24561-24563	to	_
139-7	24564-24573	determine	_
139-8	24574-24581	whether	_
139-9	24582-24585	the	_
139-10	24586-24594	reported	_
139-11	24595-24606	association	_
139-12	24607-24611	will	_
139-13	24612-24614	be	_
139-14	24615-24620	found	_
139-15	24621-24626	other	_
139-16	24627-24630	age	_
139-17	24631-24637	groups	_
139-18	24638-24642	such	_
139-19	24643-24645	as	_
139-20	24646-24657	adolescents	_
139-21	24658-24660	or	_
139-22	24661-24666	older	_
139-23	24667-24673	adults	_
139-24	24673-24674	.	_

#Text=Additionally, despite group differences in FTND scores, both groups were identified as moderately nicotine dependent and we are unable to say whether individuals with mild or severe nicotine dependence would show the same relationship between dACC Glu and DMN activity.
140-1	24675-24687	Additionally	_
140-2	24687-24688	,	_
140-3	24689-24696	despite	_
140-4	24697-24702	group	_
140-5	24703-24714	differences	_
140-6	24715-24717	in	_
140-7	24718-24722	FTND	_
140-8	24723-24729	scores	_
140-9	24729-24730	,	_
140-10	24731-24735	both	_
140-11	24736-24742	groups	_
140-12	24743-24747	were	_
140-13	24748-24758	identified	_
140-14	24759-24761	as	_
140-15	24762-24772	moderately	_
140-16	24773-24781	nicotine	_
140-17	24782-24791	dependent	_
140-18	24792-24795	and	_
140-19	24796-24798	we	_
140-20	24799-24802	are	_
140-21	24803-24809	unable	_
140-22	24810-24812	to	_
140-23	24813-24816	say	_
140-24	24817-24824	whether	_
140-25	24825-24836	individuals	_
140-26	24837-24841	with	_
140-27	24842-24846	mild	_
140-28	24847-24849	or	_
140-29	24850-24856	severe	_
140-30	24857-24865	nicotine	_
140-31	24866-24876	dependence	_
140-32	24877-24882	would	_
140-33	24883-24887	show	_
140-34	24888-24891	the	_
140-35	24892-24896	same	_
140-36	24897-24909	relationship	_
140-37	24910-24917	between	_
140-38	24918-24922	dACC	_
140-39	24923-24926	Glu	_
140-40	24927-24930	and	_
140-41	24931-24934	DMN	_
140-42	24935-24943	activity	_
140-43	24943-24944	.	_

#Text=Additionally, we did not find any association between FTND and DMN smoking vs. neutral reactivity or dACC Glu/Cr in the primary (DMN: r = − 0.21, p > 0.4, dACC Glu/Cr: 0.04, p > 0.87) or replication cohorts (DMN: r = 0.9, p > 0.01, dACC Glu/Cr: −0.23, p > 0.4).
141-1	24945-24957	Additionally	_
141-2	24957-24958	,	_
141-3	24959-24961	we	_
141-4	24962-24965	did	_
141-5	24966-24969	not	_
141-6	24970-24974	find	_
141-7	24975-24978	any	_
141-8	24979-24990	association	_
141-9	24991-24998	between	_
141-10	24999-25003	FTND	_
141-11	25004-25007	and	_
141-12	25008-25011	DMN	_
141-13	25012-25019	smoking	_
141-14	25020-25022	vs	_
141-15	25022-25023	.	_
141-16	25024-25031	neutral	_
141-17	25032-25042	reactivity	_
141-18	25043-25045	or	_
141-19	25046-25050	dACC	_
141-20	25051-25054	Glu	_
141-21	25054-25055	/	_
141-22	25055-25057	Cr	_
141-23	25058-25060	in	_
141-24	25061-25064	the	_
141-25	25065-25072	primary	_
141-26	25073-25074	(	_
141-27	25074-25077	DMN	_
141-28	25077-25078	:	_
141-29	25079-25080	r	_
141-30	25081-25082	=	_
141-31	25083-25084	−	_
141-32	25085-25089	0.21	_
141-33	25089-25090	,	_
141-34	25091-25092	p	_
141-35	25093-25094	>	_
141-36	25095-25098	0.4	_
141-37	25098-25099	,	_
141-38	25100-25104	dACC	_
141-39	25105-25108	Glu	_
141-40	25108-25109	/	_
141-41	25109-25111	Cr	_
141-42	25111-25112	:	_
141-43	25113-25117	0.04	_
141-44	25117-25118	,	_
141-45	25119-25120	p	_
141-46	25121-25122	>	_
141-47	25123-25127	0.87	_
141-48	25127-25128	)	_
141-49	25129-25131	or	_
141-50	25132-25143	replication	_
141-51	25144-25151	cohorts	_
141-52	25152-25153	(	_
141-53	25153-25156	DMN	_
141-54	25156-25157	:	_
141-55	25158-25159	r	_
141-56	25160-25161	=	_
141-57	25162-25165	0.9	_
141-58	25165-25166	,	_
141-59	25167-25168	p	_
141-60	25169-25170	>	_
141-61	25171-25175	0.01	_
141-62	25175-25176	,	_
141-63	25177-25181	dACC	_
141-64	25182-25185	Glu	_
141-65	25185-25186	/	_
141-66	25186-25188	Cr	_
141-67	25188-25189	:	_
141-68	25190-25191	−	_
141-69	25191-25195	0.23	_
141-70	25195-25196	,	_
141-71	25197-25198	p	_
141-72	25199-25200	>	_
141-73	25201-25204	0.4	_
141-74	25204-25205	)	_
141-75	25205-25206	.	_

#Text=This lack of an association is consistent with the work of others where dACC Glu showed no relationship with smoking variables such as age of first cigarette, daily cigarette consumption, or lifetime cigarette exposure.
142-1	25207-25211	This	_
142-2	25212-25216	lack	_
142-3	25217-25219	of	_
142-4	25220-25222	an	_
142-5	25223-25234	association	_
142-6	25235-25237	is	_
142-7	25238-25248	consistent	_
142-8	25249-25253	with	_
142-9	25254-25257	the	_
142-10	25258-25262	work	_
142-11	25263-25265	of	_
142-12	25266-25272	others	_
142-13	25273-25278	where	_
142-14	25279-25283	dACC	_
142-15	25284-25287	Glu	_
142-16	25288-25294	showed	_
142-17	25295-25297	no	_
142-18	25298-25310	relationship	_
142-19	25311-25315	with	_
142-20	25316-25323	smoking	_
142-21	25324-25333	variables	_
142-22	25334-25338	such	_
142-23	25339-25341	as	_
142-24	25342-25345	age	_
142-25	25346-25348	of	_
142-26	25349-25354	first	_
142-27	25355-25364	cigarette	_
142-28	25364-25365	,	_
142-29	25366-25371	daily	_
142-30	25372-25381	cigarette	_
142-31	25382-25393	consumption	_
142-32	25393-25394	,	_
142-33	25395-25397	or	_
142-34	25398-25406	lifetime	_
142-35	25407-25416	cigarette	_
142-36	25417-25425	exposure	_
142-37	25425-25426	.	_

#Text=Such findings suggest that while dACC Glu does not have an overt relationship with traditional smoking measures, dACC Glu is associated with brain function that may prime individuals to engage in self-referential processing under certain conditions such as during exposure to smoking cues.
143-1	25427-25431	Such	_
143-2	25432-25440	findings	_
143-3	25441-25448	suggest	_
143-4	25449-25453	that	_
143-5	25454-25459	while	_
143-6	25460-25464	dACC	_
143-7	25465-25468	Glu	_
143-8	25469-25473	does	_
143-9	25474-25477	not	_
143-10	25478-25482	have	_
143-11	25483-25485	an	_
143-12	25486-25491	overt	_
143-13	25492-25504	relationship	_
143-14	25505-25509	with	_
143-15	25510-25521	traditional	_
143-16	25522-25529	smoking	_
143-17	25530-25538	measures	_
143-18	25538-25539	,	_
143-19	25540-25544	dACC	_
143-20	25545-25548	Glu	_
143-21	25549-25551	is	_
143-22	25552-25562	associated	_
143-23	25563-25567	with	_
143-24	25568-25573	brain	_
143-25	25574-25582	function	_
143-26	25583-25587	that	_
143-27	25588-25591	may	_
143-28	25592-25597	prime	_
143-29	25598-25609	individuals	_
143-30	25610-25612	to	_
143-31	25613-25619	engage	_
143-32	25620-25622	in	_
143-33	25623-25639	self-referential	_
143-34	25640-25650	processing	_
143-35	25651-25656	under	_
143-36	25657-25664	certain	_
143-37	25665-25675	conditions	_
143-38	25676-25680	such	_
143-39	25681-25683	as	_
143-40	25684-25690	during	_
143-41	25691-25699	exposure	_
143-42	25700-25702	to	_
143-43	25703-25710	smoking	_
143-44	25711-25715	cues	_
143-45	25715-25716	.	_

#Text=There are several study limitations of this study that warrant discussion.
144-1	25717-25722	There	_
144-2	25723-25726	are	_
144-3	25727-25734	several	_
144-4	25735-25740	study	_
144-5	25741-25752	limitations	_
144-6	25753-25755	of	_
144-7	25756-25760	this	_
144-8	25761-25766	study	_
144-9	25767-25771	that	_
144-10	25772-25779	warrant	_
144-11	25780-25790	discussion	_
144-12	25790-25791	.	_

#Text=First, MRS is unable to determine whether the measured Glu is related to neurotransmission, metabolism, or both.
145-1	25792-25797	First	_
145-2	25797-25798	,	_
145-3	25799-25802	MRS	_
145-4	25803-25805	is	_
145-5	25806-25812	unable	_
145-6	25813-25815	to	_
145-7	25816-25825	determine	_
145-8	25826-25833	whether	_
145-9	25834-25837	the	_
145-10	25838-25846	measured	_
145-11	25847-25850	Glu	_
145-12	25851-25853	is	_
145-13	25854-25861	related	_
145-14	25862-25864	to	_
145-15	25865-25882	neurotransmission	_
145-16	25882-25883	,	_
145-17	25884-25894	metabolism	_
145-18	25894-25895	,	_
145-19	25896-25898	or	_
145-20	25899-25903	both	_
145-21	25903-25904	.	_

#Text=As such we cannot determine the specific mechanism through which heightened Glu may interact with DMN function and dACC connectivity.
146-1	25905-25907	As	_
146-2	25908-25912	such	_
146-3	25913-25915	we	_
146-4	25916-25922	cannot	_
146-5	25923-25932	determine	_
146-6	25933-25936	the	_
146-7	25937-25945	specific	_
146-8	25946-25955	mechanism	_
146-9	25956-25963	through	_
146-10	25964-25969	which	_
146-11	25970-25980	heightened	_
146-12	25981-25984	Glu	_
146-13	25985-25988	may	_
146-14	25989-25997	interact	_
146-15	25998-26002	with	_
146-16	26003-26006	DMN	_
146-17	26007-26015	function	_
146-18	26016-26019	and	_
146-19	26020-26024	dACC	_
146-20	26025-26037	connectivity	_
146-21	26037-26038	.	_

#Text=The approach that we took in the present study does not permit us to identify the causal link between these measures.
147-1	26039-26042	The	_
147-2	26043-26051	approach	_
147-3	26052-26056	that	_
147-4	26057-26059	we	_
147-5	26060-26064	took	_
147-6	26065-26067	in	_
147-7	26068-26071	the	_
147-8	26072-26079	present	_
147-9	26080-26085	study	_
147-10	26086-26090	does	_
147-11	26091-26094	not	_
147-12	26095-26101	permit	_
147-13	26102-26104	us	_
147-14	26105-26107	to	_
147-15	26108-26116	identify	_
147-16	26117-26120	the	_
147-17	26121-26127	causal	_
147-18	26128-26132	link	_
147-19	26133-26140	between	_
147-20	26141-26146	these	_
147-21	26147-26155	measures	_
147-22	26155-26156	.	_

#Text=However, the converging evidence across disciplines linking midline cortical Glu and DMN activity indicates an important relationship.
148-1	26157-26164	However	_
148-2	26164-26165	,	_
148-3	26166-26169	the	_
148-4	26170-26180	converging	_
148-5	26181-26189	evidence	_
148-6	26190-26196	across	_
148-7	26197-26208	disciplines	_
148-8	26209-26216	linking	_
148-9	26217-26224	midline	_
148-10	26225-26233	cortical	_
148-11	26234-26237	Glu	_
148-12	26238-26241	and	_
148-13	26242-26245	DMN	_
148-14	26246-26254	activity	_
148-15	26255-26264	indicates	_
148-16	26265-26267	an	_
148-17	26268-26277	important	_
148-18	26278-26290	relationship	_
148-19	26290-26291	.	_

#Text=Most telling is that varenicline-induced suppression of both dACC Glu and DMN reactivity, which supports the concept that these neurobiological factors are associated.
149-1	26292-26296	Most	_
149-2	26297-26304	telling	_
149-3	26305-26307	is	_
149-4	26308-26312	that	_
149-5	26313-26332	varenicline-induced	_
149-6	26333-26344	suppression	_
149-7	26345-26347	of	_
149-8	26348-26352	both	_
149-9	26353-26357	dACC	_
149-10	26358-26361	Glu	_
149-11	26362-26365	and	_
149-12	26366-26369	DMN	_
149-13	26370-26380	reactivity	_
149-14	26380-26381	,	_
149-15	26382-26387	which	_
149-16	26388-26396	supports	_
149-17	26397-26400	the	_
149-18	26401-26408	concept	_
149-19	26409-26413	that	_
149-20	26414-26419	these	_
149-21	26420-26435	neurobiological	_
149-22	26436-26443	factors	_
149-23	26444-26447	are	_
149-24	26448-26458	associated	_
149-25	26458-26459	.	_

#Text=Whether smoking cessation treatments disrupt the association between dACC Glu and DMN cue reactivity should be studied further.
150-1	26460-26467	Whether	_
150-2	26468-26475	smoking	_
150-3	26476-26485	cessation	_
150-4	26486-26496	treatments	_
150-5	26497-26504	disrupt	_
150-6	26505-26508	the	_
150-7	26509-26520	association	_
150-8	26521-26528	between	_
150-9	26529-26533	dACC	_
150-10	26534-26537	Glu	_
150-11	26538-26541	and	_
150-12	26542-26545	DMN	_
150-13	26546-26549	cue	_
150-14	26550-26560	reactivity	_
150-15	26561-26567	should	_
150-16	26568-26570	be	_
150-17	26571-26578	studied	_
150-18	26579-26586	further	_
150-19	26586-26587	.	_

#Text=Additionally, future research is needed to clarify the exact mechanism for the relationship between dACC Glu and DMN cue reactivity.
151-1	26588-26600	Additionally	_
151-2	26600-26601	,	_
151-3	26602-26608	future	_
151-4	26609-26617	research	_
151-5	26618-26620	is	_
151-6	26621-26627	needed	_
151-7	26628-26630	to	_
151-8	26631-26638	clarify	_
151-9	26639-26642	the	_
151-10	26643-26648	exact	_
151-11	26649-26658	mechanism	_
151-12	26659-26662	for	_
151-13	26663-26666	the	_
151-14	26667-26679	relationship	_
151-15	26680-26687	between	_
151-16	26688-26692	dACC	_
151-17	26693-26696	Glu	_
151-18	26697-26700	and	_
151-19	26701-26704	DMN	_
151-20	26705-26708	cue	_
151-21	26709-26719	reactivity	_
151-22	26719-26720	.	_

#Text=Such work would be supported by the investigation of the DMN during tasks unrelated to smoking involving healthy control participants to determine whether the relationship between dACC Glu/Cr extends to DMN engagement beyond smoking cue-reactivity.
152-1	26721-26725	Such	_
152-2	26726-26730	work	_
152-3	26731-26736	would	_
152-4	26737-26739	be	_
152-5	26740-26749	supported	_
152-6	26750-26752	by	_
152-7	26753-26756	the	_
152-8	26757-26770	investigation	_
152-9	26771-26773	of	_
152-10	26774-26777	the	_
152-11	26778-26781	DMN	_
152-12	26782-26788	during	_
152-13	26789-26794	tasks	_
152-14	26795-26804	unrelated	_
152-15	26805-26807	to	_
152-16	26808-26815	smoking	_
152-17	26816-26825	involving	_
152-18	26826-26833	healthy	_
152-19	26834-26841	control	_
152-20	26842-26854	participants	_
152-21	26855-26857	to	_
152-22	26858-26867	determine	_
152-23	26868-26875	whether	_
152-24	26876-26879	the	_
152-25	26880-26892	relationship	_
152-26	26893-26900	between	_
152-27	26901-26905	dACC	_
152-28	26906-26909	Glu	_
152-29	26909-26910	/	_
152-30	26910-26912	Cr	_
152-31	26913-26920	extends	_
152-32	26921-26923	to	_
152-33	26924-26927	DMN	_
152-34	26928-26938	engagement	_
152-35	26939-26945	beyond	_
152-36	26946-26953	smoking	_
152-37	26954-26968	cue-reactivity	_
152-38	26968-26969	.	_

#Text=Healthy controls were not included in the current work as enhanced responding to smoking cues should only be noted in drug users, a concept supported by the fact that no reliable cuereactivity has been reported in non-smokers (Engleman et al., 2011).
153-1	26970-26977	Healthy	_
153-2	26978-26986	controls	_
153-3	26987-26991	were	_
153-4	26992-26995	not	_
153-5	26996-27004	included	_
153-6	27005-27007	in	_
153-7	27008-27011	the	_
153-8	27012-27019	current	_
153-9	27020-27024	work	_
153-10	27025-27027	as	_
153-11	27028-27036	enhanced	_
153-12	27037-27047	responding	_
153-13	27048-27050	to	_
153-14	27051-27058	smoking	_
153-15	27059-27063	cues	_
153-16	27064-27070	should	_
153-17	27071-27075	only	_
153-18	27076-27078	be	_
153-19	27079-27084	noted	_
153-20	27085-27087	in	_
153-21	27088-27092	drug	_
153-22	27093-27098	users	_
153-23	27098-27099	,	_
153-24	27100-27101	a	_
153-25	27102-27109	concept	_
153-26	27110-27119	supported	_
153-27	27120-27122	by	_
153-28	27123-27126	the	_
153-29	27127-27131	fact	_
153-30	27132-27136	that	_
153-31	27137-27139	no	_
153-32	27140-27148	reliable	_
153-33	27149-27162	cuereactivity	_
153-34	27163-27166	has	_
153-35	27167-27171	been	_
153-36	27172-27180	reported	_
153-37	27181-27183	in	_
153-38	27184-27195	non-smokers	_
153-39	27196-27197	(	_
153-40	27197-27205	Engleman	_
153-41	27206-27208	et	_
153-42	27209-27211	al	_
153-43	27211-27212	.	_
153-44	27212-27213	,	_
153-45	27214-27218	2011	_
153-46	27218-27219	)	_
153-47	27219-27220	.	_

#Text=Despite these limitations, the current findings indicate that smokers with relatively greater levels of dACC Glu/Cr are more likely to engage the DMN when exposed to smoking cues suggesting that they are engaging in self-referential processing and may have difficulty disengaging from these internal smoking-related thoughts.
154-1	27221-27228	Despite	_
154-2	27229-27234	these	_
154-3	27235-27246	limitations	_
154-4	27246-27247	,	_
154-5	27248-27251	the	_
154-6	27252-27259	current	_
154-7	27260-27268	findings	_
154-8	27269-27277	indicate	_
154-9	27278-27282	that	_
154-10	27283-27290	smokers	_
154-11	27291-27295	with	_
154-12	27296-27306	relatively	_
154-13	27307-27314	greater	_
154-14	27315-27321	levels	_
154-15	27322-27324	of	_
154-16	27325-27329	dACC	_
154-17	27330-27333	Glu	_
154-18	27333-27334	/	_
154-19	27334-27336	Cr	_
154-20	27337-27340	are	_
154-21	27341-27345	more	_
154-22	27346-27352	likely	_
154-23	27353-27355	to	_
154-24	27356-27362	engage	_
154-25	27363-27366	the	_
154-26	27367-27370	DMN	_
154-27	27371-27375	when	_
154-28	27376-27383	exposed	_
154-29	27384-27386	to	_
154-30	27387-27394	smoking	_
154-31	27395-27399	cues	_
154-32	27400-27410	suggesting	_
154-33	27411-27415	that	_
154-34	27416-27420	they	_
154-35	27421-27424	are	_
154-36	27425-27433	engaging	_
154-37	27434-27436	in	_
154-38	27437-27453	self-referential	_
154-39	27454-27464	processing	_
154-40	27465-27468	and	_
154-41	27469-27472	may	_
154-42	27473-27477	have	_
154-43	27478-27488	difficulty	_
154-44	27489-27500	disengaging	_
154-45	27501-27505	from	_
154-46	27506-27511	these	_
154-47	27512-27520	internal	_
154-48	27521-27536	smoking-related	_
154-49	27537-27545	thoughts	_
154-50	27545-27546	.	_

#Text=This is a PDF file of an unedited manuscript that has been accepted for publication.
155-1	27547-27551	This	_
155-2	27552-27554	is	_
155-3	27555-27556	a	_
155-4	27557-27560	PDF	_
155-5	27561-27565	file	_
155-6	27566-27568	of	_
155-7	27569-27571	an	_
155-8	27572-27580	unedited	_
155-9	27581-27591	manuscript	_
155-10	27592-27596	that	_
155-11	27597-27600	has	_
155-12	27601-27605	been	_
155-13	27606-27614	accepted	_
155-14	27615-27618	for	_
155-15	27619-27630	publication	_
155-16	27630-27631	.	_

#Text=As a service to our customers we are providing this early version of the manuscript.
156-1	27632-27634	As	_
156-2	27635-27636	a	_
156-3	27637-27644	service	_
156-4	27645-27647	to	_
156-5	27648-27651	our	_
156-6	27652-27661	customers	_
156-7	27662-27664	we	_
156-8	27665-27668	are	_
156-9	27669-27678	providing	_
156-10	27679-27683	this	_
156-11	27684-27689	early	_
156-12	27690-27697	version	_
156-13	27698-27700	of	_
156-14	27701-27704	the	_
156-15	27705-27715	manuscript	_
156-16	27715-27716	.	_

#Text=The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form.
157-1	27717-27720	The	_
157-2	27721-27731	manuscript	_
157-3	27732-27736	will	_
157-4	27737-27744	undergo	_
157-5	27745-27756	copyediting	_
157-6	27756-27757	,	_
157-7	27758-27769	typesetting	_
157-8	27769-27770	,	_
157-9	27771-27774	and	_
157-10	27775-27781	review	_
157-11	27782-27784	of	_
157-12	27785-27788	the	_
157-13	27789-27798	resulting	_
157-14	27799-27804	proof	_
157-15	27805-27811	before	_
157-16	27812-27814	it	_
157-17	27815-27817	is	_
157-18	27818-27827	published	_
157-19	27828-27830	in	_
157-20	27831-27834	its	_
157-21	27835-27840	final	_
157-22	27841-27848	citable	_
157-23	27849-27853	form	_
157-24	27853-27854	.	_

#Text=Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
158-1	27855-27861	Please	_
158-2	27862-27866	note	_
158-3	27867-27871	that	_
158-4	27872-27878	during	_
158-5	27879-27882	the	_
158-6	27883-27893	production	_
158-7	27894-27901	process	_
158-8	27902-27908	errors	_
158-9	27909-27912	may	_
158-10	27913-27915	be	_
158-11	27916-27926	discovered	_
158-12	27927-27932	which	_
158-13	27933-27938	could	_
158-14	27939-27945	affect	_
158-15	27946-27949	the	_
158-16	27950-27957	content	_
158-17	27957-27958	,	_
158-18	27959-27962	and	_
158-19	27963-27966	all	_
158-20	27967-27972	legal	_
158-21	27973-27984	disclaimers	_
158-22	27985-27989	that	_
158-23	27990-27995	apply	_
158-24	27996-27998	to	_
158-25	27999-28002	the	_
158-26	28003-28010	journal	_
158-27	28011-28018	pertain	_
158-28	28018-28019	.	_

#Text=Contributors:
#Text=ACJ conceptualized the experiment, analyzed data, wrote the manuscript, and integrated comments from all other authors.
159-1	28031-28043	Contributors	_
159-2	28043-28044	:	_
159-3	28054-28057	ACJ	_
159-4	28058-28072	conceptualized	_
159-5	28073-28076	the	_
159-6	28077-28087	experiment	_
159-7	28087-28088	,	_
159-8	28089-28097	analyzed	_
159-9	28098-28102	data	_
159-10	28102-28103	,	_
159-11	28104-28109	wrote	_
159-12	28110-28113	the	_
159-13	28114-28124	manuscript	_
159-14	28124-28125	,	_
159-15	28126-28129	and	_
159-16	28130-28140	integrated	_
159-17	28141-28149	comments	_
159-18	28150-28154	from	_
159-19	28155-28158	all	_
159-20	28159-28164	other	_
159-21	28165-28172	authors	_
159-22	28172-28173	.	_

#Text=JB collected data, organized study days, and provided manuscript feedback.
160-1	28174-28176	JB	_
160-2	28177-28186	collected	_
160-3	28187-28191	data	_
160-4	28191-28192	,	_
160-5	28193-28202	organized	_
160-6	28203-28208	study	_
160-7	28209-28213	days	_
160-8	28213-28214	,	_
160-9	28215-28218	and	_
160-10	28219-28227	provided	_
160-11	28228-28238	manuscript	_
160-12	28239-28247	feedback	_
160-13	28247-28248	.	_

#Text=JEJ set up, and analyzed all spectroscopy data and provided manuscript feedback.
161-1	28249-28252	JEJ	_
161-2	28253-28256	set	_
161-3	28257-28259	up	_
161-4	28259-28260	,	_
161-5	28261-28264	and	_
161-6	28265-28273	analyzed	_
161-7	28274-28277	all	_
161-8	28278-28290	spectroscopy	_
161-9	28291-28295	data	_
161-10	28296-28299	and	_
161-11	28300-28308	provided	_
161-12	28309-28319	manuscript	_
161-13	28320-28328	feedback	_
161-14	28328-28329	.	_

#Text=SES offered guidance during the study and provided manuscript feedback.
162-1	28330-28333	SES	_
162-2	28334-28341	offered	_
162-3	28342-28350	guidance	_
162-4	28351-28357	during	_
162-5	28358-28361	the	_
162-6	28362-28367	study	_
162-7	28368-28371	and	_
162-8	28372-28380	provided	_
162-9	28381-28391	manuscript	_
162-10	28392-28400	feedback	_
162-11	28400-28401	.	_

#Text=All authors have approved the final article.
163-1	28402-28405	All	_
163-2	28406-28413	authors	_
163-3	28414-28418	have	_
163-4	28419-28427	approved	_
163-5	28428-28431	the	_
163-6	28432-28437	final	_
163-7	28438-28445	article	_
163-8	28445-28446	.	_

#Text=The other authors have no financial disclosures to report
#Text=Conflicts of interest: none for all authors.
164-1	28447-28450	The	_
164-2	28451-28456	other	_
164-3	28457-28464	authors	_
164-4	28465-28469	have	_
164-5	28470-28472	no	_
164-6	28473-28482	financial	_
164-7	28483-28494	disclosures	_
164-8	28495-28497	to	_
164-9	28498-28504	report	_
164-10	28505-28514	Conflicts	_
164-11	28515-28517	of	_
164-12	28518-28526	interest	_
164-13	28526-28527	:	_
164-14	28528-28532	none	_
164-15	28533-28536	for	_
164-16	28537-28540	all	_
164-17	28541-28548	authors	_
164-18	28548-28549	.	_

#Text=REFERENCES
#Text=Resting state glutamate predicts elevated pre-stimulus alpha during self-relatedness: a combined EEG-MRS study on “rest-self overlap.”
165-1	28550-28560	REFERENCES	_
165-2	28561-28568	Resting	_
165-3	28569-28574	state	_
165-4	28575-28584	glutamate	_
165-5	28585-28593	predicts	_
165-6	28594-28602	elevated	_
165-7	28603-28615	pre-stimulus	_
165-8	28616-28621	alpha	_
165-9	28622-28628	during	_
165-10	28629-28645	self-relatedness	_
165-11	28645-28646	:	_
165-12	28647-28648	a	_
165-13	28649-28657	combined	_
165-14	28658-28665	EEG-MRS	_
165-15	28666-28671	study	_
165-16	28672-28674	on	_
165-17	28675-28676	“	_
165-18	28676-28685	rest-self	_
165-19	28686-28693	overlap	_
165-20	28693-28694	.	_
165-21	28694-28695	”	_

#Text=What about the “self” is processed in the posterior cingulate cortex?
166-1	28696-28700	What	_
166-2	28701-28706	about	_
166-3	28707-28710	the	_
166-4	28711-28712	“	_
166-5	28712-28716	self	_
166-6	28716-28717	”	_
166-7	28718-28720	is	_
166-8	28721-28730	processed	_
166-9	28731-28733	in	_
166-10	28734-28737	the	_
166-11	28738-28747	posterior	_
166-12	28748-28757	cingulate	_
166-13	28758-28764	cortex	_
166-14	28764-28765	?	_

#Text=Neural substrates of resisting craving during cigarette cue exposure
#Text=Association between nicotine dependence severity, BOLD response to smoking cues, and functional connectivity
#Text=The association between cue-reactivity in the precuneus and level of dependence on nicotine and alcohol
#Text=Evaluation of the brief questionnaire of smoking urges (QSU – brief) in laboratory and clinical settings
#Text=Glutamate concentration in the medial prefrontal cortex predicts resting-state cortical-subcortical functional connectivity in humans
#Text=Neural substrates of smoking cue reactivity: a meta-analysis of fMRI studies
#Text=Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment
#Text=Resting-state glutamate level in the anterior cingulate predicts blood-oxygen level-dependent response to cognitive control
#Text=
#Text=Growth hormone–releasing hormone increases brain gaba levels in mild cognitive impairment and healthy aging
#Text=Regional cerebral glutamate concentrations and chronic tobacco consumption
#Text=Accuracy and stability of measuring GABA, glutamate, and glutamine by proton magnetic resonance spectroscopy: a phantom study at 4 tesla
#Text=Resting-state glutamate and gaba concentrations predict task-induced deactivation in the default mode network
#Text=Progressive levels of physical dependence to tobacco coincide with changes in the anterior cingulum bundle microstructure
#Text=The development and expression of physical nicotine dependence corresponds to structural and functional alterations in the anterior cingulate-precuneus pathway
#Text=An increase in tobacco craving is associated with enhanced medial prefrontal cortex network coupling
#Text=Insula-dorsal anterior cingulate cortex coupling is associated with enhanced brain reactivity to smoking cues
#Text=GABA Levels in the dorsal anterior cingulate cortex associated with difficulty ignoring smoking-related cues in tobacco-dependent volunteers
#Text=Prefrontal and limbic resting state brain network functional connectivity differs between nicotine-dependent smokers and non-smoking controls
#Text=Brain reactivity to smoking cues prior to smoking cessation predicts ability to maintain tobacco abstinence
#Text=Memory retrieval of smoking-related images induce greater insula activation as revealed by an fMRI-based delayed matching to sample task
#Text=Quantification of j-resolved proton spectra in two-dimensions with lcmodel using GAMMA-simulated basis sets at 4 tesla
#Text=Large-scale brain network coupling predicts acute nicotine abstinence effects on craving and cognitive function
#Text=Working memory for social cues recruits orbitofrontal cortex and amygdala: a functional magnetic resonance imaging study of delayed matching to sample for emotional expressions
#Text=Anterior cingulate proton spectroscopy glutamate levels differ as a function of smoking cessation outcome
#Text=A parametric manipulation of factors affecting task-induced deactivation in functional neuroimaging
#Text=Saliency, switching, attention and control: a network model of insula function
#Text=Neuroimaging markers of glutamatergic and GABAergic systems in drug addiction: relationships to resting-state functional connectivity
#Text=A default mode of brain function
#Text=A default mode of brain function: a brief history of an evolving idea
#Text=Remembering the past to imagine the future: the prospective brain
#Text=Persistence of parahippocampal representation in the absence of stimulus input enhances long-term encoding: a functional magnetic resonance imaging study of subsequent memory after a delayed match-to-sample task
#Text=Dissociable intrinsic connectivity networks for salience processing and executive control
#Text=Correspondence of the brain's functional architecture during activation and rest
#Text=The common basis of autobiographical memory, prospection, navigation, theory of mind and the default mode: a quantitative meta-analysis
#Text=Default network activity, coupled with the frontoparietal control network, supports goal-directed cognition
#Text=Resting state functional connectivity in addiction: lessons learned and a road ahead
#Text=Open label smoking cessation with varenicline is associated with decreased glutamate levels and functional changes in anterior cingulate cortex: preliminary findings
#Text=Do small lapses predict relapse to smoking behavior under bupropion treatment?
167-1	28766-28772	Neural	_
167-2	28773-28783	substrates	_
167-3	28784-28786	of	_
167-4	28787-28796	resisting	_
167-5	28797-28804	craving	_
167-6	28805-28811	during	_
167-7	28812-28821	cigarette	_
167-8	28822-28825	cue	_
167-9	28826-28834	exposure	_
167-10	28835-28846	Association	_
167-11	28847-28854	between	_
167-12	28855-28863	nicotine	_
167-13	28864-28874	dependence	_
167-14	28875-28883	severity	_
167-15	28883-28884	,	_
167-16	28885-28889	BOLD	_
167-17	28890-28898	response	_
167-18	28899-28901	to	_
167-19	28902-28909	smoking	_
167-20	28910-28914	cues	_
167-21	28914-28915	,	_
167-22	28916-28919	and	_
167-23	28920-28930	functional	_
167-24	28931-28943	connectivity	_
167-25	28944-28947	The	_
167-26	28948-28959	association	_
167-27	28960-28967	between	_
167-28	28968-28982	cue-reactivity	_
167-29	28983-28985	in	_
167-30	28986-28989	the	_
167-31	28990-28999	precuneus	_
167-32	29000-29003	and	_
167-33	29004-29009	level	_
167-34	29010-29012	of	_
167-35	29013-29023	dependence	_
167-36	29024-29026	on	_
167-37	29027-29035	nicotine	_
167-38	29036-29039	and	_
167-39	29040-29047	alcohol	_
167-40	29048-29058	Evaluation	_
167-41	29059-29061	of	_
167-42	29062-29065	the	_
167-43	29066-29071	brief	_
167-44	29072-29085	questionnaire	_
167-45	29086-29088	of	_
167-46	29089-29096	smoking	_
167-47	29097-29102	urges	_
167-48	29103-29104	(	_
167-49	29104-29107	QSU	_
167-50	29108-29109	–	_
167-51	29110-29115	brief	_
167-52	29115-29116	)	_
167-53	29117-29119	in	_
167-54	29120-29130	laboratory	_
167-55	29131-29134	and	_
167-56	29135-29143	clinical	_
167-57	29144-29152	settings	_
167-58	29153-29162	Glutamate	_
167-59	29163-29176	concentration	_
167-60	29177-29179	in	_
167-61	29180-29183	the	_
167-62	29184-29190	medial	_
167-63	29191-29201	prefrontal	_
167-64	29202-29208	cortex	_
167-65	29209-29217	predicts	_
167-66	29218-29231	resting-state	_
167-67	29232-29252	cortical-subcortical	_
167-68	29253-29263	functional	_
167-69	29264-29276	connectivity	_
167-70	29277-29279	in	_
167-71	29280-29286	humans	_
167-72	29287-29293	Neural	_
167-73	29294-29304	substrates	_
167-74	29305-29307	of	_
167-75	29308-29315	smoking	_
167-76	29316-29319	cue	_
167-77	29320-29330	reactivity	_
167-78	29330-29331	:	_
167-79	29332-29333	a	_
167-80	29334-29347	meta-analysis	_
167-81	29348-29350	of	_
167-82	29351-29355	fMRI	_
167-83	29356-29363	studies	_
167-84	29364-29373	Measuring	_
167-85	29374-29380	degree	_
167-86	29381-29383	of	_
167-87	29384-29392	physical	_
167-88	29393-29403	dependence	_
167-89	29404-29406	to	_
167-90	29407-29414	tobacco	_
167-91	29415-29422	smoking	_
167-92	29423-29427	with	_
167-93	29428-29437	reference	_
167-94	29438-29440	to	_
167-95	29441-29458	individualization	_
167-96	29459-29461	of	_
167-97	29462-29471	treatment	_
167-98	29472-29485	Resting-state	_
167-99	29486-29495	glutamate	_
167-100	29496-29501	level	_
167-101	29502-29504	in	_
167-102	29505-29508	the	_
167-103	29509-29517	anterior	_
167-104	29518-29527	cingulate	_
167-105	29528-29536	predicts	_
167-106	29537-29549	blood-oxygen	_
167-107	29550-29565	level-dependent	_
167-108	29566-29574	response	_
167-109	29575-29577	to	_
167-110	29578-29587	cognitive	_
167-111	29588-29595	control	_
167-112	29597-29603	Growth	_
167-113	29604-29621	hormone–releasing	_
167-114	29622-29629	hormone	_
167-115	29630-29639	increases	_
167-116	29640-29645	brain	_
167-117	29646-29650	gaba	_
167-118	29651-29657	levels	_
167-119	29658-29660	in	_
167-120	29661-29665	mild	_
167-121	29666-29675	cognitive	_
167-122	29676-29686	impairment	_
167-123	29687-29690	and	_
167-124	29691-29698	healthy	_
167-125	29699-29704	aging	_
167-126	29705-29713	Regional	_
167-127	29714-29722	cerebral	_
167-128	29723-29732	glutamate	_
167-129	29733-29747	concentrations	_
167-130	29748-29751	and	_
167-131	29752-29759	chronic	_
167-132	29760-29767	tobacco	_
167-133	29768-29779	consumption	_
167-134	29780-29788	Accuracy	_
167-135	29789-29792	and	_
167-136	29793-29802	stability	_
167-137	29803-29805	of	_
167-138	29806-29815	measuring	_
167-139	29816-29820	GABA	_
167-140	29820-29821	,	_
167-141	29822-29831	glutamate	_
167-142	29831-29832	,	_
167-143	29833-29836	and	_
167-144	29837-29846	glutamine	_
167-145	29847-29849	by	_
167-146	29850-29856	proton	_
167-147	29857-29865	magnetic	_
167-148	29866-29875	resonance	_
167-149	29876-29888	spectroscopy	_
167-150	29888-29889	:	_
167-151	29890-29891	a	_
167-152	29892-29899	phantom	_
167-153	29900-29905	study	_
167-154	29906-29908	at	_
167-155	29909-29910	4	_
167-156	29911-29916	tesla	_
167-157	29917-29930	Resting-state	_
167-158	29931-29940	glutamate	_
167-159	29941-29944	and	_
167-160	29945-29949	gaba	_
167-161	29950-29964	concentrations	_
167-162	29965-29972	predict	_
167-163	29973-29985	task-induced	_
167-164	29986-29998	deactivation	_
167-165	29999-30001	in	_
167-166	30002-30005	the	_
167-167	30006-30013	default	_
167-168	30014-30018	mode	_
167-169	30019-30026	network	_
167-170	30027-30038	Progressive	_
167-171	30039-30045	levels	_
167-172	30046-30048	of	_
167-173	30049-30057	physical	_
167-174	30058-30068	dependence	_
167-175	30069-30071	to	_
167-176	30072-30079	tobacco	_
167-177	30080-30088	coincide	_
167-178	30089-30093	with	_
167-179	30094-30101	changes	_
167-180	30102-30104	in	_
167-181	30105-30108	the	_
167-182	30109-30117	anterior	_
167-183	30118-30126	cingulum	_
167-184	30127-30133	bundle	_
167-185	30134-30148	microstructure	_
167-186	30149-30152	The	_
167-187	30153-30164	development	_
167-188	30165-30168	and	_
167-189	30169-30179	expression	_
167-190	30180-30182	of	_
167-191	30183-30191	physical	_
167-192	30192-30200	nicotine	_
167-193	30201-30211	dependence	_
167-194	30212-30223	corresponds	_
167-195	30224-30226	to	_
167-196	30227-30237	structural	_
167-197	30238-30241	and	_
167-198	30242-30252	functional	_
167-199	30253-30264	alterations	_
167-200	30265-30267	in	_
167-201	30268-30271	the	_
167-202	30272-30280	anterior	_
167-203	30281-30300	cingulate-precuneus	_
167-204	30301-30308	pathway	_
167-205	30309-30311	An	_
167-206	30312-30320	increase	_
167-207	30321-30323	in	_
167-208	30324-30331	tobacco	_
167-209	30332-30339	craving	_
167-210	30340-30342	is	_
167-211	30343-30353	associated	_
167-212	30354-30358	with	_
167-213	30359-30367	enhanced	_
167-214	30368-30374	medial	_
167-215	30375-30385	prefrontal	_
167-216	30386-30392	cortex	_
167-217	30393-30400	network	_
167-218	30401-30409	coupling	_
167-219	30410-30423	Insula-dorsal	_
167-220	30424-30432	anterior	_
167-221	30433-30442	cingulate	_
167-222	30443-30449	cortex	_
167-223	30450-30458	coupling	_
167-224	30459-30461	is	_
167-225	30462-30472	associated	_
167-226	30473-30477	with	_
167-227	30478-30486	enhanced	_
167-228	30487-30492	brain	_
167-229	30493-30503	reactivity	_
167-230	30504-30506	to	_
167-231	30507-30514	smoking	_
167-232	30515-30519	cues	_
167-233	30520-30524	GABA	_
167-234	30525-30531	Levels	_
167-235	30532-30534	in	_
167-236	30535-30538	the	_
167-237	30539-30545	dorsal	_
167-238	30546-30554	anterior	_
167-239	30555-30564	cingulate	_
167-240	30565-30571	cortex	_
167-241	30572-30582	associated	_
167-242	30583-30587	with	_
167-243	30588-30598	difficulty	_
167-244	30599-30607	ignoring	_
167-245	30608-30623	smoking-related	_
167-246	30624-30628	cues	_
167-247	30629-30631	in	_
167-248	30632-30649	tobacco-dependent	_
167-249	30650-30660	volunteers	_
167-250	30661-30671	Prefrontal	_
167-251	30672-30675	and	_
167-252	30676-30682	limbic	_
167-253	30683-30690	resting	_
167-254	30691-30696	state	_
167-255	30697-30702	brain	_
167-256	30703-30710	network	_
167-257	30711-30721	functional	_
167-258	30722-30734	connectivity	_
167-259	30735-30742	differs	_
167-260	30743-30750	between	_
167-261	30751-30769	nicotine-dependent	_
167-262	30770-30777	smokers	_
167-263	30778-30781	and	_
167-264	30782-30793	non-smoking	_
167-265	30794-30802	controls	_
167-266	30803-30808	Brain	_
167-267	30809-30819	reactivity	_
167-268	30820-30822	to	_
167-269	30823-30830	smoking	_
167-270	30831-30835	cues	_
167-271	30836-30841	prior	_
167-272	30842-30844	to	_
167-273	30845-30852	smoking	_
167-274	30853-30862	cessation	_
167-275	30863-30871	predicts	_
167-276	30872-30879	ability	_
167-277	30880-30882	to	_
167-278	30883-30891	maintain	_
167-279	30892-30899	tobacco	_
167-280	30900-30910	abstinence	_
167-281	30911-30917	Memory	_
167-282	30918-30927	retrieval	_
167-283	30928-30930	of	_
167-284	30931-30946	smoking-related	_
167-285	30947-30953	images	_
167-286	30954-30960	induce	_
167-287	30961-30968	greater	_
167-288	30969-30975	insula	_
167-289	30976-30986	activation	_
167-290	30987-30989	as	_
167-291	30990-30998	revealed	_
167-292	30999-31001	by	_
167-293	31002-31004	an	_
167-294	31005-31015	fMRI-based	_
167-295	31016-31023	delayed	_
167-296	31024-31032	matching	_
167-297	31033-31035	to	_
167-298	31036-31042	sample	_
167-299	31043-31047	task	_
167-300	31048-31062	Quantification	_
167-301	31063-31065	of	_
167-302	31066-31076	j-resolved	_
167-303	31077-31083	proton	_
167-304	31084-31091	spectra	_
167-305	31092-31094	in	_
167-306	31095-31109	two-dimensions	_
167-307	31110-31114	with	_
167-308	31115-31122	lcmodel	_
167-309	31123-31128	using	_
167-310	31129-31144	GAMMA-simulated	_
167-311	31145-31150	basis	_
167-312	31151-31155	sets	_
167-313	31156-31158	at	_
167-314	31159-31160	4	_
167-315	31161-31166	tesla	_
167-316	31167-31178	Large-scale	_
167-317	31179-31184	brain	_
167-318	31185-31192	network	_
167-319	31193-31201	coupling	_
167-320	31202-31210	predicts	_
167-321	31211-31216	acute	_
167-322	31217-31225	nicotine	_
167-323	31226-31236	abstinence	_
167-324	31237-31244	effects	_
167-325	31245-31247	on	_
167-326	31248-31255	craving	_
167-327	31256-31259	and	_
167-328	31260-31269	cognitive	_
167-329	31270-31278	function	_
167-330	31279-31286	Working	_
167-331	31287-31293	memory	_
167-332	31294-31297	for	_
167-333	31298-31304	social	_
167-334	31305-31309	cues	_
167-335	31310-31318	recruits	_
167-336	31319-31332	orbitofrontal	_
167-337	31333-31339	cortex	_
167-338	31340-31343	and	_
167-339	31344-31352	amygdala	_
167-340	31352-31353	:	_
167-341	31354-31355	a	_
167-342	31356-31366	functional	_
167-343	31367-31375	magnetic	_
167-344	31376-31385	resonance	_
167-345	31386-31393	imaging	_
167-346	31394-31399	study	_
167-347	31400-31402	of	_
167-348	31403-31410	delayed	_
167-349	31411-31419	matching	_
167-350	31420-31422	to	_
167-351	31423-31429	sample	_
167-352	31430-31433	for	_
167-353	31434-31443	emotional	_
167-354	31444-31455	expressions	_
167-355	31456-31464	Anterior	_
167-356	31465-31474	cingulate	_
167-357	31475-31481	proton	_
167-358	31482-31494	spectroscopy	_
167-359	31495-31504	glutamate	_
167-360	31505-31511	levels	_
167-361	31512-31518	differ	_
167-362	31519-31521	as	_
167-363	31522-31523	a	_
167-364	31524-31532	function	_
167-365	31533-31535	of	_
167-366	31536-31543	smoking	_
167-367	31544-31553	cessation	_
167-368	31554-31561	outcome	_
167-369	31562-31563	A	_
167-370	31564-31574	parametric	_
167-371	31575-31587	manipulation	_
167-372	31588-31590	of	_
167-373	31591-31598	factors	_
167-374	31599-31608	affecting	_
167-375	31609-31621	task-induced	_
167-376	31622-31634	deactivation	_
167-377	31635-31637	in	_
167-378	31638-31648	functional	_
167-379	31649-31661	neuroimaging	_
167-380	31662-31670	Saliency	_
167-381	31670-31671	,	_
167-382	31672-31681	switching	_
167-383	31681-31682	,	_
167-384	31683-31692	attention	_
167-385	31693-31696	and	_
167-386	31697-31704	control	_
167-387	31704-31705	:	_
167-388	31706-31707	a	_
167-389	31708-31715	network	_
167-390	31716-31721	model	_
167-391	31722-31724	of	_
167-392	31725-31731	insula	_
167-393	31732-31740	function	_
167-394	31741-31753	Neuroimaging	_
167-395	31754-31761	markers	_
167-396	31762-31764	of	_
167-397	31765-31778	glutamatergic	_
167-398	31779-31782	and	_
167-399	31783-31792	GABAergic	_
167-400	31793-31800	systems	_
167-401	31801-31803	in	_
167-402	31804-31808	drug	_
167-403	31809-31818	addiction	_
167-404	31818-31819	:	_
167-405	31820-31833	relationships	_
167-406	31834-31836	to	_
167-407	31837-31850	resting-state	_
167-408	31851-31861	functional	_
167-409	31862-31874	connectivity	_
167-410	31875-31876	A	_
167-411	31877-31884	default	_
167-412	31885-31889	mode	_
167-413	31890-31892	of	_
167-414	31893-31898	brain	_
167-415	31899-31907	function	_
167-416	31908-31909	A	_
167-417	31910-31917	default	_
167-418	31918-31922	mode	_
167-419	31923-31925	of	_
167-420	31926-31931	brain	_
167-421	31932-31940	function	_
167-422	31940-31941	:	_
167-423	31942-31943	a	_
167-424	31944-31949	brief	_
167-425	31950-31957	history	_
167-426	31958-31960	of	_
167-427	31961-31963	an	_
167-428	31964-31972	evolving	_
167-429	31973-31977	idea	_
167-430	31978-31989	Remembering	_
167-431	31990-31993	the	_
167-432	31994-31998	past	_
167-433	31999-32001	to	_
167-434	32002-32009	imagine	_
167-435	32010-32013	the	_
167-436	32014-32020	future	_
167-437	32020-32021	:	_
167-438	32022-32025	the	_
167-439	32026-32037	prospective	_
167-440	32038-32043	brain	_
167-441	32044-32055	Persistence	_
167-442	32056-32058	of	_
167-443	32059-32074	parahippocampal	_
167-444	32075-32089	representation	_
167-445	32090-32092	in	_
167-446	32093-32096	the	_
167-447	32097-32104	absence	_
167-448	32105-32107	of	_
167-449	32108-32116	stimulus	_
167-450	32117-32122	input	_
167-451	32123-32131	enhances	_
167-452	32132-32141	long-term	_
167-453	32142-32150	encoding	_
167-454	32150-32151	:	_
167-455	32152-32153	a	_
167-456	32154-32164	functional	_
167-457	32165-32173	magnetic	_
167-458	32174-32183	resonance	_
167-459	32184-32191	imaging	_
167-460	32192-32197	study	_
167-461	32198-32200	of	_
167-462	32201-32211	subsequent	_
167-463	32212-32218	memory	_
167-464	32219-32224	after	_
167-465	32225-32226	a	_
167-466	32227-32234	delayed	_
167-467	32235-32250	match-to-sample	_
167-468	32251-32255	task	_
167-469	32256-32267	Dissociable	_
167-470	32268-32277	intrinsic	_
167-471	32278-32290	connectivity	_
167-472	32291-32299	networks	_
167-473	32300-32303	for	_
167-474	32304-32312	salience	_
167-475	32313-32323	processing	_
167-476	32324-32327	and	_
167-477	32328-32337	executive	_
167-478	32338-32345	control	_
167-479	32346-32360	Correspondence	_
167-480	32361-32363	of	_
167-481	32364-32367	the	_
167-482	32368-32375	brain's	_
167-483	32376-32386	functional	_
167-484	32387-32399	architecture	_
167-485	32400-32406	during	_
167-486	32407-32417	activation	_
167-487	32418-32421	and	_
167-488	32422-32426	rest	_
167-489	32427-32430	The	_
167-490	32431-32437	common	_
167-491	32438-32443	basis	_
167-492	32444-32446	of	_
167-493	32447-32463	autobiographical	_
167-494	32464-32470	memory	_
167-495	32470-32471	,	_
167-496	32472-32483	prospection	_
167-497	32483-32484	,	_
167-498	32485-32495	navigation	_
167-499	32495-32496	,	_
167-500	32497-32503	theory	_
167-501	32504-32506	of	_
167-502	32507-32511	mind	_
167-503	32512-32515	and	_
167-504	32516-32519	the	_
167-505	32520-32527	default	_
167-506	32528-32532	mode	_
167-507	32532-32533	:	_
167-508	32534-32535	a	_
167-509	32536-32548	quantitative	_
167-510	32549-32562	meta-analysis	_
167-511	32563-32570	Default	_
167-512	32571-32578	network	_
167-513	32579-32587	activity	_
167-514	32587-32588	,	_
167-515	32589-32596	coupled	_
167-516	32597-32601	with	_
167-517	32602-32605	the	_
167-518	32606-32620	frontoparietal	_
167-519	32621-32628	control	_
167-520	32629-32636	network	_
167-521	32636-32637	,	_
167-522	32638-32646	supports	_
167-523	32647-32660	goal-directed	_
167-524	32661-32670	cognition	_
167-525	32671-32678	Resting	_
167-526	32679-32684	state	_
167-527	32685-32695	functional	_
167-528	32696-32708	connectivity	_
167-529	32709-32711	in	_
167-530	32712-32721	addiction	_
167-531	32721-32722	:	_
167-532	32723-32730	lessons	_
167-533	32731-32738	learned	_
167-534	32739-32742	and	_
167-535	32743-32744	a	_
167-536	32745-32749	road	_
167-537	32750-32755	ahead	_
167-538	32756-32760	Open	_
167-539	32761-32766	label	_
167-540	32767-32774	smoking	_
167-541	32775-32784	cessation	_
167-542	32785-32789	with	_
167-543	32790-32801	varenicline	_
167-544	32802-32804	is	_
167-545	32805-32815	associated	_
167-546	32816-32820	with	_
167-547	32821-32830	decreased	_
167-548	32831-32840	glutamate	_
167-549	32841-32847	levels	_
167-550	32848-32851	and	_
167-551	32852-32862	functional	_
167-552	32863-32870	changes	_
167-553	32871-32873	in	_
167-554	32874-32882	anterior	_
167-555	32883-32892	cingulate	_
167-556	32893-32899	cortex	_
167-557	32899-32900	:	_
167-558	32901-32912	preliminary	_
167-559	32913-32921	findings	_
167-560	32922-32924	Do	_
167-561	32925-32930	small	_
167-562	32931-32937	lapses	_
167-563	32938-32945	predict	_
167-564	32946-32953	relapse	_
167-565	32954-32956	to	_
167-566	32957-32964	smoking	_
167-567	32965-32973	behavior	_
167-568	32974-32979	under	_
167-569	32980-32989	bupropion	_
167-570	32990-32999	treatment	_
167-571	32999-33000	?	_

#Text=Default mode network activation is significantly less suppressed when smokers view smoking cues.
168-1	33001-33008	Default	_
168-2	33009-33013	mode	_
168-3	33014-33021	network	_
168-4	33022-33032	activation	_
168-5	33033-33035	is	_
168-6	33036-33049	significantly	_
168-7	33050-33054	less	_
168-8	33055-33065	suppressed	_
168-9	33066-33070	when	_
168-10	33071-33078	smokers	_
168-11	33079-33083	view	_
168-12	33084-33091	smoking	_
168-13	33092-33096	cues	_
168-14	33096-33097	.	_

#Text=The green overlay on the brain images shows the DMN ROI taken from used in all relevant analyses.
169-1	33098-33101	The	_
169-2	33102-33107	green	_
169-3	33108-33115	overlay	_
169-4	33116-33118	on	_
169-5	33119-33122	the	_
169-6	33123-33128	brain	_
169-7	33129-33135	images	_
169-8	33136-33141	shows	_
169-9	33142-33145	the	_
169-10	33146-33149	DMN	_
169-11	33150-33153	ROI	_
169-12	33154-33159	taken	_
169-13	33160-33164	from	_
169-14	33165-33169	used	_
169-15	33170-33172	in	_
169-16	33173-33176	all	_
169-17	33177-33185	relevant	_
169-18	33186-33194	analyses	_
169-19	33194-33195	.	_

#Text=The orange overlay shows the whole brain analysis results of the smoking vs. neutral contrast for the primary cohort, which significantly overlaps with the DMN ROI.
170-1	33196-33199	The	_
170-2	33200-33206	orange	_
170-3	33207-33214	overlay	_
170-4	33215-33220	shows	_
170-5	33221-33224	the	_
170-6	33225-33230	whole	_
170-7	33231-33236	brain	_
170-8	33237-33245	analysis	_
170-9	33246-33253	results	_
170-10	33254-33256	of	_
170-11	33257-33260	the	_
170-12	33261-33268	smoking	_
170-13	33269-33271	vs	_
170-14	33271-33272	.	_
170-15	33273-33280	neutral	_
170-16	33281-33289	contrast	_
170-17	33290-33293	for	_
170-18	33294-33297	the	_
170-19	33298-33305	primary	_
170-20	33306-33312	cohort	_
170-21	33312-33313	,	_
170-22	33314-33319	which	_
170-23	33320-33333	significantly	_
170-24	33334-33342	overlaps	_
170-25	33343-33347	with	_
170-26	33348-33351	the	_
170-27	33352-33355	DMN	_
170-28	33356-33359	ROI	_
170-29	33359-33360	.	_

#Text=The bar graph shows data from the primary cohort indicating that there is elevated DMN activity for the smoking > neutral contrast, which is driven by a lack of DMN suppression when smokers view smoking images.
171-1	33361-33364	The	_
171-2	33365-33368	bar	_
171-3	33369-33374	graph	_
171-4	33375-33380	shows	_
171-5	33381-33385	data	_
171-6	33386-33390	from	_
171-7	33391-33394	the	_
171-8	33395-33402	primary	_
171-9	33403-33409	cohort	_
171-10	33410-33420	indicating	_
171-11	33421-33425	that	_
171-12	33426-33431	there	_
171-13	33432-33434	is	_
171-14	33435-33443	elevated	_
171-15	33444-33447	DMN	_
171-16	33448-33456	activity	_
171-17	33457-33460	for	_
171-18	33461-33464	the	_
171-19	33465-33472	smoking	_
171-20	33473-33474	>	_
171-21	33475-33482	neutral	_
171-22	33483-33491	contrast	_
171-23	33491-33492	,	_
171-24	33493-33498	which	_
171-25	33499-33501	is	_
171-26	33502-33508	driven	_
171-27	33509-33511	by	_
171-28	33512-33513	a	_
171-29	33514-33518	lack	_
171-30	33519-33521	of	_
171-31	33522-33525	DMN	_
171-32	33526-33537	suppression	_
171-33	33538-33542	when	_
171-34	33543-33550	smokers	_
171-35	33551-33555	view	_
171-36	33556-33563	smoking	_
171-37	33564-33570	images	_
171-38	33570-33571	.	_

#Text=The asterisk indicates a significant difference between DMN reactivity to smoking cues and neutral cues (p < 0.001).
172-1	33572-33575	The	_
172-2	33576-33584	asterisk	_
172-3	33585-33594	indicates	_
172-4	33595-33596	a	_
172-5	33597-33608	significant	_
172-6	33609-33619	difference	_
172-7	33620-33627	between	_
172-8	33628-33631	DMN	_
172-9	33632-33642	reactivity	_
172-10	33643-33645	to	_
172-11	33646-33653	smoking	_
172-12	33654-33658	cues	_
172-13	33659-33662	and	_
172-14	33663-33670	neutral	_
172-15	33671-33675	cues	_
172-16	33676-33677	(	_
172-17	33677-33678	p	_
172-18	33679-33680	<	_
172-19	33681-33686	0.001	_
172-20	33686-33687	)	_
172-21	33687-33688	.	_

#Text=This finding was confirmed by the replication cohort.
173-1	33689-33693	This	_
173-2	33694-33701	finding	_
173-3	33702-33705	was	_
173-4	33706-33715	confirmed	_
173-5	33716-33718	by	_
173-6	33719-33722	the	_
173-7	33723-33734	replication	_
173-8	33735-33741	cohort	_
173-9	33741-33742	.	_

#Text=Representative J-resolved spectra showing the Glu and Cr peaks used in the analysis.
174-1	33743-33757	Representative	_
174-2	33758-33768	J-resolved	_
174-3	33769-33776	spectra	_
174-4	33777-33784	showing	_
174-5	33785-33788	the	_
174-6	33789-33792	Glu	_
174-7	33793-33796	and	_
174-8	33797-33799	Cr	_
174-9	33800-33805	peaks	_
174-10	33806-33810	used	_
174-11	33811-33813	in	_
174-12	33814-33817	the	_
174-13	33818-33826	analysis	_
174-14	33826-33827	.	_

#Text=Brain image shows the sagittal view of a representative T1-weighted image illustrating the 2 × 2 × 3cm voxel placement in the dACC.
175-1	33828-33833	Brain	_
175-2	33834-33839	image	_
175-3	33840-33845	shows	_
175-4	33846-33849	the	_
175-5	33850-33858	sagittal	_
175-6	33859-33863	view	_
175-7	33864-33866	of	_
175-8	33867-33868	a	_
175-9	33869-33883	representative	_
175-10	33884-33886	T1	_
175-11	33886-33887	-	_
175-12	33887-33895	weighted	_
175-13	33896-33901	image	_
175-14	33902-33914	illustrating	_
175-15	33915-33918	the	_
175-16	33919-33920	2	_
175-17	33921-33922	×	_
175-18	33923-33924	2	_
175-19	33925-33926	×	_
175-20	33927-33930	3cm	_
175-21	33931-33936	voxel	_
175-22	33937-33946	placement	_
175-23	33947-33949	in	_
175-24	33950-33953	the	_
175-25	33954-33958	dACC	_
175-26	33958-33959	.	_

#Text=There is a significant association between dACC Glu/Cr (y-axis) and the amount of DMN activation from the smoking > neutral contrast (x-axis) for both the primary and replication cohort.
176-1	33960-33965	There	_
176-2	33966-33968	is	_
176-3	33969-33970	a	_
176-4	33971-33982	significant	_
176-5	33983-33994	association	_
176-6	33995-34002	between	_
176-7	34003-34007	dACC	_
176-8	34008-34011	Glu	_
176-9	34011-34012	/	_
176-10	34012-34014	Cr	_
176-11	34015-34016	(	_
176-12	34016-34022	y-axis	_
176-13	34022-34023	)	_
176-14	34024-34027	and	_
176-15	34028-34031	the	_
176-16	34032-34038	amount	_
176-17	34039-34041	of	_
176-18	34042-34045	DMN	_
176-19	34046-34056	activation	_
176-20	34057-34061	from	_
176-21	34062-34065	the	_
176-22	34066-34073	smoking	_
176-23	34074-34075	>	_
176-24	34076-34083	neutral	_
176-25	34084-34092	contrast	_
176-26	34093-34094	(	_
176-27	34094-34100	x-axis	_
176-28	34100-34101	)	_
176-29	34102-34105	for	_
176-30	34106-34110	both	_
176-31	34111-34114	the	_
176-32	34115-34122	primary	_
176-33	34123-34126	and	_
176-34	34127-34138	replication	_
176-35	34139-34145	cohort	_
176-36	34145-34146	.	_

#Text=Demographic information for the primary and replication cohorts.
177-1	34147-34158	Demographic	_
177-2	34159-34170	information	_
177-3	34171-34174	for	_
177-4	34175-34178	the	_
177-5	34179-34186	primary	_
177-6	34187-34190	and	_
177-7	34191-34202	replication	_
177-8	34203-34210	cohorts	_
177-9	34210-34211	.	_

#Text=Significant differences between groups are indicated with an asterisk.
178-1	34212-34223	Significant	_
178-2	34224-34235	differences	_
178-3	34236-34243	between	_
178-4	34244-34250	groups	_
178-5	34251-34254	are	_
178-6	34255-34264	indicated	_
178-7	34265-34269	with	_
178-8	34270-34272	an	_
178-9	34273-34281	asterisk	_
178-10	34281-34282	.	_

#Text=Characteristic\tPrimary CohortN=18\tReplication CohortN=14\tGroupComparison\t \tAge (Years)\t31.4 ± 1.4\t26 ± 1.22\tt = 2.3, p < 0.04*\t \tEducation (years)\t14.6 ± 0.54\t15.6 ± 0.58\tt = 1.33, p > 0.18\t \tFTND\t5.33 ± 0.323\t6.43 ± 0.25\tt = 2.6, p < 0.02*\t \tAverage Cig/Day\t12.7 ± 0.82\t15.2 ± 1.0\tt = 1.9, p > 0.06\t \tPack-Year\t8.5 ± 1.02\t7.1 ± 1.3\tt = 0.88, p > 0.38\t \tExpired CO onarrival\t19.3 ± 2.6\t2.89 ± 3.7\tt = 2.2, p > 0.04*\t \tExpired COPrescan\t21.6 ± 2.2\t28.6 ± 3.5\tt = 1.8, p > 0.08\t \tExpired COPostscan\t17.2 ± 1.6\t19.7 ± 2.2\tt = 0.98, p > 0.36\t \tSubjectiveSmoking vs.Neutral Craving\t1.3 ± 0.32\t1.95 ± 0.35\tt = 1.4, p > 0.18\t \t
#Text=Highlights
#Text=The default mode network (DMN) is involved in internally focused cognition.
179-1	34283-34297	Characteristic	_
179-2	34298-34305	Primary	_
179-3	34306-34313	CohortN	_
179-4	34313-34314	=	_
179-5	34314-34316	18	_
179-6	34317-34328	Replication	_
179-7	34329-34336	CohortN	_
179-8	34336-34337	=	_
179-9	34337-34339	14	_
179-10	34340-34355	GroupComparison	_
179-11	34358-34361	Age	_
179-12	34362-34363	(	_
179-13	34363-34368	Years	_
179-14	34368-34369	)	_
179-15	34370-34374	31.4	_
179-16	34375-34376	±	_
179-17	34377-34380	1.4	_
179-18	34381-34383	26	_
179-19	34384-34385	±	_
179-20	34386-34390	1.22	_
179-21	34391-34392	t	_
179-22	34393-34394	=	_
179-23	34395-34398	2.3	_
179-24	34398-34399	,	_
179-25	34400-34401	p	_
179-26	34402-34403	<	_
179-27	34404-34408	0.04	_
179-28	34408-34409	*	_
179-29	34412-34421	Education	_
179-30	34422-34423	(	_
179-31	34423-34428	years	_
179-32	34428-34429	)	_
179-33	34430-34434	14.6	_
179-34	34435-34436	±	_
179-35	34437-34441	0.54	_
179-36	34442-34446	15.6	_
179-37	34447-34448	±	_
179-38	34449-34453	0.58	_
179-39	34454-34455	t	_
179-40	34456-34457	=	_
179-41	34458-34462	1.33	_
179-42	34462-34463	,	_
179-43	34464-34465	p	_
179-44	34466-34467	>	_
179-45	34468-34472	0.18	_
179-46	34475-34479	FTND	_
179-47	34480-34484	5.33	_
179-48	34485-34486	±	_
179-49	34487-34492	0.323	_
179-50	34493-34497	6.43	_
179-51	34498-34499	±	_
179-52	34500-34504	0.25	_
179-53	34505-34506	t	_
179-54	34507-34508	=	_
179-55	34509-34512	2.6	_
179-56	34512-34513	,	_
179-57	34514-34515	p	_
179-58	34516-34517	<	_
179-59	34518-34522	0.02	_
179-60	34522-34523	*	_
179-61	34526-34533	Average	_
179-62	34534-34537	Cig	_
179-63	34537-34538	/	_
179-64	34538-34541	Day	_
179-65	34542-34546	12.7	_
179-66	34547-34548	±	_
179-67	34549-34553	0.82	_
179-68	34554-34558	15.2	_
179-69	34559-34560	±	_
179-70	34561-34564	1.0	_
179-71	34565-34566	t	_
179-72	34567-34568	=	_
179-73	34569-34572	1.9	_
179-74	34572-34573	,	_
179-75	34574-34575	p	_
179-76	34576-34577	>	_
179-77	34578-34582	0.06	_
179-78	34585-34594	Pack-Year	_
179-79	34595-34598	8.5	_
179-80	34599-34600	±	_
179-81	34601-34605	1.02	_
179-82	34606-34609	7.1	_
179-83	34610-34611	±	_
179-84	34612-34615	1.3	_
179-85	34616-34617	t	_
179-86	34618-34619	=	_
179-87	34620-34624	0.88	_
179-88	34624-34625	,	_
179-89	34626-34627	p	_
179-90	34628-34629	>	_
179-91	34630-34634	0.38	_
179-92	34637-34644	Expired	_
179-93	34645-34647	CO	_
179-94	34648-34657	onarrival	_
179-95	34658-34662	19.3	_
179-96	34663-34664	±	_
179-97	34665-34668	2.6	_
179-98	34669-34673	2.89	_
179-99	34674-34675	±	_
179-100	34676-34679	3.7	_
179-101	34680-34681	t	_
179-102	34682-34683	=	_
179-103	34684-34687	2.2	_
179-104	34687-34688	,	_
179-105	34689-34690	p	_
179-106	34691-34692	>	_
179-107	34693-34697	0.04	_
179-108	34697-34698	*	_
179-109	34701-34708	Expired	_
179-110	34709-34718	COPrescan	_
179-111	34719-34723	21.6	_
179-112	34724-34725	±	_
179-113	34726-34729	2.2	_
179-114	34730-34734	28.6	_
179-115	34735-34736	±	_
179-116	34737-34740	3.5	_
179-117	34741-34742	t	_
179-118	34743-34744	=	_
179-119	34745-34748	1.8	_
179-120	34748-34749	,	_
179-121	34750-34751	p	_
179-122	34752-34753	>	_
179-123	34754-34758	0.08	_
179-124	34761-34768	Expired	_
179-125	34769-34779	COPostscan	_
179-126	34780-34784	17.2	_
179-127	34785-34786	±	_
179-128	34787-34790	1.6	_
179-129	34791-34795	19.7	_
179-130	34796-34797	±	_
179-131	34798-34801	2.2	_
179-132	34802-34803	t	_
179-133	34804-34805	=	_
179-134	34806-34810	0.98	_
179-135	34810-34811	,	_
179-136	34812-34813	p	_
179-137	34814-34815	>	_
179-138	34816-34820	0.36	_
179-139	34823-34840	SubjectiveSmoking	_
179-140	34841-34851	vs.Neutral	_
179-141	34852-34859	Craving	_
179-142	34860-34863	1.3	_
179-143	34864-34865	±	_
179-144	34866-34870	0.32	_
179-145	34871-34875	1.95	_
179-146	34876-34877	±	_
179-147	34878-34882	0.35	_
179-148	34883-34884	t	_
179-149	34885-34886	=	_
179-150	34887-34890	1.4	_
179-151	34890-34891	,	_
179-152	34892-34893	p	_
179-153	34894-34895	>	_
179-154	34896-34900	0.18	_
179-155	34904-34914	Highlights	_
179-156	34915-34918	The	_
179-157	34919-34926	default	_
179-158	34927-34931	mode	_
179-159	34932-34939	network	_
179-160	34940-34941	(	_
179-161	34941-34944	DMN	_
179-162	34944-34945	)	_
179-163	34946-34948	is	_
179-164	34949-34957	involved	_
179-165	34958-34960	in	_
179-166	34961-34971	internally	_
179-167	34972-34979	focused	_
179-168	34980-34989	cognition	_
179-169	34989-34990	.	_

#Text=We show less DMN suppression when nicotine-dependent smokers view smoking cues.
180-1	34991-34993	We	_
180-2	34994-34998	show	_
180-3	34999-35003	less	_
180-4	35004-35007	DMN	_
180-5	35008-35019	suppression	_
180-6	35020-35024	when	_
180-7	35025-35043	nicotine-dependent	_
180-8	35044-35051	smokers	_
180-9	35052-35056	view	_
180-10	35057-35064	smoking	_
180-11	35065-35069	cues	_
180-12	35069-35070	.	_

#Text=The dorsal anterior cingulate cortex (dACC) may play a role in modulating the DMN.
181-1	35071-35074	The	_
181-2	35075-35081	dorsal	_
181-3	35082-35090	anterior	_
181-4	35091-35100	cingulate	_
181-5	35101-35107	cortex	_
181-6	35108-35109	(	_
181-7	35109-35113	dACC	_
181-8	35113-35114	)	_
181-9	35115-35118	may	_
181-10	35119-35123	play	_
181-11	35124-35125	a	_
181-12	35126-35130	role	_
181-13	35131-35133	in	_
181-14	35134-35144	modulating	_
181-15	35145-35148	the	_
181-16	35149-35152	DMN	_
181-17	35152-35153	.	_

#Text=We show an association between dACC glutamate and DMN reactivity to smoking cues.
182-1	35154-35156	We	_
182-2	35157-35161	show	_
182-3	35162-35164	an	_
182-4	35165-35176	association	_
182-5	35177-35184	between	_
182-6	35185-35189	dACC	_
182-7	35190-35199	glutamate	_
182-8	35200-35203	and	_
182-9	35204-35207	DMN	_
182-10	35208-35218	reactivity	_
182-11	35219-35221	to	_
182-12	35222-35229	smoking	_
182-13	35230-35234	cues	_
182-14	35234-35235	.	_
